![]() | Stephen V Faraone∗Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 | Departments of Psychiatry and Neuroscience and ... |
KOL简历 Stephen V Faraone∗
Year | |
---|---|
2022 | Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 |
2021 | Department of Neuroscience and Physiology, State University of New York Upstate Medical University, Syracuse, New York Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts, USA |
2020 | K.G. Jebsen Centre for Psychiatric Disorders, Department of Biomedicine, University of Bergen, Bergen, Norway Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical Center, Syracuse, NY, USA Department of Psychiatry and of Neuroscience and Physiology, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, United States The full list of authors in the ENIGMA working groups, author affiliations, author disclosures, and acknowledgments are provided in online supplements. |
2019 | Departments of Psychiatry and Neuroscience and Physiology, SUNY Upstate Medical University, New York, USA The Department of Human Genetics, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Klein, Bralten, Roth Mota, Arias-Vasquez, Franke); University Medical Center Utrecht, UMC Utrecht Brain Center, Department of Psychiatry, Utrecht, the Netherlands (Klein); the Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Walters, Neale); Program in Medical and Population Genetics (Walters) and Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Mass (Walters, Neale); the Department of Biomedicine and the Center for Integrative Sequencing, Aarhus University, Aarhus, Denmark (Demontis, Mattheisen, Børglum); the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Denmark (Demontis, Børglum); the Department of Genetics and the Neuroscience Center, University of North Carolina, Chapel Hill (Stein); the Imaging Genetics Center, USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles (Hibar, Thompson); the Department of Epidemiology and the Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands (Adams); the Department of Psychiatry and the Research Institute, Hospital for Sick Children, University of Toronto, Toronto (Schachar); the Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Sonuga-Barke); the Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany (Mattheisen); the Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institute, Stockholm (Mattheisen); Stockholm Health Care Services, Stockholm County Council, Stockholm (Mattheisen); the Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles (Thompson); the Quantitative Genetics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Medland); the Department of Psychiatry and the Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, N.Y. (Faraone); the K.G. Jebsen Center for Neuropsychiatric Disorders, University of Bergen, Bergen, Norway (Faraone); and the Department of Psychiatry, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Roth Mota, Arias-Vasquez, Franke). Department of Psychiatry, Upstate Medical University, Syracuse, New York; Department of Neuroscience and Physiology, Upstate Medical University, Syracuse, New York. SUNY Upstate Medical University, Syracuse, NY |
Stephen V Faraone∗:影响统计
Concept | World rank |
---|---|
stimulant nmu | #1 |
adhd slc6a3 genotype | #1 |
“schizotypes | #1 |
inattention shr | #1 |
comt odd | #1 |
greater risk adhd | #1 |
type adhd | #1 |
depression symptoms aggregation | #1 |
pathways adhd | #1 |
cgsq ermph | #1 |
genetic studies sud | #1 |
daodisc1 | #1 |
or133 | #1 |
diagnoses valid | #1 |
adhd gwas | #1 |
sud adolescent patients | #1 |
disorganized symptom dimensions | #1 |
adults neurodevelopmental disorder | #1 |
ldx amses | #1 |
inattentive symptoms adults | #1 |
masir | #1 |
innovative sms intervention | #1 |
european treatment guideline | #1 |
hyperactivity child | #1 |
bmi mts | #1 |
odd familial disorders | #1 |
competitivep | #1 |
rationaleadhd | #1 |
adhd dbds | #1 |
adhdrs5 | #1 |
week treatment response | #1 |
autism symptoms adhd | #1 |
bpi disorder efds | #1 |
vcfs manic symptoms | #1 |
adhd sample | #1 |
offspring parental adhd | #1 |
probands comorbidity | #1 |
diagnoses relatives | #1 |
educational failure | #1 |
nhe inhibitors adhd | #1 |
dsm5 adult adhd | #1 |
studies method | #1 |
bipolar disorder switches | #1 |
adult persistence | #1 |
htf9c gene | #1 |
adhd brain alterations | #1 |
nr3c1 stress exposure | #1 |
controls adhd children | #1 |
adhd sexes | #1 |
hyperactivity | #1 |
77e08 | #1 |
adhd african | #1 |
growth outcomes adhd | #1 |
cbt intervention adolescents | #1 |
2327ct | #1 |
adhd aes | #1 |
youth adhd | #1 |
diagnostic efficiency analysis | #1 |
inattention adhd | #1 |
expected growth children | #1 |
oros methylphenidate orosmph | #1 |
learning disorders adhd | #1 |
emotional symptoms adhd | #1 |
increased expression methylation | #1 |
children growth delays | #1 |
nonverbal social–emotional cues | #1 |
nplz | #1 |
rs1799835 | #1 |
2 familial factors | #1 |
cigarette smoking metaanalysis | #1 |
relatives multiplex families | #1 |
neuropsychological performance adhd | #1 |
treatment mts | #1 |
gender familial risk | #1 |
pdd mania mania | #1 |
specific psychopathology children | #1 |
adhd subjects controls | #1 |
adhddbds | #1 |
emotional problems pmee | #1 |
adolescence longitudinal analysis | #1 |
83097 | #1 |
association evidence schizophrenia | #1 |
diagnostic continuity adhd | #1 |
adhd chinese population | #1 |
referred parents | #1 |
mr006 | #1 |
qms adhd | #1 |
children mania diagnosis | #1 |
families adhd | #1 |
highiq youths adhd | #1 |
differences medications | #1 |
adhd clinical | #1 |
association tph2 | #1 |
pdd criteria | #1 |
deficits expected growth | #1 |
infas | #1 |
meaningful anxiety phenotype | #1 |
risk substance disorders | #1 |
administration marijuana | #1 |
rutters | #1 |
trait educational attainment | #1 |
adhd psychiatric | #1 |
phenotype adhd | #1 |
daorasd2 | #1 |
notch4 polymorphisms schizophrenia | #1 |
schizotaxia subjects | #1 |
slc6a4 gene risk | #1 |
association dopamine receptors | #1 |
patients adhdpi | #1 |
adhd background | #1 |
suggestive linkage signals | #1 |
parents sud | #1 |
efficacy outcome adhd | #1 |
confusability analyses | #1 |
21 circadian genes | #1 |
morbidity adhd | #1 |
hartsough | #1 |
ldx sizes adults | #1 |
nonpsychotic relatives controls | #1 |
htf9c | #1 |
bpi disorder aspd | #1 |
metaanalysis controlled study | #1 |
motor preference asthma | #1 |
rs550818 | #1 |
risk childhood onset | #1 |
adhd conduct disorder | #1 |
d10s195 | #1 |
manic symptoms disorder | #1 |
children idiopathic adhd | #1 |
conduct disorder probands | #1 |
hyperactivity pdi | #1 |
n122 | #1 |
evidence stimulant treatment | #1 |
adhd control probands | #1 |
adhd diagnosed | #1 |
risk opioid dependence | #1 |
anxiety disorders siblings | #1 |
adhd efds | #1 |
adverse impact adhd | #1 |
mwq inattention items | #1 |
substantial genetic component | #1 |
tidqam | #1 |
mania manic features | #1 |
relatives pediatric probands | #1 |
nonreferred adult | #1 |
bipolar mdd | #1 |
volume alterations | #1 |
adhd aud | #1 |
schizophrenia families smoking | #1 |
prescription stimulant nonmedical | #1 |
familial evidence | #1 |
children ermph | #1 |
aud alcohol disorders | #1 |
1350t | #1 |
schizophrenia current knowledge | #1 |
adhd iiv | #1 |
fbxo33 | #1 |
stimulant treatment youth | #1 |
cadhd aadhd | #1 |
aggregate cutoff score | #1 |
motorendophenotype | #1 |
mwq adhd module | #1 |
2064 trios | #1 |
stimulant treatment differences | #1 |
adhd responders | #1 |
boys female gender | #1 |
gsprss | #1 |
pepple | #1 |
rs2469770 | #1 |
psychopathology implications | #1 |
adhd risk factors | #1 |
odd affective symptoms | #1 |
schizophrenia fhrs | #1 |
adhd adhd probands | #1 |
adhd dat1 gene | #1 |
valid diagnosis | #1 |
valid psychiatric disorder | #1 |
adhd bipolar studies | #1 |
treatment moderated | #1 |
pediatric bipolar spectrum | #1 |
neurocognitive traits | #1 |
rels persons | #1 |
association attention | #1 |
dat1 vntr | #1 |
disorders comorbid mania | #1 |
adhd module | #1 |
adhd symptom counts | #1 |
discipline problem | #1 |
neural network correlates | #1 |
higher prevalence girls | #1 |
17year | #1 |
relbps | #1 |
sbrv adhd | #1 |
aud adhd | #1 |
genetic correlations schizophrenia | #1 |
comorbid problems adhd | #1 |
probands adhd | #1 |
high‐risk adolescent offspring | #1 |
affective symptoms dbds | #1 |
adhd total score | #1 |
low attention | #1 |
combination scientific data | #1 |
training raters | #1 |
subjects adhd | #1 |
maternal inattention anxiety | #1 |
bipolar disorders psud | #1 |
mph controls | #1 |
authors adhd | #1 |
locus adhd | #1 |
adhd proband | #1 |
addictive drugs dust | #1 |
stimulant treatment alcohol | #1 |
severe emotional dysregulation | #1 |
hyperactivity cognition | #1 |
mania rates | #1 |
downward extension adolescents | #1 |
schizophrenia familybased studies | #1 |
lifetime impairment | #1 |
concurrent adhd sud | #1 |
onset criterion adhd | #1 |
ptsd bpi disorder | #1 |
13052159 | #1 |
rs6000200 | #1 |
relatives drug dependence | #1 |
studies adhd children | #1 |
distal genomic region | #1 |
ptsd familial disorders | #1 |
slc9a9 disease associations | #1 |
patients attentional disorders | #1 |
adult adhd treatment | #1 |
p44e05 | #1 |
adhddbds adhd | #1 |
n55374 | #1 |
vall66 | #1 |
parental bpd | #1 |
age stimulant treatment | #1 |
structural differences children | #1 |
adhd maternal smoking | #1 |
teacher combined | #1 |
cbclbp profile | #1 |
drd2 risk gene | #1 |
quantitative phenotype snp | #1 |
sob association adhd | #1 |
142 combined subtype | #1 |
masir ldx | #1 |
morbidity bipolar disorder | #1 |
asrs aisrs | #1 |
diagnostic criteria adhd | #1 |
maf⩾1 | #1 |
depressed children adhd | #1 |
common genetic risk | #1 |
adhd girls | #1 |
disorder follow | #1 |
molecular genetic studies | #1 |
referred juveniles | #1 |
age 7repeat allele | #1 |
disorder report | #1 |
subjects lateonset adhd | #1 |
palauans maps loci | #1 |
parental suds | #1 |
relatives diagnoses | #1 |
stimulant misuse | #1 |
rs1076560t | #1 |
psychiatric comorbidities adhd | #1 |
adhd medications placebo | #1 |
adhd smoking | #1 |
comorbid problems | #1 |
genes hallucinations states | #1 |
cbcl clinical scales | #1 |
gene attention | #1 |
rs3916970 | #1 |
neuropsychologic function schizophrenia | #1 |
adhd long term | #1 |
offspring parental md | #1 |
key conceptual issues | #1 |
manic children pdd | #1 |
snpssnpsa | #1 |
dsmiv subtypes adhd | #1 |
lod213 | #1 |
adhd susceptibility genes | #1 |
methylphenidate efficacy | #1 |
maoa neuropsychological functioning | #1 |
tourettes syndrome adhd | #1 |
re‐review | #1 |
gene studies | #1 |
autism‐associated brain regions | #1 |
onset distribution | #1 |
longacting medications | #1 |
illness child comorbidity | #1 |
bpi disorder | #1 |
pharmacological treatment adolescents | #1 |
hyperactivity child genome | #1 |
adulthood genetic architecture | #1 |
chi25762 | #1 |
autistic traits presence | #1 |
context adhd | #1 |
familial links | #1 |
aspd youth | #1 |
add pdics | #1 |
asds clinical scales | #1 |
acting medications | #1 |
oral methylphenidate treatment | #1 |
adhd depressed children | #1 |
adhd mini | #1 |
twin adoption studies | #1 |
new psychometric definition | #1 |
10repeats | #1 |
height ldx | #1 |
comorbidity conduct | #1 |
girls disorder | #1 |
bpi probands | #1 |
adhd desr probands | #1 |
genetic overlap adhd | #1 |
rs916455 | #1 |
subcortical volumes adhd | #1 |
criteria mania | #1 |
hyperactivity female | #1 |
cbclbp profile children | #1 |
report adhd | #1 |
hyperactivity biomarkers | #1 |
smoking schizophrenia families | #1 |
neurocognitive marker | #1 |
visual memory deficit | #1 |
nonreferred subjects | #1 |
adhd valid | #1 |
hyperactivity child humans | #1 |
genes association studies | #1 |
children behavioral inhibition | #1 |
linkage wave | #1 |
add opd | #1 |
normal sexual dimorphisms | #1 |
validity adhd | #1 |
odd disruptive behavior | #1 |
timely renewal | #1 |
sp067 | #1 |
variants aggressive behavior | #1 |
hyperactivity body | #1 |
behavioral disinhibition offspring | #1 |
taf9bp2 | #1 |
bpd bpd anx | #1 |
association evidence | #1 |
association behavioral inhibition | #1 |
mspi allele | #1 |
disorders parents | #1 |
galantamine hydrogen bromide | #1 |
h2053 | #1 |
behavioral inhibition parents | #1 |
adhd antisocial | #1 |
neuropsychological probes | #1 |
tic persistence | #1 |
clock genes rorb | #1 |
benefit‐risk ratio | #1 |
bpi disorder sexes | #1 |
sud phenotypes | #1 |
unexplored void | #1 |
adhd neuropsychological functioning | #1 |
adhd comorbid dbds | #1 |
genotype calling procedures | #1 |
20183 | #1 |
regions lgi | #1 |
neurocognitive functions suds | #1 |
fhrscz | #1 |
mtbi adhd | #1 |
parental adhd sud | #1 |
impactnl | #1 |
adhd genetic | #1 |
inattentive subtype adhd | #1 |
adhd children ld | #1 |
d10s2327 | #1 |
relation stress exposure | #1 |
children behavioral | #1 |
european treatment guidelines | #1 |
twin adoption | #1 |
persistence childhood adhd | #1 |
adhd stimulant treatment | #1 |
clinical correlates ocd | #1 |
elaborative verbal encoding | #1 |
efds functional outcomes | #1 |
adhd comorbid disorders | #1 |
genes sexdifferentiated effects | #1 |
deficits time | #1 |
chi28783 | #1 |
controls rels | #1 |
syp female adhd | #1 |
genetic frontal schizophrenia | #1 |
adhd genetic studies | #1 |
paediatric adhd | #1 |
neurocognitive dysfunctions | #1 |
persistence pediatric disorder | #1 |
orosmph adult adhd | #1 |
drd4 association | #1 |
siblings adolescent | #1 |
robust familiality | #1 |
adolescent patients adhd | #1 |
impact tic disorders | #1 |
dyscalculia adhd | #1 |
unfamiliar challenges | #1 |
adhd highiq youths | #1 |
prsanalyses | #1 |
asrs scores | #1 |
risk factor psud | #1 |
association adhd | #1 |
parents proband youth | #1 |
c759t | #1 |
adhd oxidative stress | #1 |
efficacy outcome week | #1 |
adhdmethodcurves | #1 |
adhd female individuals | #1 |
5q23q31 | #1 |
paternal overtransmission | #1 |
adult probands siblings | #1 |
aadhd cadhd | #1 |
ermph clinical response | #1 |
elevated risk adhd | #1 |
hyperactivity disorder adults | #1 |
stimulant therapy youths | #1 |
association maoa | #1 |
sensitive adhd | #1 |
anxiety disorders twins | #1 |
sob sob association | #1 |
relatives adhd girls | #1 |
adhd genetic receptors | #1 |
24 gm day | #1 |
preschool comorbidity | #1 |
osa genetic heterogeneity | #1 |
dao gene schizophrenia | #1 |
adolescents genetic risk | #1 |
sud adolescent | #1 |
gsprs adhd | #1 |
adhd baseline | #1 |
adhd scores | #1 |
bmi ldx | #1 |
smoking cessation controls | #1 |
stimulants abuse potential | #1 |
subjects ldx | #1 |
siblings adhd probands | #1 |
adhd adverse impact | #1 |
parental children | #1 |
efds bpi disorder | #1 |
female humans inhibition | #1 |
valid disorder | #1 |
disorder attention | #1 |
sud risk offspring | #1 |
adhd adolescent | #1 |
adhdrsivinv | #1 |
rs1633445 | #1 |
adhd adult disorder | #1 |
adhd structural abnormalities | #1 |
adolescents sud treatment | #1 |
volumes participants | #1 |
adhdassociated alleles | #1 |
cdbpd | #1 |
adhd 11 years | #1 |
treatment stimulant | #1 |
asthma motor preference | #1 |
p0499 | #1 |
dat1 untranslated regions | #1 |
adhd asm snps | #1 |
chronological age age | #1 |
adhd gender | #1 |
adhd seconddegree relatives | #1 |
antisocial disorder relatives | #1 |
parental panic depression | #1 |
selfreport adhd symptoms | #1 |
rs3792452 | #1 |
evidence sud phenotypes | #1 |
motor preference disability | #1 |
highiq youths | #1 |
adherence stimulant treatment | #1 |
covariates dopamine receptors | #1 |
adhd asthma | #1 |
p902e−07 | #1 |
sexdifferentiated effects traits | #1 |
stimulants height | #1 |
subsets linkage | #1 |
regulation desr | #1 |
cdh13 memory performance | #1 |
adhd probands | #1 |
adhd functional | #1 |
association syp | #1 |
rs552655 | #1 |
childhood predictors adhd | #1 |
social adjustment inventory | #1 |
quantitative analyses treatment | #1 |
ld addh children | #1 |
multi‐stage study | #1 |
haplotypes adhd | #1 |
clinical controls | #1 |
illness adolescent | #1 |
nonreferred siblings probands | #1 |
bpi disorder children | #1 |
adhd bipolar comorbidity | #1 |
sex bpi disorder | #1 |
odd relatives | #1 |
bpd relatives | #1 |
dsm bipolar disorder | #1 |
adhd probands adhd | #1 |
adhd social disability | #1 |
exposure parental adhd | #1 |
15q13 deletions | #1 |
proband youth bpdsud | #1 |
brain activity flow | #1 |
genes adhd | #1 |
adhd pdics | #1 |
rs2279805 | #1 |
reproducibility adolescent | #1 |
adhd antisocial comorbidity | #1 |
autistic traits youth | #1 |
children bpi disorder | #1 |
disorders aa | #1 |
maoa adhd | #1 |
pinslbl | #1 |
adhd children depression | #1 |
self‐reported adhd | #1 |
adhd studies | #1 |
adult samples model | #1 |
onset attention | #1 |
persons rels | #1 |
asrs‐v11 | #1 |
d15s1012 | #1 |
longitudinal outcome boys | #1 |
dust addictive drug | #1 |
proband youth bpd | #1 |
shifting sands | #1 |
p647e07 | #1 |
desr adult probands | #1 |
schizophrenia code | #1 |
35191 controls | #1 |
95 hrr | #1 |
adhdfamilies | #1 |
1236a | #1 |
23 candidate genes | #1 |
slc9a9 | #1 |
association psychiatric comorbidity | #1 |
adolescent attention | #1 |
actual motor performance | #1 |
diagnosis adhd | #1 |
overweight obesity males | #1 |
diagnosis bpi disorder | #1 |
children disorder | #1 |
relatives adhd status | #1 |
mania pdd | #1 |
pooleddata | #1 |
bpi sza | #1 |
children pdag parents | #1 |
adhd concurrent sud | #1 |
adhd disorders comorbidity | #1 |
gender adhd | #1 |
analysis adhd | #1 |
ldx sizes | #1 |
bipolar disorder girls | #1 |
siblings adhd children | #1 |
familial moderators | #1 |
qelbree | #1 |
highiq adults adhd | #1 |
maoa impulsivity | #1 |
psud adhd probands | #1 |
adhd gsprs | #1 |
odd disorders follow | #1 |
neuropsychological testing individuals | #1 |
adhd personality traits | #1 |
2276tc | #1 |
items 99item cbs | #1 |
ldx sizes children | #1 |
placebo ldx treatment | #1 |
parental panic disorder | #1 |
pain tolerance oih | #1 |
drd4 7repeat allele | #1 |
criteria☆ | #1 |
molecular genetics network | #1 |
foursnp | #1 |
co‐expression modules | #1 |
transmission adhd | #1 |
adhd linkage | #1 |
adhd teenage parents | #1 |
112 80 | #1 |
scqscore | #1 |
p81e06 | #1 |
relatives bipolar | #1 |
relatives 3 probands | #1 |
psychiatric comorbidity md | #1 |
adhd familial | #1 |
subthreshold diagnoses valid | #1 |
hypothesis disorders | #1 |
impaired sensorimotor timing | #1 |
groups girls | #1 |
consensus combination | #1 |
adhd drd4 | #1 |
insular lobule | #1 |
bpprss | #1 |
stimulant treatment risk | #1 |
adhd prs rtv | #1 |
adhd euphoria | #1 |
palau scz | #1 |
concurrent adhd | #1 |
mdd pdag mdd | #1 |
adhd risk alleles | #1 |
drugplacebo response curve | #1 |
biased maternal reporting | #1 |
comt intelligence | #1 |
oih cpt | #1 |
risk aggressive symptoms | #1 |
distinct subtype | #1 |
hamiltondepression | #1 |
males overweight obesity | #1 |
pharmacogenetics predictors | #1 |
adhd clinical trial | #1 |
criteria 14 children | #1 |
sbrv | #1 |
adhd familial disorder | #1 |
oral nmu nmu | #1 |
suggestive linkage | #1 |
aadhd hyperactivity biomarkers | #1 |
type attention | #1 |
adhde | #1 |
latrophilin 3 gene | #1 |
anx relatives | #1 |
child psychiatry referrals | #1 |
distribution child | #1 |
relatives default network | #1 |
adhd | #1 |
comorbidity major depression | #1 |
adhd comorbid | #1 |
genetics adhd | #1 |
40basepairrepeat | #1 |
rorb bipolar disorder | #1 |
years adhd | #1 |
gene aggressive behavior | #1 |
rs9325032 | #1 |
tass adhd | #1 |
moderating effects patterns | #1 |
cortical thickness adhd | #1 |
inflation personal satisfaction | #1 |
faraone | #1 |
mgh studies | #1 |
positive peer affiliation | #1 |
asrs | #1 |
genetic heterogeneity adhd | #1 |
endosomal genes asds | #1 |
dbds adhddbds | #1 |
ermph cgsq | #1 |
snps drd4 gene | #1 |
followup assessment | #1 |
disorder relatives | #1 |
disorder molecular | #1 |
9 nhe9 | #1 |
findings adhd | #1 |
sodasmph | #1 |
adhd switches | #1 |
adhd conclusions | #1 |
daily parent rating | #1 |
adhd dyscalculia | #1 |
deficit hyperactivity | #1 |
hyperactivity disorder scores | #1 |
allele adhd | #1 |
dat110 6 | #1 |
adhd dsm | #1 |
896 cases | #1 |
efficacy adderall | #1 |
larger samples | #1 |
smoking wm microstructure | #1 |
transient financial stress | #1 |
experts abstinence | #1 |
inattention items | #1 |
conduct bipolar disorders | #1 |
symptoms aggregation | #1 |
candidate genes adhd | #1 |
interaction adhd | #1 |
familially | #1 |
140 adhd probands | #1 |
antisocial disorders risk | #1 |
odd control | #1 |
callingalgorithms | #1 |
prodromal overt psychosis | #1 |
paliperidone monotherapy | #1 |
repeat allele | #1 |
add parent report | #1 |
adhd fam | #1 |
p446e08 | #1 |
pilot study adhd | #1 |
suds crosssectional studies | #1 |
studies depressed children | #1 |
male individuals adhd | #1 |
inattentive hyperactive | #1 |
intellectual delays | #1 |
mania criteria | #1 |
hyperactive impulsive symptoms | #1 |
boys social disability | #1 |
pdd subjects mania | #1 |
mania conduct disorder | #1 |
disorder schizotaxia | #1 |
adhd sex | #1 |
referred samples | #1 |
adhd familial risk | #1 |
s034 | #1 |
suds adhd | #1 |
stimulants childhood | #1 |
drug frequency variables | #1 |
smoking adhd | #1 |
neuroleptic nonresponse | #1 |
healthy cortical development | #1 |
male adolescents adhdct | #1 |
juvenile antisocial traits | #1 |
lifetime adhd | #1 |
personality traits adults | #1 |
comt maoa | #1 |
adhd bpi disorder | #1 |
nfspd | #1 |
4q3121 | #1 |
adhd educational deficits | #1 |
drug dependence relatives | #1 |
children antisocial disorders | #1 |
cases adhd | #1 |
rtv adhd prs | #1 |
adhd hyperactivity automobile | #1 |
asd youth adhd | #1 |
predicted clinical response | #1 |
motor preference adhd | #1 |
12allele | #1 |
treatment stimulants | #1 |
135–526 | #1 |
time qualitative review | #1 |
expressed emotion children | #1 |
adhd treatment treatment | #1 |
adhd alcohol dependence | #1 |
oih pain tolerance | #1 |
rs1482337–rs2252471 | #1 |
dopamine d4 gene | #1 |
idir aversion | #1 |
racial heterogeneity | #1 |
adhd clinical characteristics | #1 |
affective psychosis hraff | #1 |
rs9610449 | #1 |
neuropsychological impairments relatives | #1 |
p20e04 | #1 |
cortical surface adhd | #1 |
adhd asd youth | #1 |
adhdoddcd | #1 |
kiaa1292 | #1 |
anxiety disorders relatives | #1 |
medications adult adhd | #1 |
relatives control | #1 |
thermenos | #1 |
pediatric bpi disorder | #1 |
shared endophenotypes | #1 |
growth deficits deficits | #1 |
lateonset adhd | #1 |
sud bpdsud | #1 |
risk subsequent substance | #1 |
conduct disorder aspd | #1 |
genomesignificance | #1 |
np functioning chr | #1 |
antisocial disorders bpd | #1 |
asd weaknesses | #1 |
compared adhd | #1 |
female individuals adhd | #1 |
vcfsadhd adhd | #1 |
druggable genome disorder | #1 |
bpi disorder adhd | #1 |
weaknesses comorbidity | #1 |
deletioncarrier | #1 |
anxiety disorders families | #1 |
adhd antisocial disorders | #1 |
adult adhd differences | #1 |
5ht1b receptor gene | #1 |
mania clinical interview | #1 |
adhd cbcl | #1 |
parents behavioral disinhibition | #1 |
adhd findings | #1 |
disorder boys | #1 |
adhd psychiatric conditions | #1 |
major depression share | #1 |
adults life | #1 |
youth bpi disorder | #1 |
age groups cohorts | #1 |
nmu oral | #1 |
adhd prss adhd | #1 |
smaller total brain | #1 |
tova api aklt01 | #1 |
risk female relatives | #1 |
children motor domain | #1 |
adhd volumetric reductions | #1 |
unaffected siblings volumes | #1 |
cigarette smoking siblings | #1 |
adhd pattern | #1 |
endophenotypic construct | #1 |
diagnoses adhd | #1 |
predictors persistence | #1 |
ldx growth | #1 |
relatives bpi | #1 |
rs7118422 | #1 |
hypothesized precursors | #1 |
lifetime impairment survey | #1 |
opd add opd | #1 |
adhd context | #1 |
model ermph | #1 |
stimulant treatment adhd | #1 |
manic symptoms vcfs | #1 |
ermph placebo groups | #1 |
female gender boys | #1 |
neuropsychological functioning boys | #1 |
adhd alleles | #1 |
parental sud adhd | #1 |
stress exposure connectivity | #1 |
impulsiveness inattention | #1 |
adhd reliability | #1 |
lateandmoderate | #1 |
adhd predictors | #1 |
suds neurocognitive functions | #1 |
ldx bmi | #1 |
mr005 | #1 |
adhd children exposure | #1 |
genetic variants adhd | #1 |
relatives bpi probands | #1 |
adhd adult adhd | #1 |
dopamine receptor polymorphism | #1 |
future dsm | #1 |
starsadhd | #1 |
adhd children mania | #1 |
dna methylation adhd | #1 |
cognitive endophenotypes adhd | #1 |
stress adhd severity | #1 |
multiplex sample | #1 |
99item cbs | #1 |
adhd somatosensory functioning | #1 |
disorder hyperactivity | #1 |
adhd neuropsychological | #1 |
adhd probands relatives | #1 |
ptsd siblings | #1 |
adhd comorbid odd | #1 |
school reliability | #1 |
md parents | #1 |
assess adult adhd | #1 |
control probands | #1 |
desr subjects | #1 |
adhd children | #1 |
scz palau | #1 |
trait impulsivity adhdct | #1 |
effects lisdexamfetamine dimesylate | #1 |
adhd higher | #1 |
adhd methods | #1 |
snps quantitative phenotypes | #1 |
suds nicotine dependence | #1 |
hyperactivity child child | #1 |
cyp2d6 hypothesis | #1 |
druggable genome adhd | #1 |
mothers fam | #1 |
adhd learning | #1 |
depressed children depression | #1 |
interviews disease humans | #1 |
efs girls | #1 |
add antisocial disorders | #1 |
motor problems adhd | #1 |
bpd anx relatives | #1 |
adhd neuroimage study | #1 |
adhd girls adhd | #1 |
individuals adhd | #1 |
prs rtv | #1 |
ats siblings | #1 |
adolescent psychiatric cohort | #1 |
braingenie | #1 |
genes disorder | #1 |
exposure clinical features | #1 |
depression offspring variables | #1 |
cacng2 genes schizophrenia | #1 |
genes etiology | #1 |
etiology adhd | #1 |
abnormalities adhd | #1 |
relatives adhd probands | #1 |
stimulant treatment | #1 |
comorbid odd adhd | #1 |
african children adhd | #1 |
adhd income loss | #1 |
adhd adhd cases | #1 |
adult samples adhd | #1 |
desr siblings | #1 |
relatives risk adhd | #1 |
adhd cognition | #1 |
adhd cigarette smoking | #1 |
desr adults | #1 |
trypotphan hydroxylase | #1 |
comorbid psychopathology childhood | #1 |
genetic risk severity | #1 |
pdi impulsiveness | #1 |
adhd smoking risk | #1 |
pippi longstocking | #1 |
hyperactivity comorbidity | #1 |
hyperactivity comorbidity humans | #1 |
severe dysregulation | #1 |
adhd vntr | #1 |
prevalence attention | #1 |
dat1 adhd | #1 |
35191 | #1 |
1 relatives | #1 |
nonreferred adults | #1 |
matching fallacy | #1 |
impulsive behavioral aggression | #1 |
“3 | #1 |
abstinence pharmacological treatment | #1 |
sud adolescence | #1 |
adhd efficacy outcome | #1 |
rs1051312 | #1 |
biological schizophrenia stress | #1 |
antisocial families | #1 |
siblings adhd | #1 |
genetic variation nr3c1 | #1 |
9r allele | #1 |
schizotaxia negative schizotypy | #1 |
nonreferred samples | #1 |
addh dmi | #1 |
children general psychopathology | #1 |
method authors | #1 |
standardized manner | #1 |
sample adhd | #1 |
adhd prs gwas | #1 |
probands rates | #1 |
notch4 polymorphisms | #1 |
risk anxiety disorders | #1 |
mania referred children | #1 |
suds relatives | #1 |
prescription stimulant nmu | #1 |
aklt01 adhd | #1 |
psychiatric comorbidity girls | #1 |
adhd follow | #1 |
mddprss | #1 |
childhood adhd adulthood | #1 |
relatives wm performance | #1 |
rates relatives | #1 |
late‐onset adhd | #1 |
ldx growth delays | #1 |
genetic correlation adhd | #1 |
structured interview pdd | #1 |
ctcata | #1 |
rs2498799 | #1 |
structured interview mania | #1 |
adhd mp | #1 |
convergent functional genomic | #1 |
interobserver agreement measures | #1 |
treatment bsd | #1 |
adhd drug dependence | #1 |
major depression youth | #1 |
psud controls | #1 |
symptom burden adults | #1 |
transmission parents | #1 |
adhd attention | #1 |
peer environmental factors | #1 |
adhd african children | #1 |
earlyandmoderate | #1 |
adhd siblings | #1 |
siblings males | #1 |
familial risk analyses | #1 |
tass adhdrs | #1 |
controls adhd probands | #1 |
oral nmu | #1 |
adhd genetic exome | #1 |
new phenotype definition | #1 |
ldx size children | #1 |
lobe mri measures | #1 |
adhd oppositional | #1 |
fspds | #1 |
rare protective allele | #1 |
teacher report | #1 |
nonaffected siblings children | #1 |
youth adhd prss | #1 |
comparison subjects participants | #1 |
relatives 1 probands | #1 |
bipolar adhd | #1 |
adhd population | #1 |
matter volumes volumes | #1 |
versus disability | #1 |
git1 adhd | #1 |
mph adult adhd | #1 |
aisrs asrs | #1 |
persistent adhd symptoms | #1 |
desr probands siblings | #1 |
memory adults | #1 |
ldx masir | #1 |
connectivity executive control | #1 |
adhd 5 | #1 |
“forgetfulness | #1 |
adhd screening | #1 |
pair health | #1 |
large controlled study | #1 |
higher adhd | #1 |
hyperactivity cross | #1 |
20183 cases | #1 |
adhd serotonin | #1 |
amses amrs | #1 |
pdics | #1 |
interaction adhd severity | #1 |
onset distributions | #1 |
discordant twin study | #1 |
adult persistence adhd | #1 |
loci asd symptoms | #1 |
adhd genetic correlation | #1 |
adhd sample model | #1 |
familial transmission adhd | #1 |
2276ct | #1 |
impairments adults | #1 |
persistence disorder | #1 |
prospective datasets | #1 |
2455 controls | #1 |
add aff | #1 |
smd greater severity | #1 |
network‐level assessment | #1 |
desipraminestimulants | #1 |
apol1 schizophrenia | #1 |
shr iiv | #1 |
risk disorder | #1 |
risk psud | #1 |
studies attention | #1 |
onset chronological age | #1 |
affs add | #1 |
pdag mdd mdd | #1 |
adhdtd | #1 |
pain tolerance fm | #1 |
unique impairments | #1 |
14 children pdd | #1 |
exposure maternal smoking | #1 |
familial disorders adhd | #1 |
childhoodonset mania | #1 |
add 73 probands | #1 |
mp adhd | #1 |
schizophrenia notch4 | #1 |
motorendophenotypes | #1 |
rs7124601 | #1 |
disorder | #1 |
sud nicotine dependence | #1 |
adhd phenotypes | #1 |
paternal smoking conception | #1 |
opd add | #1 |
zmynd17 genes | #1 |
familial risk gender | #1 |
deficit | #1 |
sob adhd | #1 |
offspring sud parents | #1 |
parental md | #1 |
psud relatives | #1 |
adhd baseline assessment | #1 |
temperamental risk factor | #1 |
subthreshold adhd subjects | #1 |
dsmiiir dsmiv adhd | #1 |
229 families | #1 |
aff add | #1 |
subtype adhd | #1 |
psychiatric disorders adhd | #1 |
adhd youth ld | #1 |
patients adhdct | #1 |
onset adult subjects | #1 |
diagnostic continuity | #1 |
adhd stronger connectivity | #1 |
bpd hypothesis | #1 |
48basepairrepeat | #1 |
prescription stimulant adults | #1 |
adolescents concurrent adhd | #1 |
diagnoses probands | #1 |
parental polygenic risk | #1 |
potential endophenotypes adhd | #1 |
anxiousdepressed | #1 |
children adolescents cohorts | #1 |
unipolar relatives bipolars | #1 |
bipolar disorder parents | #1 |
vivo neuroreceptor imaging | #1 |
anxiety disorders baseline | #1 |
hamshere | #1 |
n6979 | #1 |
adults cadhd | #1 |
genetic sexual dimorphism | #1 |
adhd highly | #1 |
disorder meta | #1 |
population screen | #1 |
family‐based association test | #1 |
adults ldx sizes | #1 |
anterior insular lobule | #1 |
comt fsiq | #1 |
drd5 vntr | #1 |
18 items impairment | #1 |
siblings control probands | #1 |
marijuana smoking metaanalysis | #1 |
adhd desr | #1 |
nfspds | #1 |
oih fm | #1 |
risk comt gene | #1 |
bpd firstdegree relatives | #1 |
schizotypal relatives | #1 |
children motor competence | #1 |
smd higher rates | #1 |
187 children | #1 |
subcortical structure volume | #1 |
vntr haplotype | #1 |
firstdegree relatives children | #1 |
ldx expected height | #1 |
clinical interview mania | #1 |
nimh genetics initiative | #1 |
a409p | #1 |
hyperactivity databases | #1 |
nonmental diseases | #1 |
adhd outcome | #1 |
adhd candidate | #1 |
selfreport adhd | #1 |
girls learning disabilities | #1 |
marijuana cocaine crack | #1 |
stimulant nonmedical | #1 |
etiology disorder | #1 |
p758e08 | #1 |
hyperactivity disorder | #1 |
onset mania | #1 |
17yearold boys | #1 |
pdd pdd subjects | #1 |
cohorts age groups | #1 |
nmu nasal nmu | #1 |
familial subtype | #1 |
nonreferred siblings | #1 |
symptoms adult | #1 |
fm pain tolerance | #1 |
non‐random error | #1 |
non‐adhd children | #1 |
31item | #1 |
bipolar disorder bpprss | #1 |
persistence adhd | #1 |
prss adhd | #1 |
bpi relatives | #1 |
motor preference | #1 |
iiv shr | #1 |
highiq adults | #1 |
serotonin genetic | #1 |
hyperactive impulsive | #1 |
overlapping symptoms | #1 |
stable behavioral inhibition | #1 |
sud parents | #1 |
teachers cbt intervention | #1 |
dependence controls | #1 |
adhd community | #1 |
add relatives | #1 |
behaviors substances | #1 |
subthreshold adhd | #1 |
pdd mania | #1 |
adult adhd diagnosis | #1 |
molecular psychiatric genetics | #1 |
psychopathology reward dysfunction | #1 |
relatives multiplex | #1 |
postmortem brain identifies | #1 |
relszs | #1 |
p27e05 | #1 |
idir proteins siblings | #1 |
impulsive subtype | #1 |
intelligence additive effects | #1 |
disorder familial | #1 |
life adult adhd | #1 |
adhd candidate genes | #1 |
groundskeeper | #1 |
4q28 | #1 |
rs2469758–rs2461489 | #1 |
anx bpd | #1 |
familial vulnerability schizophrenia | #1 |
pdi hyperactivity | #1 |
youth informant source | #1 |
risk factors opd | #1 |
criteria age | #1 |
medications adhd | #1 |
schizophrenia european samples | #1 |
validity diagnosis | #1 |
masxr treatment | #1 |
bpi disorder relatives | #1 |
schizophrenia bipolar psychoses | #1 |
expected height weight | #1 |
noninhibited children | #1 |
african‐american pedigrees | #1 |
adhd maoa | #1 |
stimulant treatment adults | #1 |
relatives greater activation | #1 |
probands add | #1 |
adhd ads | #1 |
iiv hyperactivity behavior | #1 |
remission definition | #1 |
fsiq comt | #1 |
sexes bpi disorder | #1 |
studies adhd | #1 |
based association study | #1 |
bpd bpdsud | #1 |
motheronly | #1 |
anxious depressed subscales | #1 |
symptoms versus impairment | #1 |
teenage parents individuals | #1 |
biomarkers adhd | #1 |
dbds adhd | #1 |
greater risk add | #1 |
affective symptoms children | #1 |
fhraff | #1 |
adhd specific | #1 |
adhd community sample | #1 |
cardinal symptom mania | #1 |
disorder adhd | #1 |
adhd obesity overweight | #1 |
patterns psychiatric comorbidity | #1 |
5‐generation | #1 |
children teaes | #1 |
time reproduction children | #1 |
higher pdi | #1 |
hyperactivity biomarkers aadhd | #1 |
metabias | #1 |
adhd mdd prss | #1 |
adoption studies | #1 |
vulnerability indicators schizophrenia | #1 |
adhd module mwq | #1 |
adhd prss | #1 |
bpdsud bpd | #1 |
adhd increased | #1 |
akt1 snp markers | #1 |
suds genetic studies | #1 |
rs2449340 | #1 |
clinical response orosmph | #1 |
fidgety philipp | #1 |
adhd snps | #1 |
rs41084 | #1 |
measurement invariance study | #1 |
adhd symptoms crf | #1 |
model adult samples | #1 |
nonmental diseases adhd | #1 |
relatives children | #1 |
adhd single nucleotide | #1 |
risk adhd | #1 |
adhd psychoactive substance | #1 |
51 genes | #1 |
substance disorders relatives | #1 |
rs3776512 | #1 |
anxiety disorders findings | #1 |
treatment masxr | #1 |
120 normal controls | #1 |
norepinephrine transporter gene | #1 |
paediatric patients adhd | #1 |
adolescent sud | #1 |
stimulant treatment profiles | #1 |
bipolars unipolar relatives | #1 |
motor skills attention | #1 |
anachronisms | #1 |
subthreshold pediatric | #1 |
bpd parents | #1 |
depression adhd child | #1 |
new diagnoses age | #1 |
adhd haplotype block | #1 |
comorbid adult adhd | #1 |
falconer3 | #1 |
adhd females | #1 |
adhd france | #1 |
ainslbl | #1 |
criteria pdd | #1 |
attention deficit | #1 |
outcome adhd | #1 |
clinical features adhd | #1 |
age1542 | #1 |
mitigates stimulant | #1 |
tomoxetine adult adhd | #1 |
adhd degree relatives | #1 |
drd2 disrupts | #1 |
df39 | #1 |
–rs2272080 | #1 |
p97e−03 | #1 |
140 adhd | #1 |
drugplacebo | #1 |
intron8 | #1 |
psychiatric risk vcfs | #1 |
childhood genetic background | #1 |
tass internal consistency | #1 |
alcohol dependence relatives | #1 |
siblings antisocial families | #1 |
genetic studies adhd | #1 |
parental sud sud | #1 |
chinese outpatient sample | #1 |
rf041 | #1 |
4‐year follow‐up study | #1 |
p179e06 | #1 |
shlod | #1 |
offspring behavioral disinhibition | #1 |
qms adult adhd | #1 |
genetic association rorb | #1 |
rs6077690 | #1 |
sud remittent adhd | #1 |
cbcldesr | #1 |
rs12843268 | #1 |
probands clinical status | #1 |
treatment effects values | #1 |
comorbid oppositional | #1 |
adhd social class | #1 |
putamen volume alterations | #1 |
schizophrenia rs1076560t | #1 |
clinically diagnosed obesity | #1 |
rs9627183 | #1 |
disability asthma | #1 |
adolescent follow youth | #1 |
impulsive drive | #1 |
adhdi prenatal exposure | #1 |
adhd adhdtd | #1 |
c2orf82 | #1 |
mania pdd subjects | #1 |
schizophrenic probands1portions | #1 |
adhd followup | #1 |
learning disabilities girls | #1 |
trypotphan | #1 |
female adhd | #1 |
rs11133767 | #1 |
relatives girls | #1 |
bpd anx | #1 |
familybased studies association | #1 |
efds youth | #1 |
relatives add probands | #1 |
pediatric panic disorder | #1 |
pregnancy adhd | #1 |
nonreferred sample | #1 |
palau early | #1 |
disorder versus disability | #1 |
loci adhd | #1 |
familiar disease | #1 |
placebo cgsq | #1 |
rs2272080 | #1 |
neuroanatomic predictors | #1 |
variance oppositional symptoms | #1 |
arch ger psychiatry | #1 |
adhd gene | #1 |
rate symptoms | #1 |
increased adhd symptoms | #1 |
adhd clinical obesity | #1 |
predictors adhd | #1 |
adhd rat | #1 |
adhd genetic variants | #1 |
comt maoa interaction | #1 |
gene comt | #1 |
adults diagnosis | #1 |
nasal nmu nmu | #1 |
adhd child comorbidity | #1 |
schizotaxia negative symptoms | #1 |
adhd maternal | #1 |
rs11568324 | #1 |
adhd druggable genes | #1 |
74±77 | #1 |
impulsive symptoms | #1 |
psychopharmacologic | #1 |
desr adhd | #1 |
regions age | #1 |
fam mothers | #1 |
adhd neuropsychological impairments | #1 |
slc9a9 adhd | #1 |
psychiatric conditions adults | #1 |
adhd adolescent patients | #1 |
switches bipolar disorder | #1 |
cbclbp | #1 |
expression adhd | #1 |
alphaglx | #1 |
efficacy medications | #1 |
ptsd adhd probands | #1 |
individuals attention | #1 |
consensus statement combination | #1 |
parents md | #1 |
adhdtd siblings | #1 |
relatives alcohol dependence | #1 |
adults stimulant sizes | #1 |
snp quantitative phenotype | #1 |
prs58502974 | #1 |
bpd girls | #1 |
longitudinal analysis childhood | #1 |
relatives conduct disorder | #1 |
euphoria cardinal symptom | #1 |
pediatric bipolari disorder | #1 |
relatives control probands | #1 |
chronic emotional dysregulation | #1 |
nonreferred | #1 |
familial association adhd | #1 |
rs3746544 rs1051312 | #1 |
schizotaxia schizophrenia | #1 |
copy organization | #1 |
elevated rates adhd | #1 |
increased methylation genes | #1 |
risk tourette spectrum | #1 |
schizophrenia nonpsychotic relatives | #1 |
gene interaction comt | #1 |
rs3027400 | #1 |
bpd anx bpd | #1 |
productivity adhd | #1 |
parental probands | #1 |
fiveminutespeechsample | #1 |
adherence stimulant medication | #1 |
treating adhd | #1 |
tdt analysis | #1 |
rs1040399 | #1 |
adhd disorder | #1 |
adolescent outcome adhd | #1 |
git1 association adhd | #1 |
growth delays weight | #1 |
schizophrenia hrscz | #1 |
levels dysfunction | #1 |
adhd children bpd | #1 |
adult adhd | #1 |
adherence xr | #1 |
aklt01 tova api | #1 |
association snap25 | #1 |
2327t | #1 |
adhd adoption studies | #1 |
cortical networks attention | #1 |
aggressive symptoms risk | #1 |
stimulants comorbidity | #1 |
alcohol disorders offspring | #1 |
rf025 | #1 |
age onset criterion | #1 |
proband child | #1 |
persistent adhd adults | #1 |
daonrg1 | #1 |
cacng2 gene | #1 |
risk suds | #1 |
adolescent response inhibition | #1 |
prss psychiatric disorders | #1 |
bpd probands | #1 |
features adhd | #1 |
familial underpinnings | #1 |
paternal over‐transmission | #1 |
disorders hypothesis | #1 |
association slc6a3 | #1 |
laboratory driving simulation | #1 |
adults adhd subjects | #1 |
dysfunctional gene | #1 |
hyperactivity case | #1 |
executive functioning adults | #1 |
bpi disorder youth | #1 |
late onset adhd | #1 |
scales risk | #1 |
ldx adult adhd | #1 |
caregiver strain cgsq | #1 |
increasing resource demand | #1 |
treatment sud patients | #2 |
n2246 | #2 |
dsm subtypes | #2 |
efds adults | #2 |
treatment childhood adhd | #2 |
morbidity dysfunction | #2 |
5 loci adhd | #2 |
parental anxiety disorders | #2 |
masxr | #2 |
adhd neuropsychological tests | #2 |
risk female cases | #2 |
deficit hyperactivity disorder | #2 |
disorder inattentive | #2 |
p161e05 | #2 |
concurrent attention | #2 |
developmental subtype | #2 |
disorder conclusions | #2 |
deficit sustained attention | #2 |
disorder add | #2 |
chromosomes inclusion | #2 |
assessed structured | #2 |
bpd sud | #2 |
consecutively referred children | #2 |
adhd objective | #2 |
d2s410 | #2 |
schizotypy handedness | #2 |
rates odd | #2 |
comorbid conduct problems | #2 |
emf impairments | #2 |
patterns comorbidity | #2 |
adults attention | #2 |
levels comorbidity | #2 |
psychiatric comorbidity | #2 |
juvenile antisocial | #2 |
disorder adolescent | #2 |
qualitative literature review | #2 |
hypothalamic abnormalities | #2 |
hrscz | #2 |
adhd relatives | #2 |
female probands | #2 |
disorders adhd | #2 |
relatives add | #2 |
adhd comparison subjects | #2 |
genome‐wide association data | #2 |
enigma adhd | #2 |
comparison probands | #2 |
initial stimulant | #2 |
adhd adhd children | #2 |
subthreshold diagnoses | #2 |
manic children | #2 |
consecutively referred | #2 |
neuroleptic dose reduction | #2 |
n2455 | #2 |
eye vergence responses | #2 |
adhdonly | #2 |
s038 | #2 |
girls adhd | #2 |
ldsc heritability | #2 |
method subjects | #2 |
adhd subjects | #2 |
status rating scales | #2 |
aklt01 | #2 |
disorder children | #2 |
disorder findings | #2 |
rs6938431 | #2 |
subsequent substance | #2 |
comorbid conduct | #2 |
euphorigenic effects | #2 |
wky ncrl | #2 |
adhd families | #2 |
hyperactivity impulsiveness | #2 |
aggressive symptoms | #2 |
association meta analysis | #2 |
investigator ratings | #2 |
bidirectional overlap | #2 |
disorders similarities | #2 |
schizophrenia pedigrees | #2 |
adhd choice | #2 |
mood disorders adhd | #2 |
schizotaxia discussion | #2 |
adhd growth | #2 |
comorbidity attention | #2 |
deficits sustained attention | #2 |
wwwhapmaporg | #2 |
methylphenidate attention | #2 |
small literature | #2 |
cbcljbd children | #2 |
stimulants adhd | #2 |
ncrl wky | #2 |
deficits efds | #2 |
screening diagnosis treatment | #2 |
ncrl | #2 |
adhd comorbid problems | #2 |
childhood adolescent adhd | #2 |
≥210 | #2 |
somatosensory functioning | #2 |
desr children | #2 |
drug abuse dependence | #2 |
odd girls | #2 |
systematized delusions | #2 |
adhd impact | #2 |
wiatii | #2 |
executive function outcome | #2 |
child comorbidity | #2 |
scale asrs | #2 |
disorder impact | #2 |
allele schizophrenia | #2 |
youth meaningful | #2 |
lgi regions | #2 |
studies adderall | #2 |
parent rating | #2 |
life social adjustment | #2 |
stimulant therapy | #2 |
quetiapine monotherapy treatment | #2 |
comorbidity adhd | #2 |
cnvs copy variants | #2 |
adhd comparison | #2 |
naltrexone adults | #2 |
disorder studies | #2 |
clinically referred children | #2 |
association data | #2 |
items screener | #2 |
rs3746544 | #2 |
unipolar relatives | #2 |
separation attention deficit | #2 |
personal satisfaction | #2 |
age onset distribution | #2 |
schizophrenia parahippocampal gyrus | #2 |
key cognitive phenotypes | #2 |
male psychiatric | #2 |
stimulants | #2 |
parents disorder | #2 |
mirsky | #2 |
evidence adhd | #2 |
efficacy stimulants | #2 |
blind raters | #2 |
adhd physical conditions | #2 |
structure adult adhd | #2 |
deficits adults | #2 |
familial risk analysis | #2 |
default network schizophrenia | #2 |
performancemeasures | #2 |
control subjects adhd | #2 |
trauma adhd | #2 |
risk panic disorder | #2 |
adra2a polymorphism | #2 |
models adhd | #2 |
adhd lower | #2 |
ermph children | #2 |
adhd conduct | #2 |
adhd report | #2 |
probands relatives | #2 |
adhdliability | #2 |
multicenter adhd | #2 |
variants adhd | #2 |
conners adult adhd | #2 |
bipolar disorder relatives | #2 |
viloxazine extendedrelease | #2 |
rs40184 | #2 |
psychotic relatives | #2 |
maoa comt | #2 |
work needed | #2 |
shared genetic background | #2 |
n1934 | #2 |
health organization asrs | #2 |
comorbid aggression | #2 |
proinflammatory expansion | #2 |
affective probands | #2 |
molecular genetics schizophrenia | #2 |
enigma adventure | #2 |
efds | #2 |
probands | #2 |
combinedtype | #2 |
cbsk | #2 |
familial adhd | #2 |
role adhd | #2 |
immune disorder | #2 |
clinically referred | #2 |
factors attention | #2 |
psychiatrically | #2 |
bmi adhd symptoms | #2 |
adhd neuropsychological deficits | #2 |
subjects conduct disorder | #2 |
adhd control subjects | #2 |
expanded versions | #2 |
adhd combined | #2 |
wm deficits | #2 |
adhd bpd | #2 |
antisocial disorders relatives | #2 |
relatives adhd | #2 |
schizophrenia calcineurin | #2 |
cpt oih | #2 |
weaknesses youth | #2 |
referred youth | #2 |
maternal smoking mothers | #2 |
actively reducing severity | #2 |
scales adolescent | #2 |
scales sex | #2 |
adhd genes | #2 |
comorbid oppositional defiant | #2 |
adhd combined subtype | #2 |
18 dsm | #2 |
nonpsychotic relatives | #2 |
pediatrically | #2 |
schizophrenia twin studies | #2 |
polygenic resilience score | #2 |
adhd case subjects | #2 |
n‐acetylcysteine treatment | #2 |
relatives simplex families | #2 |
infancy complications | #2 |
subsyndromal manifestations | #2 |
adhd icv | #2 |
underlying bipolarity | #2 |
actively reducing | #2 |
neuropsychoanalytic treatment | #2 |
subjects criteria | #2 |
multigenic inheritance | #2 |
acpts | #2 |
dysfunction offspring | #2 |
methodological complexities | #2 |
adhd genetics | #2 |
adverse effects subjects | #2 |
familybased studies | #2 |
problems adhd | #2 |
childhoodonset adhd | #2 |
twin studies adhd | #2 |
checklist scales | #2 |
hyperactivity diagnostic | #2 |
6 17 years | #2 |
n11221 | #2 |
adult samples | #2 |
oral prescription | #2 |
dsmiv adhd | #2 |
versus controls | #2 |
diabetes disorders | #2 |
cbcl profile | #2 |
structured diagnostic | #2 |
adhd ldx | #2 |
conjfdr005 | #2 |
rs1800955 | #2 |
6p243 | #2 |
adolescents substance disorder | #2 |
preventing schizophrenia | #2 |
symptoms neuropsychological | #2 |
variance adult | #2 |
adhd surface area | #2 |
spectrum phenotypes | #2 |
strong heritability | #2 |
pdd overlap | #2 |
hyperactivity attention deficit | #2 |
specific haplotype | #2 |
manic switches | #2 |
adhd risk icv | #2 |
hypothetical task | #2 |
stimulants adults | #2 |
chromosomes 6 14 | #2 |
disorder background | #2 |
attention‐deficit hyperactivity | #2 |
familial trait | #2 |
selfmedicating | #2 |
disorders findings | #2 |
rs1801028 | #2 |
adhd african americans | #2 |
risk add | #2 |
risk factor adhd | #2 |
ppv hyperactivity diagnostic | #2 |
cbcl clinical | #2 |
deficits executive | #2 |
adhd disability | #2 |
adhd suds | #2 |
sud bpd | #2 |
bipolar disorder sud | #2 |
checklist clinical | #2 |
parents major depression | #2 |
millennium consortium | #2 |
adhd outcomes | #2 |
cigarette smoking suds | #2 |
adhd risk factor | #2 |
adhd major | #2 |
sex differences adhd | #2 |
major depression findings | #2 |
rates adhd | #2 |
subjects adults | #2 |
internal distractibility | #2 |
hantac | #2 |
regions studies | #2 |
activation trigger | #2 |
cacng2 genes | #2 |
diagnosis attention | #2 |
adhd odd | #2 |
addicted | #2 |
alleles attention | #2 |
adhd bipolar | #2 |
d10s1432 | #2 |
large controlled | #2 |
disease humans receptors | #2 |
genome‐wide association scan | #2 |
7point | #2 |
young adult years | #2 |
disorder oppositional | #2 |
youth attention | #2 |
n328917 | #2 |
case subjects adhd | #2 |
comorbidity disorders comorbidity | #2 |
subjects desr | #2 |
snp12snp2ctgn | #2 |
adhd birth | #2 |
bpd adhd | #2 |
adhd risk gene | #2 |
ratio081 | #2 |
juvenile bipolar phenotype | #2 |
adhd autism symptoms | #2 |
2q143 | #2 |
ldsc genetic correlations | #2 |
child comorbidity illness | #2 |
genetic transmission | #2 |
g72 daao | #2 |
testretest reliability screener | #2 |
bsfq | #2 |
lallele homozygotes | #2 |
prior reports | #2 |
stress adhd | #2 |
psychotic mood disorder | #2 |
adhd mph response | #2 |
current adult adhd | #2 |
617 years | #2 |
effects paternal smoking | #2 |
relatives | #2 |
bias child child | #2 |
derived phenotypes | #2 |
families schizophrenia patients | #2 |
140 girls | #2 |
disorder girls | #2 |
amses | #2 |
candidate genetic pathways | #2 |
relatives schizophrenic | #2 |
function deficits | #2 |
stin2vntr | #2 |
jackknife procedure | #2 |
cbcl desr | #2 |
suggestive linkage loci | #2 |
dimesylate treatment | #2 |
consortium neuroscience | #2 |
reward‐related activation | #2 |
neuropsychological function girls | #2 |
informant source | #2 |
adhd major depression | #2 |
disorders suds | #2 |
elusive indicators | #2 |
adhd lifespan | #2 |
pilot adult | #2 |
adhd height | #2 |
factors adhd | #2 |
adhdprss | #2 |
adhd method | #2 |
dsmjbd | #2 |
adhd adults | #2 |
familial association | #2 |
n3199 | #2 |
unweighted screener asrs | #2 |
cognition youth | #2 |
expert clinician | #2 |
qualitative review | #2 |
adhd psychiatric disorders | #2 |
youth rates | #2 |
comorbid conduct disorder | #2 |
correlates adhd | #2 |
child behavioral inhibition | #2 |
psychoactive substance disorders | #2 |
disorder adults | #2 |
association mtbi | #2 |
target features | #2 |
adults adhd | #2 |
siblings youth | #2 |
adhd emotional symptoms | #2 |
findings children | #2 |
adherence stimulants | #2 |
disease humans inhibition | #2 |
galantamine hbr placebo | #2 |
eye vergence | #2 |
adhd acc | #2 |
morning behavior | #2 |
wky nhsd | #2 |
n17666 | #2 |
antisocial disorders | #2 |
background attention | #2 |
schizophrenia genetic studies | #2 |
adhd assessed | #2 |
comparative profile analysis | #2 |
hypothesis adhd | #2 |
qtl linkage adhd | #2 |
idiopathic adhd | #2 |
persistent attention | #2 |
anx bipolar disorder | #2 |
10092 | #2 |
dsm adhd | #2 |
dsmiv subtypes | #2 |
adhd adhd patients | #2 |
bipolar disorder symptomatology | #2 |
attentional control effects | #2 |
hyperactivity female humans | #2 |
modest evidence | #2 |
postcleavage | #2 |
iii attention | #2 |
derived diagnosis | #2 |
comorbidity probands | #2 |
nicotine substance | #2 |
heterogeneity schizophrenia | #2 |
galantamine hbr | #2 |
boys maoa | #2 |
schizophrenia interactions | #2 |
serum neuroleptic activity | #2 |
6 17 | #2 |
age onset distributions | #2 |
support genetic factors | #2 |
6‐year longitudinal study | #2 |
expanded symptom criteria | #2 |
dsmiiir adhd | #2 |
overlap mania | #2 |
rates bpd | #2 |
youth selfreports | #2 |
scz data | #2 |
opioid induced hyperalgesia | #2 |
comorbidity disorder | #2 |
tourette spectrum | #2 |
add probands | #2 |
d0·18 | #2 |
structured diagnostic interviews | #2 |
iii adhd | #2 |
asrs health organization | #2 |
n2271 | #3 |
children adhd | #3 |
snps haplotype | #3 |
caarsss | #3 |
sud youths | #3 |
7 repeat | #3 |
rs6565113 | #3 |
variance severity | #3 |
response methylphenidate | #3 |
pdd adhd | #3 |
adhd presence | #3 |
chromosome 10q22 | #3 |
ermph | #3 |
adhd mtbi | #3 |
adhd bipolar disorder | #3 |
predisposition schizophrenia | #3 |
enigma neuroimaging genetics | #3 |
sud children | #3 |
tic disorders adhd | #3 |
abstraction verbal memory | #3 |
simulated workplace laboratory | #3 |
md adhd | #3 |
risk factors sud | #3 |
disorder comorbid | #3 |
studies square | #3 |
deficient emotional | #3 |
drug nicotine | #3 |
pairwise correlations disorders | #3 |
familial nature | #3 |
disease humans interviews | #3 |
n1777 | #3 |
subjects sud | #3 |
methylphenidate studies | #3 |
sirolimus 12 months | #3 |
impulsivity errors | #3 |
nicotine disorders | #3 |
european‐american | #3 |
lambdasib | #3 |
structural imaging findings | #3 |
dat1 | #3 |
md females | #3 |
observed age | #3 |
disproportionate impairment | #3 |
lbw adhd | #3 |
adhd comorbid conditions | #3 |
zakzanis | #3 |
drd5 marker | #3 |
sibling trait | #3 |
comorbidity panic disorder | #3 |
adhd psychiatric comorbidity | #3 |
508e7 | #3 |
cpt deficits | #3 |
schizophrenia neurocognitive performance | #3 |
ocd groups asd | #3 |
schizophrenic outpatients | #3 |
ptsd adhd | #3 |
notch4 schizophrenia | #3 |
relatives bipolar disorder | #3 |
smoking probands | #3 |
sud offspring | #3 |
z280 | #3 |
schizophrenia schizotaxia | #3 |
adhd implications | #3 |
smds scz | #3 |
potential gene | #3 |
adhd common | #3 |
vcfsadhd | #3 |
large battery | #3 |
teacher reports | #3 |
adhd systematic review | #3 |
adhd mdd | #3 |
bpd rates | #3 |
girls attention | #3 |
tsuang | #3 |
comt promoter | #3 |
common disorders brain | #3 |
9rcarriers | #3 |
genetic receptors serotonin | #3 |
n5827 | #3 |
model adhd | #3 |
adhd control | #3 |
adhd polygenic | #3 |
anxiety disorders authors | #3 |
siblings young | #3 |
deficits height | #3 |
checklist cbcl | #3 |
neuropsychiatric disorders similarities | #3 |
alcohol adhd | #3 |
adolescent adhd | #3 |
brain methylation | #3 |
adult psychiatric outcomes | #3 |
childhood attention‐deficit | #3 |
hyperactivity central | #3 |
weight effects | #3 |
schizotaxia | #3 |
longitudinal follow | #3 |
major depression comorbidity | #3 |
remittent | #3 |
enuresis adhd | #3 |
highly heritable disorder | #3 |
bipolar disease | #3 |
adhd rare cnvs | #3 |
schizoaffective bipolar disorder | #3 |
global neuroscience decade | #3 |
controls 6 disorders | #3 |
drd4 7 | #3 |
neurological polymorphism | #3 |
sexdifferentiated effects | #3 |
nmu prescription stimulants | #3 |
13q222 | #3 |
desr | #3 |
children vcfsadhd | #3 |
learning disabilities adhd | #3 |
evidence genetic association | #3 |
comt adhd | #3 |
adhd data | #3 |
excess transmission | #3 |
prenatal adversities | #3 |
emotional dysregulation adhd | #3 |
morbidity risk | #3 |
adhd combined type | #3 |
nonpsychotic relatives persons | #3 |
dmi addh | #3 |
hyperactivity bipolar | #3 |
adolescents mania | #3 |
hyperactivity attention | #3 |
parents panic | #3 |
conduct disorder adhd | #3 |
association confounders | #3 |
relatives proband groups | #3 |
asd ocd groups | #3 |
control probands relatives | #3 |
gsprs | #3 |
metadoxine extended release | #3 |
psychiatric comorbidity adhd | #3 |
educational deficits | #3 |
adhd mania | #3 |
mania disorders | #3 |
dose response effects | #3 |
mania children | #3 |
adhd emotional | #3 |
clinically referred adults | #3 |
schizophrenia allele | #3 |
manic symptoms children | #3 |
67e07 | #3 |
topic adolescent | #3 |
ldx amphetamine | #3 |
comorbidity diagnosis | #3 |
naltrexone methylphenidate | #3 |
mtbi studies | #3 |
dsmiiir diagnosis | #3 |
cgsq | #3 |
inattentive subtype | #3 |
amphetamines attention | #3 |
children mania | #3 |
syndromatic | #3 |
adhdpi | #3 |
adhd ptsd | #3 |
disorder conduct | #3 |
genetics initiative | #3 |
adhd psud | #3 |
bipolar psychoses | #3 |
cbcl scales | #3 |
cognition comorbidity | #3 |
asthma adhd | #3 |
youths ocd | #3 |
impact adhd | #3 |
adhd stimulant medication | #3 |
impairment adhd | #3 |
enigma wgs wgs | #3 |
adhd risk | #3 |
firstdegree relatives | #3 |
children adhd diagnosis | #3 |
anxiety disorders parents | #3 |
htr1e | #3 |
oprm1 variants | #3 |
adhd metaanalysis | #3 |
defined adhd | #3 |
similarities genetic etiology | #3 |
cortical thickness cases | #3 |
networks adhd | #3 |
qtl linkage | #3 |
n2323 | #3 |
enigma global neuroscience | #3 |
disabilities male | #3 |
npl scores | #3 |
interactions schizophrenia | #3 |
social perception skills | #3 |
wonderlic personnel test | #3 |
intra‐individual variability | #3 |
psychotic behaviour | #3 |
substances symptoms | #3 |
atomoxetine response | #3 |
persistence psychiatric disorders | #3 |
experienced pain | #3 |
asrs v11 | #3 |
psychopathologic conditions | #3 |
intron13 | #3 |
cigarette smoking children | #3 |
7repeat allele | #3 |
adhd wm deficits | #3 |
morning school | #3 |
manic symptoms youth | #3 |
non500 | #3 |
growth deficits | #3 |
anxiety behavioral inhibition | #3 |
vulnerability indicators | #3 |
familial risk factors | #3 |
relatives persons | #3 |
schizophrenia genotype | #3 |
adhd mental disorders | #3 |
substance disorders adhd | #3 |
comorbidities adhd | #3 |
risk panic | #3 |
“negativity | #3 |
faraone reply | #3 |
parental substance disorders | #3 |
international adhd | #3 |
27 risk loci | #3 |
temperamental correlates | #3 |
petronis | #3 |
adhd pairwise correlations | #3 |
disorders conclusions | #3 |
nervous stimulants | #3 |
resilience score | #3 |
candidate gene studies | #3 |
reln promoter | #3 |
relationship adhd | #3 |
probands parental | #3 |
stimulants treatment | #3 |
parents panic disorder | #3 |
risk factors bpd | #4 |
disorders panic | #4 |
nonoral routes administration | #4 |
sud bpd sud | #4 |
adhd participants | #4 |
handedness schizotypy | #4 |
rutters indicators | #4 |
adhd youth | #4 |
acting formulations | #4 |
subjects schizotaxia | #4 |
treatment stimulant medication | #4 |
vulnerability schizophrenia | #4 |
suds adolescents | #4 |
vcfs adhd | #4 |
adhd md | #4 |
gxr adhd | #4 |
impaired intellect | #4 |
reported adhd | #4 |
snps intelligence | #4 |
poor motor performance | #4 |
female probands relatives | #4 |
psychiatrically referred | #4 |
schizophrenia genetic factors | #4 |
onset adhd | #4 |
intelligence snps | #4 |
openlabel studies | #4 |
comorbid psychiatric | #4 |
height deficits | #4 |
developmental improvement | #4 |
rs140700 | #4 |
deficits executive functioning | #4 |
substance disorders suds | #4 |
executive function deficits | #4 |
offspring sud | #4 |
psychiatric gene discoveries | #4 |
panic disorder pregnancy | #4 |
psychiatric comorbidity risk | #4 |
total score week | #4 |
cbcljbd phenotype | #4 |
homogeneous subtypes | #4 |
objective studies | #4 |
disorders neuropsychological | #4 |
adhd based | #4 |
treatment adhd | #4 |
rs3916971 | #4 |
adhd children mph | #4 |
risk variants adhd | #4 |
adhd controls | #4 |
reward dysfunction | #4 |
pediatric mania | #4 |
adolescent outcome | #4 |
cbclaps | #4 |
pavgrnk000417 | #4 |
safren | #4 |
fmri replication | #4 |
treatment adult adhd | #4 |
comorbidity humans | #4 |
bpd sud patients | #4 |
jbd | #4 |
notch4 locus | #4 |
inhibition anxiety | #4 |
distinct disorder | #4 |
adhd impairments | #4 |
differences adults | #4 |
genetic heterogeneity schizophrenia | #4 |
aggregation adhd | #4 |
rels | #4 |
metaanalyzes | #4 |
adhd association | #4 |
adults | #4 |
children comorbid adhd | #4 |
increased neural responses | #4 |
risk factors adhd | #4 |
17q111q12 | #4 |
remittent adhd | #4 |
mhlod | #4 |
selenbp1 schizophrenia | #4 |
d4s1644 | #4 |
psud | #4 |
adhd pharmacogenetic studies | #4 |
adhd adulthood | #4 |
child behavior checklist | #4 |
global neuroscience | #4 |
stimulantnaïve | #4 |
bipolar disorder linkage | #4 |
families girls | #4 |
receiver operator characteristic | #4 |
independent transmission | #4 |
psychiatrically referred youth | #4 |
adhd subgroups | #4 |
46222 | #4 |
secondary psychotic symptoms | #4 |
sd133 | #4 |
rs3916968 | #4 |
expected height | #4 |
subthreshold | #4 |
4year followup | #4 |
subsequent substance disorders | #4 |
rutter | #4 |
chinese sample | #4 |
bpd sud bpd | #4 |
adhd substance abuse | #4 |
adhd status | #4 |
factors substance | #4 |
quantitative models | #4 |
rates psychiatric | #4 |
strattera | #4 |
neuropsychological performance schizophrenia | #4 |
inattentive adhd | #4 |
maoa | #4 |
risk gene schizophrenia | #4 |
adhd control children | #4 |
adderall methylphenidate | #4 |
adhd reported | #4 |
asd mood disorders | #4 |
motor coordination problems | #4 |
depression parental depression | #4 |
md individuals | #4 |
comorbid attention | #4 |
adolescent years | #4 |
snpbased | #4 |
d4s2361 | #4 |
report scale | #4 |
roh risk | #4 |
4th international meeting | #4 |
adhd brain regions | #4 |
presence adhd | #4 |
adhd individuals | #4 |
primary substance abuse | #4 |
disorder objective | #4 |
image sample | #4 |
achievement goal orientation | #4 |
familial vulnerability | #4 |
odd adhd | #4 |
rate switching | #4 |
adhd pharmacotherapy | #4 |
enigmaadhd | #4 |
behavior checklist | #4 |
shr ncrl | #4 |
transporter genotypes | #4 |
vcfs sample | #4 |
enrichment adhd | #4 |
mts growth | #4 |
health female | #4 |
adhd neuropsychological performance | #4 |
attention adhd | #4 |
psc35 | #4 |
functioning adhd | #4 |
metadoxine placebo | #4 |
humans lisdexamfetamine | #4 |
rs1079727 | #4 |
adhd pdd | #4 |
comorbid aggression adhd | #4 |
disorders attention | #4 |
support mechanism | #4 |
controls basal ganglia | #4 |
pord05 | #4 |
relatives normal controls | #4 |
lgi age | #4 |
addictive drug | #4 |
preterm sample | #4 |
coordination problems | #4 |
rs3785143 | #4 |
boys higher prevalence | #4 |
relatives controls | #4 |
anxiety disorders mdd | #4 |
disorders comorbidity | #4 |
hypescheme | #4 |
reported findings | #4 |
cbcl | #4 |
parents bpd | #4 |
maternal smoking alcohol | #4 |
findings risk | #4 |
quantitative phenotype | #4 |
angerirritability | #4 |
tests psychiatric | #4 |
treatment seeking patients | #4 |
disease genome humans | #4 |
anxiety disorders offspring | #4 |
time reproduction | #4 |
neuropsychoanalytic | #4 |
gender children | #4 |
choice adhd | #4 |
phenotypes adhd | #4 |
adhd symptom | #4 |
parental panic | #4 |
lifetime dimensions | #4 |
adhd etiology | #4 |
hemmings | #4 |
growing literature | #4 |
scores adhd | #4 |
familial distribution | #5 |
ppp3cc schizophrenia | #5 |
behavioral inhibition children | #5 |
diagnosis mania | #5 |
adhd adult | #5 |
risk anxiety | #5 |
adhd inattentive type | #5 |
report screening | #5 |
genetic linkage schizophrenia | #5 |
2nd cohort | #5 |
pdmd | #5 |
d22s683 | #5 |
conventional medications | #5 |
checklist child | #5 |
wcst scores | #5 |
cardinal symptom | #5 |
lifetime impact | #5 |
tass | #5 |
psychosis scale | #5 |
adolescence adhd | #5 |
parental adhd | #5 |
shared haplotypes | #5 |
3q13 | #5 |
disorders psychiatric | #5 |
adults adult | #5 |
comorbid disorders | #5 |
major depression parents | #5 |
interview psychological | #5 |
height weight | #5 |
resilience project | #5 |
parental sud | #5 |
dsm age | #5 |
ncrl rats | #5 |
adhd response | #5 |
combined subtype | #5 |
zmynd17 | #5 |
youth vcfs | #5 |
adhd comorbid anxiety | #5 |
dopamine risk | #5 |
desistent | #5 |
psychiatric correlates | #5 |
clinical obesity | #5 |
neuropsychiatric comorbidity | #5 |
social disability | #5 |
grubb | #5 |
serum neuroleptic | #5 |
nonmedical nmu | #5 |
bipolar disorder bpd | #5 |
humans interview | #5 |
organization adult | #5 |
boys attention | #5 |
cbcl data | #5 |
large collaborative study | #5 |
symptoms hyperactivity | #5 |
inhibited children | #5 |
risk factors schizophrenia | #5 |
disorder rating | #5 |
psychiatric disorders study | #5 |
adult attention | #5 |
adhd tic disorders | #5 |
impairment baseline | #5 |
panic disorder parents | #5 |
female individuals | #5 |
referred children | #5 |
torture review | #5 |
disorder anxiety | #5 |
etiopathologies | #5 |
kuntsi | #5 |
relatives female probands | #5 |
prembr | #5 |
sex adhd | #5 |
mothers anxiety disorders | #5 |
adolescent alleles | #5 |
parents psychiatric | #5 |
children dbds | #5 |
iiv adhd | #5 |
highly heritable | #5 |
impairment survey | #5 |
intellectually capable adults | #5 |
bipolar disorder pedigrees | #5 |
impaired parents humans | #5 |
sud | #5 |
adult probands | #5 |
initial responsiveness | #5 |
methylphenidate adults | #5 |
desipramine placebo | #5 |
asrs screener | #5 |
oppositional defiant disorder | #5 |
schizophrenia palau | #5 |
proband risk | #5 |
adhd nonaffected siblings | #5 |
adhd treated | #5 |
adhd ld | #5 |
referred sample | #5 |
neuropsychological risk | #5 |
children ldx | #5 |
maternal reports | #5 |
adhd youths | #5 |
palauan | #5 |
psychosis velocardiofacial syndrome | #5 |
hechtman | #5 |
adhdlike symptoms | #5 |
multivariate endophenotypes | #5 |
ascertainment source | #5 |
familial risk adhd | #5 |
disorders follow | #5 |
memantine hydrochloride | #5 |
pathways association | #5 |
growth dysregulation | #5 |
function adhd | #5 |
referred youths | #5 |
aagc | #5 |
hyperactivity clinical trials | #5 |
adhd bupropion | #5 |
severe scores | #5 |
elevated rates | #5 |
adhd cases | #5 |
hyperactivity caregivers | #5 |
auditory vigilance | #5 |
criteria schizotaxia | #5 |
effects adhd | #5 |
disorder sud | #5 |
anxiety disorders anx | #5 |
pleiotropic effects disorders | #5 |
year prospective | #5 |
disorder parents | #5 |
3 probands | #5 |
familial subtypes | #5 |
rs1799836 | #5 |
unipolar mdd | #5 |
study genetic factors | #5 |
mood disorders asd | #5 |
nonaffected siblings | #5 |
depression panic disorder | #5 |
xr adults | #5 |
inattentive symptoms | #5 |
oosterlaan | #5 |
risk relatives | #5 |
kiddieschedule | #5 |
puwma | #5 |
disorder genetic | #5 |
screener | #5 |
mania adhd | #5 |
child child behavior | #5 |
sms intervention | #5 |
nt5dc1 | #5 |
pdd subjects | #5 |
scale adhd | #5 |
onset criterion | #5 |
disorders relatives | #6 |
familial loadings | #6 |
psychiatric | #6 |
bpdsud | #6 |
schizophrenic probands | #6 |
adhd firstdegree relatives | #6 |
combined subtypes | #6 |
gxr efficacy | #6 |
depression panic | #6 |
premorbid cognitive ability | #6 |
benefitrisk ratio | #6 |
adhd women | #6 |
literature efficacy | #6 |
hierarchical factor model | #6 |
adhd mood disorders | #6 |
differences cortical thickness | #6 |
neuropsychological functioning | #6 |
interpreting estimates | #6 |
value09 | #6 |
bpd comorbid | #6 |
children relatives | #6 |
paternal age schizophrenia | #6 |
adhd compared | #6 |
environmental adversity | #6 |
psychiatric disorders prss | #6 |
unfamiliar situations | #6 |
symptoms adhd | #6 |
adhd variability | #6 |
facial memory | #6 |
cbcljbd | #6 |
nhe inhibitors | #6 |
t518 | #6 |
xp114p113 | #6 |
clinical features children | #6 |
association studies schizophrenia | #6 |
psychopathology children | #6 |
risk sud | #6 |
t515 | #6 |
symptoms disorder | #6 |
taan | #6 |
seidman | #6 |
pediatric mood disorders | #6 |
schizophrenia g72 | #6 |
ppp3cb | #6 |
cognitive impairments adhd | #6 |
objective marker | #6 |
disorder combined | #6 |
adhd tic | #6 |
cpg sites methylation | #6 |
scales psychometrics | #6 |
year recall | #6 |
groups adults | #6 |
referred children adolescents | #6 |
schizophrenia deficit | #6 |
pavgrnk | #6 |
referred adults | #6 |
parental major depression | #6 |
behavioral inhibition | #6 |
druggable genome | #6 |
loci autism | #6 |
140 children | #6 |
liability schizophrenia | #6 |
child delayed | #6 |
niacin schizophrenia | #6 |
females adhd | #6 |
life adults | #6 |
large heterogeneous | #6 |
ascertained | #6 |
irmph | #6 |
adhd mental retardation | #6 |
dsm iii | #6 |
relatives probands | #6 |
total gray matter | #6 |
criteria adhd | #6 |
neuroleptic activity | #6 |
male odds | #6 |
clinical scales | #6 |
schizophrenia premorbid | #6 |
downward extension | #6 |
pediatric bpd | #6 |
concurrent validation | #6 |
prior stimulant treatment | #6 |
maniclike symptoms | #6 |
teenage parenthood | #6 |
adhd children adults | #6 |
adults disorder | #6 |
genetic child | #6 |
oppositional defiant | #6 |
vulnerability indicator | #6 |
prevalence adult adhd | #6 |
nonparanoid schizophrenia | #6 |
psychoactive substance | #6 |
schizophrenia spectrum schizophrenia | #6 |
risk attention | #6 |
adhd increased risk | #6 |
pseudocontrols | #6 |
enigma wgs | #6 |
genetic linkage genome | #6 |
hyperactivity disease models | #6 |
adhdia | #6 |
combined condition | #6 |
mixed amphetamine | #6 |
placebo response response | #6 |
driving simulation | #6 |
normal sexual dimorphism | #6 |
genome‐wide | #6 |
dopamine transporter gene | #6 |
specific predictor | #6 |
males adhd | #6 |
individual alleles | #6 |
p1e04 | #6 |
4634 | #6 |
tmcq | #6 |
dnajc9 | #6 |
cognition adults | #6 |
chromosome 15 locus | #6 |
followup studies | #6 |
anxiety disorder relatives | #6 |
hyperactivity child chromosomes | #6 |
stimulant prescription | #6 |
adhd genetic factors | #6 |
stimulant treatment children | #6 |
fspd | #6 |
oceanic palau | #6 |
wm performance patients | #6 |
adhd life | #6 |
disorders adolescent | #6 |
altered neural connectivity | #6 |
pediatric bipolar | #6 |
parents major | #6 |
nmu | #6 |
bpd controls | #6 |
odd | #7 |
locus haplotypes | #7 |
qlesqsf | #7 |
dimensional measures | #7 |
spn812 | #7 |
adhd boys girls | #7 |
methylomics | #7 |
adhd criteria | #7 |
adhd symptoms association | #7 |
sensorimotor timing | #7 |
velo‐cardio‐facial | #7 |
relatives risk | #7 |
pdag mdd | #7 |
studies dopamine | #7 |
candidate gene schizophrenia | #7 |
nalysis | #7 |
hraff | #7 |
idir | #7 |
saica | #7 |
bipolar unipolar disorders | #7 |
adhdct | #7 |
parents psychiatric disorders | #7 |
teachers boys | #7 |
children learning disorders | #7 |
childhood disorder | #7 |
conduct disorder girls | #7 |
exome chip analyses | #7 |
n1031 | #7 |
adhdrs | #7 |
mdd pdag | #7 |
pdqr | #7 |
dependence rates | #7 |
palauans | #7 |
children bpd | #7 |
nrp104 | #7 |
coming years | #7 |
combined type adhd | #7 |
authors goal | #7 |
confusability | #7 |
wonderlic | #7 |
measures adhd | #7 |
statistical measure | #7 |
adhd emotional dysregulation | #7 |
myosin5b | #7 |
controls probands | #7 |
members schizophrenia | #7 |
prevention schizophrenia | #7 |
adhd persistence | #7 |
exon15 | #7 |
pediatric major depression | #7 |
disorder substance | #7 |
swedish registry data | #7 |
snap25 adhd | #7 |
genome‐wide association | #7 |
adhd sud sud | #7 |
systematic chart review | #7 |
parent reports | #7 |
attention task | #7 |
asd youth | #7 |
adhd symptoms | #7 |
development adhd | #7 |
neurocognitive performances | #7 |
parents prevalence | #7 |
boys adhd | #7 |
tomoxetine | #7 |
persistence anxiety disorders | #7 |
highrisk siblings | #7 |
haplotype schizophrenia | #7 |
long repeats | #7 |
association cdh13 | #7 |
relatives schizophrenic patients | #7 |
neuroimage study | #7 |
adhd asrs | #7 |
drd5 | #7 |
adhd authors | #7 |
children tourettes syndrome | #7 |
seeking substance | #7 |
kgas | #7 |
ancestry attention | #7 |
child impaired | #7 |
disorders probands | #7 |
skin flush response | #7 |
methylphenidate therapy | #7 |
adhd improvement | #7 |
asd asd youth | #7 |
outpatient child | #7 |
implicating | #7 |
ldx treatment | #7 |
hyperactivity brain | #7 |
6 psychiatric disorders | #7 |
polygenic scores adhd | #7 |
pmee | #7 |
adhd substance disorders | #7 |
mph adhd | #7 |
markov chain analysis | #7 |
flush response | #7 |
chromosome workshop | #7 |
nmu prescription | #7 |
adhd overweight obesity | #7 |
mph adhd adults | #7 |
pempirical | #8 |
unaffected siblings adhd | #8 |
abbreviated questionnaire | #8 |
male multifactorial inheritance | #8 |
n1314 | #8 |
behavioral inhibition risk | #8 |
familybased association study | #8 |
treatment lead | #8 |
symptoms behaviors | #8 |
volumetric reductions | #8 |
control adhd | #8 |
prescription stimulant | #8 |
pvalues005 | #8 |
schizophrenia members | #8 |
disorders families | #8 |
schizophrenia polymorphisms | #8 |
subjects children | #8 |
adhd adolescence | #8 |
stimulanttreated | #8 |
impaired motor performance | #8 |
offspring trios | #8 |
participants adhd | #8 |
pliszka | #8 |
familial aggregation adhd | #8 |
promising directions | #8 |
disorder probands | #8 |
rs3916966 | #8 |
negative symptoms scale | #8 |
impulsivity adhd | #8 |
multigenerational pedigree | #8 |
human aggression | #8 |
studies provide | #8 |
mph adults | #8 |
adhd manic symptoms | #8 |
psychiatric genomics | #8 |
adhd remission | #8 |
hemideletion | #8 |
shared familial effects | #8 |
avoidant disorder | #8 |
biological relatives | #8 |
presence autistic traits | #8 |
disorders baseline | #8 |
bpd disorders | #8 |
differential utility | #8 |
mwq | #8 |
rs3916965 | #8 |
nonpsychotic | #8 |
behavior attention | #8 |
nonverbal social | #8 |
euphoria | #8 |
diagnosed adhd | #8 |
symptoms impairment | #8 |
ordered subsets | #8 |
substantial evidence | #8 |
attention | #8 |
probands risk | #8 |
analysis association | #8 |
chromosome schizophrenia | #8 |
adhd dat1 | #8 |
aversion adhd | #8 |
crossover comparison | #8 |
diagnosis major depression | #8 |
affairs cooperative | #8 |
adhd inattentive | #8 |
adhd rtv | #8 |
adhd symptom scores | #8 |
10q223 | #8 |
adhd stimulant | #8 |
adhd unaffected | #8 |
controls relatives | #8 |
cadhd | #8 |
treatment sirolimus | #8 |
disease humans polymorphism | #8 |
onset bpd | #8 |
therapeutic dilemmas | #8 |
adhd associations | #8 |
autistic traits children | #8 |
notch4 | #8 |
adhdcd | #8 |
sample youth | #8 |
attention deficit adhd | #8 |
metaanalysis schizophrenia | #8 |
polygenic associations | #8 |
indicators schizophrenia | #8 |
agreement measures | #8 |
childhood mania | #8 |
behavioral inhibition anxiety | #8 |
dimesylate ldx | #8 |
gender effects | #8 |
link adhd | #8 |
biederman | #8 |
adhd boys | #8 |
adhdhi | #8 |
child diagnostic | #8 |
adhdi | #9 |
symptoms mania | #9 |
comparison girls | #9 |
childhood psychosis | #9 |
adhd healthy | #9 |
schizotaxic | #9 |
rs685012 | #9 |
adult report | #9 |
adhd loci | #9 |
ldps | #9 |
adult symptoms | #9 |
adderall | #9 |
nuremberg code | #9 |
adhd article | #9 |
endophenotypic | #9 |
stimulant medication | #9 |
snp7 | #9 |
adhd enuresis | #9 |
extendedrelease methylphenidate | #9 |
sustained attention schizophrenia | #9 |
sud bipolar disorder | #9 |
schizophrenia resilience | #9 |
neuropsychologic function | #9 |
hyperactivity humans | #9 |
genes risk factors | #9 |
25e07 | #9 |
haplotype snps | #9 |
subtypes adhd | #9 |
alzheimer disease schizophrenia | #9 |
deficit disruptive | #9 |
disorders sex interaction | #9 |
depression offspring | #9 |
lag sequential analysis | #9 |
proband groups | #9 |
children assessed | #9 |
dao gene | #9 |
etiologically | #9 |
hhrr | #9 |
ecpbhs | #9 |
g×s interaction disorders | #9 |
moderate sensitivity | #9 |
39 datasets | #9 |
gwas psychiatric disorders | #9 |
hum genet | #9 |
addh | #9 |
serotonin gene polymorphisms | #9 |
festschrift | #9 |
ads individuals | #9 |
orosmph irmph | #9 |
rasd2 | #9 |
serotonin genes | #9 |
male nuclear | #9 |
n41 | #9 |
mdd youth | #9 |
netherlands twin registry | #9 |
inattentive | #9 |
rpdr | #9 |
diagnostic efficiency | #9 |
comorbidity female | #9 |
aisrs | #9 |
nonreplications | #9 |
nonparanoids | #9 |
hyperactivity automobile | #9 |
pregnancy depression | #9 |
blindly | #9 |
disruptive behavior disorders | #9 |
taiwanese families | #9 |
substantial risk | #9 |
nephews | #10 |
pthreshold | #10 |
adhd quality | #10 |
nonpharmacologic treatments | #10 |
comorbidity depressive | #10 |
new specialty | #10 |
untreated adhd | #10 |
groups boys | #10 |
genes disorders | #10 |
4th | #10 |
noninhibited | #10 |
diminished risk | #10 |
psychiatric clinic | #10 |
bipolar disorder probands | #10 |
case identification | #10 |
comorbid odd | #10 |
ascertainment methods | #10 |
adhd substance disorder | #10 |
stimulants humans | #10 |
adhd sud | #10 |
comorbid bpd | #10 |
irmph orosmph | #10 |
panic depression | #10 |
adhd unaffected siblings | #10 |
preschool depressive | #10 |
severity adhd | #10 |
stimulants child | #10 |
parent‐of‐origin effects | #10 |
linkage analyses | #10 |
drd4 | #10 |
cbclap | #10 |
amphetamine salts | #10 |
association dat1 | #10 |
risk md | #10 |
aged attention | #10 |
adhd difficulties | #10 |
asd tourette syndrome | #10 |
rates abuse | #10 |
adhd childhood | #10 |
shared neurobiology | #10 |
genetic vulnerability schizophrenia | #10 |
association death | #10 |
image project | #10 |
normal sexual | #10 |
slod | #10 |
d4 receptor gene | #10 |
caadid | #10 |
small effects | #10 |
gwas adhd | #10 |
comorbidity | #10 |
preteen | #10 |
childhood adhd symptoms | #10 |
adult years | #10 |
evidence genetic | #10 |
psychiatric genetic studies | #10 |
probands bpd | #10 |
disorder age | #10 |
sexual dimorphisms | #10 |
genetics network | #10 |
conduct disorder | #10 |
kruglyak | #10 |
anxiety disorders children | #10 |
deficits adhd | #10 |
dms1 | #10 |
systematic qualitative review | #10 |
young adult outcome | #10 |
adulthood association | #10 |
rorb | #10 |
reassessed | #10 |
sleep problems adhd | #10 |
offspring bipolar parents | #11 |
attention deficit disorder | #11 |
maternal antenatal anxiety | #11 |
inhibition adhd | #11 |
juvenile mania | #11 |
adhd time | #11 |
symptom subtype | #11 |
diagnosis adults | #11 |
hyperactivity child cross | #11 |
differences adhd | #11 |
4372 | #11 |
neuropsychological test scores | #11 |
n136 | #11 |
etiology pathophysiology | #11 |
adolescents adhd | #11 |
lisdexamfetamine ldx | #11 |
effects genes | #11 |
disorders mothers | #11 |
vcfs | #11 |
differentiated genetic | #11 |
shared familial | #11 |
achievement adolescent | #11 |
disorders | #11 |
cutraits | #11 |
remission adhd | #11 |
gene adhd | #11 |
study perspective | #11 |
ppp3cc | #11 |
release methylphenidate | #11 |
dimesylate | #11 |
children addh | #11 |
adhd intellectual disability | #11 |
paternal smoking | #11 |
adhd onset | #11 |
disease humans schizophrenia | #11 |
adhd substance | #11 |
adult relatives | #11 |
comorbidity patterns | #11 |
agoraphobia anxiety | #11 |
children bipolar | #11 |
defiant disorder | #11 |
disorder pedigrees | #11 |
adhd psychopathology | #11 |
rs1137070 | #11 |
inattentive type | #11 |
deficits schizophrenia patients | #11 |
prodromal psychosis | #11 |
dopamine d5 receptors | #11 |
panic disorder comorbidity | #11 |
female relatives | #11 |
studies mtbi | #11 |
informativeness | #11 |
familybased association test | #11 |
youth bpd | #11 |
fbatpc | #11 |
nosologists | #11 |
growth delays | #11 |
pediatric bipolar disorder | #11 |
sample adults | #11 |
nonadhd controls | #11 |
real progress | #11 |
ldx placebo | #11 |
polymorphism 5 | #11 |
adhd female humans | #11 |
serotonin genetic receptor | #11 |
preschool depressive disorder | #11 |
hydrochloride attention | #11 |
shr model | #11 |
major depression adhd | #11 |
multiple domains | #11 |
rora rorb | #11 |
psychiatric disorders youth | #11 |
differences parents | #11 |
markers adhd | #11 |
cardinal symptoms | #11 |
adhd dopamine | #12 |
systematized | #12 |
obesity adhd | #12 |
common psychiatric | #12 |
adhd symptoms adults | #12 |
treatment attention | #12 |
obesity risk alleles | #12 |
sample consisted | #12 |
sexually dimorphic effects | #12 |
adhd age | #12 |
defiant | #12 |
pleiotropic mechanisms | #12 |
onelevel | #12 |
studies relatives | #12 |
impulsivity children | #12 |
psychiatric clinics | #12 |
epilepsy mothers | #12 |
neurocognitive measures | #12 |
sud patients adhd | #12 |
cbcl children | #12 |
unaffected siblings individuals | #12 |
convergent functional | #12 |
stimulant medication children | #12 |
n1397 | #12 |
symptom rating | #12 |
deficits attention | #12 |
cnvs risk | #12 |
twins humans models | #12 |
salts extended | #12 |
perceived motor competence | #12 |
comorbid disorder | #12 |
nhe9 | #12 |
psychiatric genetics | #12 |
kappa coefficients | #12 |
scales treatment | #12 |
amfetamine | #12 |
lossavoidance | #12 |
covid19 restrictions children | #12 |
adult outcome | #12 |
sec23ip | #12 |
variable age | #12 |
ksadse | #12 |
impaired parents | #12 |
functional impairments | #12 |
juvenile bipolar | #12 |
disorder adult | #12 |
genes methylation | #12 |
multiplex schizophrenia | #12 |
test wcst | #12 |
rs947267 | #12 |
assessment adhd | #12 |
effects time | #12 |
impaired parents child | #12 |
youths bpd | #12 |
girls relationship | #12 |
common disorders | #12 |
response atomoxetine | #12 |
striatal sensitivity | #12 |
psychotic mood disorders | #12 |
comorbidity diagnostic | #12 |
adhd core symptoms | #12 |
early psychosis study | #12 |
hawi | #12 |
digital treatment | #12 |
thalamic activation | #12 |
dat1 polymorphism | #12 |
nonoral | #12 |
rs778293 | #12 |
sud adhd | #12 |
adolescent adult age | #12 |
treatment paliperidone | #12 |
adhd offspring | #12 |
40–48 | #12 |
unaffected sibs | #12 |
metan | #12 |
disorder subjects | #12 |
psychotic behavior | #12 |
probands siblings | #12 |
methods subjects | #13 |
weight bmi | #13 |
risk mood | #13 |
adderall mph | #13 |
psychometric measure | #13 |
necrotic death | #13 |
adverseevents | #13 |
specific hypotheses | #13 |
girls | #13 |
transdermal methylphenidate | #13 |
risk parents | #13 |
adhd alterations | #13 |
longallele | #13 |
pkcm | #13 |
disorders sud | #13 |
persistence remission | #13 |
taiwanese sample | #13 |
adhd alcohol | #13 |
humans methylphenidate | #13 |
psychotic mood | #13 |
disorder youth | #13 |
male samples | #13 |
diagnostic threshold | #13 |
iiv | #13 |
114 years | #13 |
overanxious | #13 |
late onset | #13 |
adhd diagnosis | #13 |
chi12 | #13 |
colorado springs | #13 |
rates comorbidity | #13 |
bpd offspring | #13 |
convergent functional genomics | #13 |
adhd cognitive | #13 |
robust effects | #13 |
scale studies | #13 |
response inhibition adolescents | #13 |
disorders child | #13 |
familial risk schizophrenia | #13 |
velocardiofacial syndrome vcfs | #13 |
label studies | #13 |
psychometrics reproducibility | #13 |
ravg | #13 |
genomewide significance | #13 |
studies bipolar | #13 |
disorder childhood | #13 |
symptoms attention | #13 |
permutation testing | #13 |
adhdodd | #13 |
diagnostic concepts | #13 |
nonoral routes | #13 |
morbidity risks | #13 |
cognitive impulsivity | #13 |
environment adolescent | #13 |
pair 6 chromosomes | #13 |
psychiatric risk | #13 |
hillside | #14 |
disorder odd | #14 |
children criteria | #14 |
diagnosis mdd | #14 |
economic psychology | #14 |
adhd phenotype | #14 |
genetic studies schizophrenia | #14 |
children bipolar disorder | #14 |
siblings probands | #14 |
genes schizophrenia | #14 |
familial disorder | #14 |
mixed amphetamine salts | #14 |
stimulant abuse | #14 |
suds | #14 |
quetiapine bipolar disorder | #14 |
siblings cases | #14 |
disorder child | #14 |
lphn3 adhd | #14 |
associations adhd | #14 |
nimh genetics | #14 |
studies adults | #14 |
attention executive | #14 |
disorders comorbid | #14 |
bipolar probands | #14 |
relatives male probands | #14 |
early precursors | #14 |
n643 | #14 |
adhd brain | #14 |
unaffected siblings controls | #14 |
selfcontained | #14 |
older adults adhd | #14 |
adhd symptoms adulthood | #14 |
worldwide prevalence | #14 |
cnvs park2 | #14 |
symptoms psychiatric disorders | #14 |
ocd scz | #14 |
factors schizophrenia | #14 |
lisdexamfetamine dimesylate ldx | #14 |
common disorder | #14 |
cautiously | #14 |
aadhd | #14 |
emotional impulsivity | #14 |
social school | #14 |
mph adderall | #14 |
comorbid condition | #14 |
teachers reports | #14 |
differential heritability | #14 |
wraadds | #14 |
prss mdd | #14 |
geschwind | #14 |
children stimulants | #14 |
subcortical brain volume | #14 |
sud patients | #14 |
sackett | #15 |
gxr children | #15 |
card sorting | #15 |
adhd performance | #15 |
schizophrenia families | #15 |
symptom count | #15 |
executive function theory | #15 |
snps methylation | #15 |
ocd comorbid adhd | #15 |
methylation gene expression | #15 |
disord | #15 |
behavior disorders | #15 |
paediatric bipolar disorder | #15 |
substance disorder patients | #15 |
diagnostic interviews | #15 |
psychiatric interviews | #15 |
nhsd | #15 |
cbclpbd | #15 |
chi2 | #15 |
persons schizophrenia | #15 |
prodromal symptoms psychosis | #15 |
wfirsp | #15 |
daily living administration | #15 |
symptoms adulthood | #15 |
male relatives | #15 |
adhd study | #15 |
adhd treatment | #15 |
poor perception | #15 |
male mood | #15 |
zranb2 | #15 |
study design features | #15 |
pregnancy risk factor | #15 |
risk substance | #15 |
association schizophrenia | #15 |
rs2652511 | #15 |
genderdifferences | #15 |
adhd diagnostic | #15 |
agents attention | #15 |
tests psychomotor | #15 |
seconddegree relatives | #15 |
disorder evidence | #15 |
4669 | #15 |
asd mdd | #15 |
adhd disorders | #15 |
treatment xr | #15 |
adults substance disorders | #15 |
metabolic syndrome obesity | #15 |
adhd functional connectivity | #15 |
mphmlr | #15 |
d10s1423 | #15 |
49 children | #15 |
bipolar schizoaffective disorder | #15 |
healthy comparison subjects | #15 |
interaction genotype | #15 |
velocardiofacial | #15 |
drug disorder | #16 |
adhd diagnoses | #16 |
delayed action | #16 |
regional cortical thickness | #16 |
scz risk | #16 |
“difficulty | #16 |
growth children | #16 |
n424 | #16 |
factual factor analysis | #16 |
rdoc framework | #16 |
control participants participants | #16 |
adhd anxiety symptoms | #16 |
special classes | #16 |
risk psychotic disorders | #16 |
dbds | #16 |
parents anxiety disorders | #16 |
linkage findings | #16 |
geneenvironment interaction | #16 |
pervasive developmental disorder | #16 |
cprsr | #16 |
ntac | #16 |
adhd symptom severity | #16 |
familial relationship | #16 |
onset anticipation | #16 |
brainbody | #16 |
informant assessment | #16 |
dexedrine | #16 |
hyperkinetic disorders | #16 |
adhd obesity | #16 |
multiple test | #16 |
youths adhd | #16 |
longitudinal assessments | #16 |
prospective follow | #17 |
combined type | #17 |
nonparametric linkage | #17 |
childhood predictors | #17 |
schizophrenia psychosis | #17 |
disability adhd | #17 |
association scan | #17 |
young offspring | #17 |
assessment positive symptoms | #17 |
ocd age | #17 |
hyperactivity attitude | #17 |
diagnostic statistical | #17 |
neuropsychiatric evaluation | #17 |
adulthood adhd | #17 |
association markers | #17 |
larger sample | #17 |
multiple anxiety disorders | #17 |
rbfox1 | #17 |
studies psychiatric | #17 |
accn2 | #17 |
psychology schizotypal | #17 |
ldx children | #17 |
pediatric disorder | #17 |
study adhd | #17 |
medication type | #17 |
random forest regression | #17 |
driving behaviors | #17 |
factors siblings | #17 |
samples children | #17 |
prevalence adhd | #17 |
response inhibition network | #17 |
considerable overlap | #17 |
mania | #17 |
substance disorders sud | #17 |
condfdr | #17 |
bipolar disorder subjects | #17 |
depression md | #17 |
parents adhd | #17 |
asd ocd | #17 |
a161t | #17 |
resultsfirst | #17 |
persistent adhd | #17 |
pediatric samples | #17 |
5071 | #17 |
method participants | #17 |
relation adhd | #17 |
stimulant | #18 |
low dose naltrexone | #18 |
schizophrenia dtnbp1 | #18 |
adhd sud patients | #18 |
preschool diagnostic | #18 |
bipolar choice trial | #18 |
lisdexamfetamine dimesylate | #18 |
poor tolerability | #18 |
transporter gene | #18 |
linkage regions | #18 |
illness twins | #18 |
single nucleotide severity | #18 |
depression genetic risk | #18 |
kcnj4 | #18 |
adhd cannabis | #18 |
dcdq | #18 |
primary substance | #18 |
4286 | #18 |
symptom overlap | #18 |
behavior scale | #18 |
anxiety mdd | #18 |
risk disorders | #18 |
unaffected siblings | #18 |
adhd severity | #18 |
psuds | #18 |
schizophrenia patients relatives | #18 |
potential contributor | #18 |
conduct disorder children | #18 |
adhd groups | #18 |
relatives control subjects | #18 |
childhood traumas | #18 |
unemotionality | #18 |
fullsiblings | #18 |
children vcfs | #18 |
bipolar major | #18 |
neuropsychologic | #18 |
hrr 95 | #18 |
operationalized | #18 |
prolonged therapy | #18 |
minisatellite repeats | #18 |
meet criteria | #18 |
marijuana age | #18 |
euphoric effects | #19 |
symptoms adolescent | #19 |
adolescent age | #19 |
scz ocd | #19 |
adhd neurodevelopmental | #19 |
casecontrol sample | #19 |
substance adhd | #19 |
comorbidity rates | #19 |
nature nurture | #19 |
action preparations | #19 |
rs3918342 | #19 |
lod1 | #19 |
adolescent age onset | #19 |
psychosocial features | #19 |
improvement symptoms | #19 |
assessing outcome | #19 |
disconfirmations | #19 |
addicted patients | #19 |
adhd young adults | #19 |
candidate loci | #19 |
mcgue | #19 |
mental health human | #19 |
medication trials | #19 |
familial transmission | #19 |
disorders adults | #19 |
verbal memory task | #19 |
hyperconnectivity | #19 |
parent origin | #20 |
inhibition children | #20 |
manual mental | #20 |
slc6a2 | #20 |
mflynn | #20 |
parents risk | #20 |
outcome attention | #20 |
adolescent | #20 |
gsma | #20 |
notch4 gene | #20 |
dicap | #20 |
nonpsychotic siblings | #20 |
schizophrenia attention | #20 |
kiddie | #20 |
neuropsychological function | #20 |
prenatal exposure nicotine | #20 |
pedigree selection | #20 |
controlled pilot study | #20 |
neuropsychologically | #20 |
linkage scans | #20 |
biological families | #20 |
disorders polymorphism | #20 |
rbfox1 gene | #20 |
ratings adhd | #20 |
illness female humans | #20 |
transmission ratio distortion | #20 |
response curve | #20 |
deficits children | #20 |
neuroleptic dose | #20 |
human ortholog | #20 |
humanhap550v3 | #20 |
sibpair | #20 |
depression adhd | #20 |
schizophrenia united | #21 |
children pdd | #21 |
sodium hydrogen exchanger | #21 |
prevalent cases | #21 |
linkage chromosomes | #21 |
childhood conduct disorder | #21 |
rat shr | #21 |
treatment growth | #21 |
genehunterplus | #21 |
rs778294 | #21 |
psychiatric symptoms patients | #21 |
humans linkage | #21 |
cacng2 | #21 |
comorbid adhd | #21 |
prescription stimulants | #21 |
prenatal exposure alcohol | #21 |
bipolar pedigrees | #21 |
11year followup | #21 |
schizophrenia taiwan | #21 |
risk offspring | #21 |
chronic tics | #21 |
male probands | #21 |
palau | #21 |
life enjoyment | #21 |
gender comparisons | #21 |
agler | #21 |
prospective longitudinal | #21 |
schizophrenia disease humans | #21 |
motor problems | #21 |
monoamine oxidase maoa | #21 |
schizotypals | #21 |
methods age | #21 |
children comorbid | #21 |
adhd impulsivity | #22 |
amphetamine methylphenidate | #22 |
association prs | #22 |
pre‐school | #22 |
preliminary reliability | #22 |
neurocognitive performance schizophrenia | #22 |
controls | #22 |
neuropsychological profiles | #22 |
10p | #22 |
overtransmission | #22 |
depression treatment patients | #22 |
partial replication | #22 |
adhd stimulants | #22 |
adderall xr | #22 |
adhd rating scale | #22 |
adhd susceptibility | #22 |
6 disorders | #22 |
children attention | #22 |
schizophrenia pgc | #22 |
youth bipolar | #22 |
study methodology | #22 |
youth mdd | #22 |
ldx | #22 |
polygenic overlap | #22 |
disruptive | #22 |
familiality | #22 |
stimulants children | #22 |
rg022 | #22 |
amygdala structure | #22 |
disorders major | #22 |
niacin skin | #22 |
adhd anxiety | #22 |
genetic phenotype | #22 |
bpd subjects | #22 |
syndrome vcfs | #22 |
diagnostic interview | #22 |
scq asd | #23 |
risk studies | #23 |
siblings | #23 |
serotonin receptor gene | #23 |
interacting molecules | #23 |
executive functions efs | #23 |
interview dsm | #23 |
syp | #23 |
diagnostician | #23 |
male individuals | #23 |
disequilibrium male | #23 |
asd scq | #23 |
adhd symptoms childhood | #23 |
n449 | #23 |
adolescents bpd | #23 |
phenotype definition | #23 |
rs464049 | #23 |
comprehensively | #23 |
intrinsic curvature | #23 |
snapiv | #23 |
genetic investigation | #23 |
wide linkage | #23 |
heterogeneity genetic | #23 |
wechsler scales | #23 |
kotkin | #23 |
neuroleptic withdrawal | #23 |
mdd anxiety disorders | #23 |
twins genetic predisposition | #23 |
metadoxine | #23 |
oppositional | #23 |
anxious mothers | #23 |
notch4 receptors | #23 |
handful | #23 |
propylamines | #23 |
child female humans | #24 |
symptoms psychosis | #24 |
sassr | #24 |
adhd characteristics | #24 |
stress exposure | #24 |
lithium bipolar disorder | #24 |
statistical manual | #24 |
children meeting | #24 |
adhd comorbidities | #24 |
0535 | #24 |
intelligence schizophrenia | #24 |
quantitative phenotypes | #24 |
refilled | #24 |
genome‐wide linkage scans | #24 |
receptor d4 | #24 |
adra2a | #24 |
expected growth | #24 |
neural activation patterns | #24 |
aggression anxiety | #24 |
mental control | #24 |
chromosomes 6 | #24 |
nieces | #24 |
dsmiiir criteria | #24 |
nonstimulant | #24 |
female humans illness | #24 |
conduct problems adhd | #24 |
snorting | #24 |
actigraphy studies | #24 |
amrs | #24 |
15q13 | #24 |
guanfacine extended release | #24 |
deficits | #24 |
ocd asd | #24 |
stroop task performance | #24 |
age regions | #24 |
task patients | #25 |
wkht | #25 |
clinical interviews | #25 |
psychiatric disorders children | #25 |
–environment interactions | #25 |
bipolar choice | #25 |
copy variants schizophrenia | #25 |
liker | #25 |
baseline assessment | #25 |
exposure adhd | #25 |
dapple | #25 |
young relatives | #25 |
behavioral disinhibition | #25 |
unique profile | #25 |
neurocognitive predictors | #25 |
biased transmission | #25 |
or194 | #25 |
school failure | #25 |
screening scale | #25 |
vietnam twin registry | #25 |
anticipation schizophrenia | #25 |
psychiatric nosology | #25 |
splicing regulator | #25 |
conners parent | #25 |
dyscalculia | #25 |
efficacy atomoxetine | #25 |
association snps | #25 |
slc6a3 gene | #25 |
d22s283 | #25 |
nudt3 | #25 |
psychometrically | #25 |
maternal criticism | #25 |
major affective disorders | #25 |
symptom subtypes | #25 |
understanding adhd | #25 |
decreased volume | #25 |
adults symptoms | #26 |
adrenergic uptake | #26 |
voxel based morphometry | #26 |
twins humans | #26 |
wm microstructure | #26 |
affair | #26 |
association allele | #26 |
screening diagnosis | #26 |
bipolar phenotype | #26 |
n81 | #26 |
selfmonitor | #26 |
alcohol drug abuse | #26 |
agreement raters | #26 |
inrich | #26 |
social impairment | #26 |
orosmethylphenidate | #26 |
structured interviews | #26 |
htr1d | #26 |
prenatal health | #26 |
label study | #26 |
psychometric measures | #26 |
controls adhd | #26 |
maob gene | #26 |
major depression md | #26 |
nonmedical prescription stimulants | #26 |
gender risk | #26 |
add | #26 |
neurodevelopmental genes | #26 |
core symptoms adhd | #26 |
rs3730358 | #26 |
adhd mothers | #26 |
efpc | #26 |
behavioral disorder | #26 |
rate remission | #27 |
genetic susceptibility schizophrenia | #27 |
consecutively | #27 |
d22s278 | #27 |
asherson | #27 |
based association | #27 |
bipolar disorder comorbidity | #27 |
t102c polymorphism | #27 |
aff | #27 |
offspring risk | #27 |
treatment atomoxetine | #27 |
cnvs adhd | #27 |
disorders executive | #27 |
intelligence male | #27 |
ptsd adults | #27 |
osterrieth | #27 |
greater severity | #27 |
schizophrenia genetic | #27 |
hyperactivity disorder adhd | #27 |
mdd asd | #27 |
childreniv | #27 |
weaker effects | #27 |
potential confounds | #27 |
international meeting | #27 |
association signals | #27 |
adults study | #28 |
preliminary findings | #28 |
clinical correlates | #28 |
families schizophrenia | #28 |
image study | #28 |
emotional dysregulation | #28 |
male methylphenidate | #28 |
metaalgorithm | #28 |
dopamine transporter binding | #28 |
maternal adhd | #28 |
assessment negative symptoms | #28 |
genomewide studies | #28 |
child clinical | #28 |
adhd differences | #28 |
persons bipolar disorder | #28 |
new genetics | #28 |
ocd disorders | #28 |
sustained attention deficits | #28 |
adhd autism | #28 |
dopamine receptor d4 | #28 |
vigilance performance | #28 |
raters | #28 |
polysomnography actigraphy | #28 |
cortical gyrification | #28 |
subjects bpd | #28 |
slc6a3 | #28 |
rest task | #28 |
symptom reports | #28 |
symptoms inattention | #28 |
guze | #28 |
genetic etiology | #28 |
disorder compared | #28 |
schizophrenia onset | #28 |
6179 | #28 |
snp18 | #28 |
parent teacher | #28 |
disorders offspring | #29 |
kcnn3 | #29 |
medication usage | #29 |
studies genes | #29 |
parents bipolar disorder | #29 |
comorbidity ptsd | #29 |
attention‐deficit | #29 |
african‐american | #29 |
psychosocial dysfunction | #29 |
dsmiiir | #29 |
shared genetic basis | #29 |
infants weight | #29 |
disorder bipolar | #29 |
male polymorphism | #29 |
childhood diagnosis | #29 |
adhd patients controls | #29 |
bipolar disorder youth | #29 |
medication misuse | #29 |
childhood antecedents | #29 |
etiological heterogeneity | #29 |
offspring parents | #29 |
hyperactivity impulsivity | #29 |
misuse diversion | #29 |
inattention hyperactivity impulsivity | #29 |
nonaffected | #30 |
treatment adolescents | #30 |
hyperactive symptoms | #30 |
nimh | #30 |
robust statistical methods | #30 |
genetic perspective | #30 |
antisocial behavior asb | #30 |
structural brain features | #30 |
relatives age | #30 |
individual studies | #30 |
caarsinv | #30 |
specific psychopathology | #30 |
nicotine pregnancy | #30 |
growth childhood | #30 |
association paternal age | #30 |
bmi growth | #30 |
problems attention | #30 |
adhd child | #30 |
juvenile bipolar disorder | #30 |
comorbid | #30 |
parental predictors | #30 |
diagnosticians | #30 |
rgs4 schizophrenia | #31 |
impulsivity inattention | #31 |
variable tandem | #31 |
charles river | #31 |
discriminates | #31 |
depression genetic | #31 |
methylphenidate | #31 |
lodscore | #31 |
neuropsychologic deficits | #31 |
reanalyzed | #31 |
prs adhd | #31 |
nonadhd | #31 |
n305 | #31 |
extant literature | #31 |
twin concordance | #31 |
kif16b | #31 |
potential endophenotypes | #31 |
neuroimage | #31 |
genotype haplotypes | #31 |
sex effects | #31 |
bpd risk | #31 |
smoking substance | #31 |
95 adhd | #31 |
psdq | #32 |
psychosis youth | #32 |
70–80 | #32 |
kremen | #32 |
bipolar disorder bpi | #32 |
rs206936 | #32 |
impulsecontrol | #32 |
randomized crossover study | #32 |
anxiety disorders | #32 |
repeat length | #32 |
schizophrenia affective psychosis | #32 |
studies schizophrenia | #32 |
wiscr | #32 |
asd symptoms children | #32 |
10p13 | #32 |
subfields hippocampus | #32 |
adhd adolescents | #32 |
anterior insular | #32 |
attentiondeficit | #32 |
child psychiatric | #32 |
studies adolescent | #32 |
parents child | #32 |
psychiatric disorders | #32 |
gender | #32 |
aggression attention | #32 |
psychiatric genetic | #32 |
slc6a4 | #32 |
rs1130214 | #33 |
autism symptoms | #33 |
maternal smoking pregnancy | #33 |
ld adhd | #33 |
neural reward processing | #33 |
subcortical brain | #33 |
adhd patients | #33 |
comorbidity cross | #33 |
animal model adhd | #33 |
disorder symptom | #33 |
children risk | #33 |
val allele | #33 |
pharmacotherapy trials | #33 |
youth bipolar disorder | #33 |
wfirs | #33 |
current adhd | #33 |
original study | #33 |
frontopolar | #33 |
briefa | #33 |
aspd bpd | #33 |
single snps | #33 |
quetiapine monotherapy | #33 |
association genes | #33 |
twins factor analysis | #33 |
rhobtb3 | #33 |
prior findings | #33 |
adhd evidence | #33 |
qsf | #33 |
neuropsychological deficits | #33 |
psychiatric status | #33 |
psychiatric sample | #33 |
neuropsychiatric sle | #33 |
mood anxiety | #33 |
10repeat allele | #33 |
risk psychiatric disorders | #34 |
psychological tests | #34 |
treatment memantine | #34 |
gxr | #34 |
cognition interaction | #34 |
harvard | #34 |
disorders diagnostic | #34 |
treatment sud | #34 |
disorder traits | #34 |
linkage studies | #34 |
grm5 | #34 |
structural brain asymmetries | #34 |
dsm5 dsmiv | #34 |
social anxiety children | #34 |
snp4 | #34 |
disorders mood | #34 |
pharmacotherapy adhd | #34 |
emerging consensus | #34 |
candidate gene polymorphisms | #34 |
md risk | #34 |
young adults adhd | #34 |
inattention | #34 |
lifetime rates | #35 |
hyperactive disorder | #35 |
bipolar disorder offspring | #35 |
adhd sleep problems | #35 |
#35 | |
adhd rating | #35 |
risk females | #35 |
familial risk | #35 |
humans intelligence | #35 |
n265 | #35 |
complex figure | #35 |
schizophrenia gene | #35 |
catechol‐o‐methyltransferase | #35 |
n64 | #35 |
choice impulsivity | #35 |
schizophrenia schizotypy | #35 |
participants bpd | #35 |
recall patients | #35 |
htr1b | #35 |
lithium quetiapine | #35 |
schizophrenia relatives | #35 |
sample description | #35 |
plink | #35 |
bipolar spectrum disorders | #35 |
adhd control groups | #36 |
young adult females | #36 |
comorbidity children | #36 |
structure psychopathology | #36 |
95 siblings | #36 |
adult antisocial | #36 |
nocebo response | #36 |
neurocognitive markers | #36 |
schizophrenia genes | #36 |
annett | #36 |
groups adhd | #36 |
overanxious disorder | #36 |
disorder bpd | #36 |
intracranial volume icv | #36 |
adhd drug | #36 |
n185 | #36 |
d6s274 | #36 |
siblings controls | #36 |
orosmph | #36 |
suny | #36 |
infant gender | #36 |
term neuropsychological | #36 |
neurotransmissions | #36 |
retrospective recall | #36 |
stimulant medications | #36 |
gypc | #36 |
disorder severity | #37 |
rs5 | #37 |
studies comorbidity | #37 |
combined sample | #37 |
predictive utility | #37 |
n278 | #37 |
child behavioral | #37 |
slc22a16 | #37 |
adhd asd | #37 |
dat1 gene | #37 |
functioning adults | #37 |
odd dimensions | #37 |
symptom criteria | #37 |
tests schizophrenia | #37 |
genetics | #37 |
parents adhd children | #37 |
mapping genomic loci | #37 |
lisdexamfetamine | #37 |
offspring association | #37 |
delayedaction preparations | #37 |
pik4ca | #38 |
rs2391191 | #38 |
genetic risk schizophrenia | #38 |
pediatric adhd | #38 |
unfamiliar | #38 |
genome‐wide search | #38 |
family‐based | #38 |
kiddie schedule | #38 |
familial risk depression | #38 |
d15s1360 | #38 |
methylphenidate treatment | #38 |
boys | #38 |
height children | #38 |
school age children | #38 |
16 genes | #38 |
dsm criteria | #38 |
polymorphism gene | #38 |
adhd problems | #38 |
wisconsin card | #39 |
washu | #39 |
increased risk adhd | #39 |
mlod | #39 |
female cases | #39 |
mdd ocd | #39 |
onset children | #39 |
git1 | #39 |
ocd adhd | #39 |
antisocial traits | #39 |
manic symptoms | #39 |
adhd behavior | #39 |
markers genetic | #39 |
iii personality | #39 |
behavioral traits | #39 |
suggestive | #39 |
structural brain abnormalities | #39 |
mood stabilization | #39 |
asthma systematic review | #39 |
nonparanoid | #39 |
test association | #39 |
dsm5 criteria | #39 |
pharmacologic treatment | #39 |
diagnosis bipolar disorder | #40 |
chromosome 10p | #40 |
onset | #40 |
heinrichs | #40 |
genetics schizophrenia | #40 |
rs2283265 | #40 |
genetic studies | #40 |
brainspan | #40 |
rare copy variants | #40 |
anx | #40 |
genome scan | #40 |
dsmiv criteria | #40 |
bipolars | #40 |
reln gene | #40 |
familial effects | #40 |
cardiovascular adverse effects | #40 |
gxe | #40 |
schizophrenia severity illness | #41 |
bdnf adhd | #41 |
male parents | #41 |
psychosocial adversity | #41 |
methylphenidate response | #41 |
neuropsychiatr | #41 |
sirolimus patients | #41 |
methodological advances | #41 |
parent‐of‐origin | #41 |
chromosomes 6q | #41 |
pediatric subjects | #41 |
sibpairs | #41 |
normal comparison subjects | #41 |
fhrs | #41 |
effects growth | #41 |
dtnbp1 schizophrenia | #42 |
schizophrenia disorders | #42 |
gwas meta | #42 |
fiveyear followup | #42 |
male panic | #42 |
tic disorders | #42 |
disorder social | #42 |
schizophrenia | #42 |
diagnostic comorbidity | #42 |
adhd deficits | #42 |
child female | #42 |
n262 | #42 |
serotonergic pathway | #42 |
individual items | #42 |
sorting test | #42 |
digs | #43 |
n242 | #43 |
practitioner review | #43 |
youngadult | #43 |
snp1 | #43 |
n232 | #43 |
candidate endophenotype | #43 |
simplex families | #43 |
adhd prs | #43 |
neuropsychological differences | #43 |
p094 | #43 |
mri study | #43 |
neuropsychological tasks | #43 |
n176 | #43 |
p023 | #43 |
massachusetts general | #43 |
disorder prevalence | #43 |
children enuresis | #43 |
adhd depression | #43 |
brain scans | #43 |
treatment adult | #44 |
mental disorders diseases | #44 |
secondborns | #44 |
odds ratio association | #44 |
sidp | #44 |
n140 | #44 |
prior studies | #44 |
multidimensionality | #44 |
asd adults | #44 |
immediaterelease | #44 |
nosologic | #44 |
adolescents attention | #44 |
dopamine d5 | #44 |
risk schizophrenia | #45 |
uncaring | #45 |
genetic underpinnings | #45 |
adhd parents | #45 |
schizophrenia genome | #45 |
illness stress | #45 |
institute mental | #45 |
offspring adhd | #45 |
wnl | #45 |
genetic loading | #45 |
snpbased heritability | #45 |
baseline adhd | #45 |
altered brain activation | #45 |
controls subjects | #45 |
prevalence psychiatric | #45 |
substance disorder | #45 |
risk reduction strategies | #45 |
volume reductions | #45 |
pharmacogenetic studies | #45 |
suggestive associations | #45 |
inflation rate | #45 |
tcerg1l | #45 |
behavior rating | #45 |
cep85l | #45 |
pooled size | #45 |
n164 | #46 |
previous findings | #46 |
cbt intervention | #46 |
response mph | #46 |
lyons | #46 |
natural reward | #46 |
referral bias | #46 |
neuropsychological performance | #46 |
nat genet | #46 |
sex bias | #46 |
machine learning study | #46 |
10year followup | #46 |
converging evidence | #46 |
12 months treatment | #46 |
gender influences | #46 |
stronger connectivity | #46 |
adhd effects | #46 |
familial coaggregation | #46 |
shared polygenic risk | #47 |
trauma risk | #47 |
n280 | #47 |
compromised | #47 |
childhood disorders | #47 |
meehl | #47 |
desipramine dmi | #47 |
abstract objective | #47 |
loci chromosomes | #47 |
pooled odds ratio | #47 |
association bipolar disorder | #47 |
genetic study | #47 |
parents depression | #47 |
or125 | #47 |
ocd mdd | #47 |
comt | #47 |
schizophrenia alleles | #47 |
velocardiofacial syndrome | #47 |
psychiatric status rating | #47 |
disorders studies | #47 |
baiap2 | #47 |
oppositional symptoms | #47 |
adhd prevalence | #48 |
scientific foundation | #48 |
disorder case | #48 |
revised | #48 |
effects gender | #48 |
n27 | #48 |
adhd dyslexia | #48 |
nullhypothesis | #48 |
association test | #48 |
shared heritability | #48 |
rtv | #48 |
mpp3 | #48 |
1711 | #48 |
n103 | #48 |
snap‐25 | #49 |
rs2494732 | #49 |
familial loading | #49 |
drug holidays | #49 |
hyperactivity autism | #49 |
mental disorders children | #49 |
anxa7 | #49 |
weak evidence | #49 |
schizophrenia cognition | #49 |
nurture | #49 |
inbred wky rats | #49 |
disorder cognitive | #49 |
negative schizotypy | #49 |
volume differences | #49 |
serotonin plasma | #49 |
life outcomes | #50 |
rocf | #50 |
parent teacher ratings | #50 |
geneenvironment interactions | #50 |
studies biomarkers | #50 |
dsmiv dsm5 | #50 |
intergenerational effects | #50 |
wiat | #50 |
vdm | #50 |
pair 6 | #50 |
n168 | #50 |
genomic relationships | #50 |
maoauvntr | #50 |
early onset schizophrenia | #50 |
proteins polymorphism | #50 |
impulsivity symptoms | #50 |
caseness | #50 |
wais | #50 |
extended pedigrees | #50 |
peer affiliation | #51 |
male personality | #51 |
1542 | #51 |
gender association | #51 |
bpd | #51 |
compelling | #51 |
common psychiatric disorders | #51 |
adults ocd | #51 |
adhd knowledge | #51 |
psychology adult | #51 |
substantial role | #51 |
epilepsy adhd | #51 |
manovas | #51 |
disorders children | #51 |
combined adhd | #52 |
asdadhd | #52 |
metaanalysis association | #52 |
growth height | #52 |
youth asd | #52 |
chronic schizophrenia patients | #52 |
major depression | #52 |
schizophrenia controls | #52 |
intracranial volume | #52 |
schizophrenia sex | #52 |
selenbp1 | #52 |
oros methylphenidate | #52 |
adra1a | #52 |
a218c | #52 |
bipolar disorder children | #52 |
gray matter alterations | #52 |
scales schizophrenia | #53 |
mania depression | #53 |
risk analysis | #53 |
n138 | #53 |
extended‐release | #53 |
risktaking behavior | #53 |
smoking schizophrenia | #53 |
dopamine plasma | #53 |
snps candidate genes | #53 |
adhdc | #53 |
parahippocampal gyrus | #53 |
schizophrenia adolescent | #53 |
adoption study | #53 |
psychopathology | #53 |
ppm1h | #53 |
placebo children | #53 |
tourettes disorder | #53 |
bpd children | #54 |
onset bipolar | #54 |
unphased | #54 |
dnms | #54 |
genetic reproducibility | #54 |
alcohol drug | #54 |
risk study | #54 |
schizophrenia psychotic disorders | #54 |
chromosome 6p | #54 |
pregnancy time | #54 |
jackknife | #54 |
psychlit | #54 |
ablim1 | #54 |
disorders risk | #55 |
child behavior | #55 |
mid adolescence | #55 |
gene interaction | #55 |
longitudinal case | #55 |
childhood trauma exposure | #55 |
neuropsychological studies | #55 |
emotional lability | #55 |
endophenotype | #55 |
flat affect | #55 |
1252 | #55 |
tova | #55 |
viloxazine | #55 |
sample children | #55 |
disorders prevalence | #55 |
children diagnosis | #55 |
schizophrenia offspring | #56 |
cotwin | #56 |
alcohol substance | #56 |
n43 | #56 |
children siblings | #56 |
hyperactive | #56 |
extendedrelease | #56 |
disorder agoraphobia | #56 |
tics children | #56 |
degree relatives | #56 |
entry points | #56 |
pair chromosomes | #56 |
subfield | #56 |
methylphenidate hydrochloride | #57 |
interregional profiles differences | #57 |
zdhhc8 | #57 |
model attention | #57 |
shared genetic etiology | #57 |
oddsratio | #57 |
etdt | #57 |
barkley | #57 |
atomoxetine hydrochloride | #57 |
brain structure function | #57 |
apol | #57 |
rating inventory | #57 |
single snp | #58 |
repeat alleles | #58 |
compelling evidence | #58 |
comorbid psychiatric disorders | #58 |
vntr polymorphisms | #58 |
association comt | #58 |
controlled study | #58 |
100 children | #58 |
children | #58 |
function schizophrenia | #58 |
controls children | #58 |
tests attention | #58 |
dbq | #58 |
conners | #58 |
heritable receptors | #58 |
analysis schizophrenia | #58 |
adhd atomoxetine | #58 |
childhood young adulthood | #58 |
mdd adhd | #59 |
schizophrenia smoking | #59 |
rtn4r | #59 |
neuroleptic | #59 |
mdd children | #59 |
comt schizophrenia | #59 |
risk psychiatric | #59 |
risk siblings | #59 |
executive functioning | #60 |
reported associations | #60 |
lphn3 | #60 |
3 domains | #60 |
abuse dependence | #60 |
disorders including | #60 |
functional remission | #60 |
generalize | #60 |
disruptive behavior disorder | #60 |
duval | #60 |
inattention hyperactivity | #60 |
homogeneous subgroups | #61 |
13q32 | #61 |
uncles | #61 |
dysregulation profile | #61 |
disorders asd | #61 |
comparison subjects | #61 |
unipolars | #61 |
uninhibited | #61 |
study adherence | #61 |
study adults | #61 |
cronbachs alpha | #61 |
oih | #61 |
disruptive behavior | #61 |
wide scan | #61 |
4 year | #62 |
polygenic risk schizophrenia | #62 |
relatives schizophrenia | #62 |
factors anxiety | #62 |
schizophrenia human | #62 |
mph treatment | #62 |
1537 | #62 |
inhibition memory | #62 |
maternal psychopathology | #62 |
tdts | #62 |
symptoms | #62 |
bipolar youth | #62 |
substantial heritability | #62 |
treatments adhd | #63 |
risk severity | #63 |
n179 | #63 |
structured interview | #63 |
stability time | #63 |
disorders bipolar | #63 |
ksads | #63 |
neurocognitive | #63 |
behavioral dysregulation | #63 |
accounted | #63 |
schizophrenia schizophrenic | #63 |
rating scales | #64 |
methylation cpg sites | #64 |
males association | #64 |
linkage | #64 |
child | #64 |
prefrontal dysfunction | #64 |
diagnostic utility | #64 |
40 countries | #64 |
europeanamerican | #64 |
endosomal | #64 |
children mph | #64 |
qlesq | #64 |
adhd 95 | #64 |
childhood onset | #64 |
methylphenidate adhd | #64 |
phacking | #64 |
methylphenidate mph | #64 |
treatment desipramine | #64 |
risk trauma | #64 |
comorbid diagnosis | #65 |
occurrence adhd | #65 |
temperamental | #65 |
marry | #65 |
emo | #65 |
small sample size | #65 |
adhd epilepsy | #65 |
disorders genetic | #65 |
etiology schizophrenia | #65 |
controls siblings | #65 |
net gene | #65 |
emotional regulation | #65 |
zcchc4 | #65 |
function female | #65 |
oxidase gene | #65 |
male siblings | #65 |
neuropsychological impairments | #65 |
prior work | #65 |
schizophrenic | #65 |
tic disorder | #66 |
behavioral genetic | #66 |
disorder chromosome | #66 |
attention hyperactivity | #66 |
afternoons | #66 |
cbcldp | #66 |
global ratings | #66 |
extended release | #66 |
ci105 | #66 |
simple phobia | #66 |
adhd dcd | #66 |
vswm | #66 |
children mental retardation | #66 |
tourettes syndrome | #66 |
neuropsychological profile | #66 |
study studies | #66 |
substance disorder sud | #67 |
label trial | #67 |
entire sample | #67 |
grade retention | #67 |
risk bipolar | #67 |
chronic tic disorder | #67 |
parents teachers | #67 |
patients bipolar disorders | #67 |
treatment quetiapine | #67 |
n217 | #67 |
nonrighthandedness | #67 |
mental diseases | #67 |
questionnaires treatment | #67 |
subjects | #67 |
findings association | #67 |
variance attention | #67 |
brain gene | #68 |
hypofrontality | #68 |
conceptual issues | #68 |
delay aversion | #68 |
qms | #68 |
offspring | #68 |
naturalistic | #68 |
snparray | #68 |
scale assessment | #69 |
clarifying | #69 |
humans schizophrenia | #69 |
ctgn | #69 |
panic disorder | #69 |
regulatory enzymes | #69 |
low adherence | #69 |
stress response genes | #69 |
symptom checklist | #69 |
illicit substances | #69 |
physical anhedonia | #69 |
impulsivity hyperactivity | #69 |
people adhd | #69 |
polymorphism schizophrenia | #69 |
chronological age | #69 |
latrophilin | #70 |
oros mph | #70 |
smoking children | #70 |
a2bp1 | #70 |
core adhd symptoms | #70 |
new diagnoses | #70 |
nonrandom mating | #70 |
npl | #70 |
subsequent diagnosis | #70 |
neuropsychological consequences | #70 |
linkage scan | #70 |
interactions genes | #70 |
vergence | #71 |
treated children | #71 |
mspi polymorphism | #71 |
adhd behaviors | #71 |
adhd anxiety disorders | #71 |
genetic | #71 |
genes role | #71 |
neuroimaging genetics | #71 |
objective examine | #71 |
digital health intervention | #72 |
learning disorders | #72 |
methodological issues | #72 |
molecular genetic | #72 |
digital intervention | #72 |
genetic receptors | #72 |
ocd subjects | #72 |
school functioning | #72 |
boys age | #72 |
adult | #73 |
etiological | #73 |
patients rest | #73 |
cellular models | #73 |
relapse depression | #73 |
adhd subtype | #73 |
schizophrenia genetics | #73 |
cortical abnormalities | #73 |
anxiety adhd | #73 |
poison control centers | #73 |
disorders childhood | #73 |
candidate endophenotypes | #73 |
3372 | #73 |
logodds | #73 |
kagan | #73 |
adhd medications | #73 |
youth | #73 |
pfkfb2 | #74 |
age schizophrenia | #74 |
reaction time variability | #74 |
allele association | #74 |
transmission disequilibrium | #74 |
preferential transmission | #74 |
desipramine | #74 |
based diagnosis | #74 |
weight body mass | #75 |
antisocial | #75 |
drd4 gene | #75 |
child china | #75 |
impairment children | #75 |
mind wandering | #75 |
efficacy outcome | #75 |
neale | #75 |
slc1a1 | #75 |
onset anxiety | #75 |
adhd traits | #75 |
linkage schizophrenia | #75 |
akl | #75 |
risk sample | #75 |
referred | #75 |
hyperactivity adhd | #75 |
chronic tic | #76 |
schizophrenia young | #76 |
child humans | #76 |
centers disease control | #76 |
child depressive | #76 |
adhd total | #76 |
depression pregnancy | #76 |
yates | #76 |
positive schizotypy | #76 |
disorders brain | #76 |
nondeficit | #76 |
wcst performance | #77 |
performance adhd | #77 |
cortex schizophrenia | #77 |
lod score | #77 |
performance schizophrenia | #77 |
childhood adhd | #77 |
atomoxetine children | #77 |
psychological male | #77 |
local gyrification | #78 |
disorders female | #78 |
bipolar disorder adhd | #78 |
rare copy | #78 |
bpi | #78 |
pharmacologic treatments | #78 |
adhd impairment | #78 |
predixcan | #78 |
women antidepressants | #78 |
student athletes | #79 |
schizophrenic patients | #79 |
genetic linkage studies | #79 |
studies relationship | #79 |
pregnancy mothers | #79 |
age adhd | #79 |
n46 | #79 |
retrospective assessment | #79 |
anxiety separation | #79 |
obesity metabolic syndrome | #79 |
nosological | #79 |
additive effects | #79 |
patients adhd | #79 |
cardinal | #79 |
disorder panic | #79 |
linkage chromosome | #80 |
adhd drugs | #80 |
siblings schizophrenia | #80 |
clinical interview | #80 |
adhd rats | #80 |
total brain | #80 |
maternal smoking | #80 |
subcortical brain volumes | #81 |
major diagnostic | #81 |
bipolar disorder | #81 |
differences age | #81 |
interregional profiles | #81 |
hacking | #81 |
treatment adults | #81 |
children parents | #81 |
endophenotypes | #81 |
eyhs | #81 |
pathophysiology adhd | #81 |
body mass diabetes | #81 |
oral routes | #81 |
disliking | #81 |
gene schizophrenia | #82 |
behavior assessment | #82 |
frontopolar cortex | #82 |
comorbidity disorders | #82 |
association maternal smoking | #82 |
adults asd | #82 |
square distribution | #82 |
auditory verbal | #82 |
cumulative evidence | #82 |
impaired quality life | #82 |
comorbidity survey | #82 |
symptoms diagnosis | #82 |
genes pathways | #82 |
adult form | #83 |
tests risk | #83 |
paterson | #83 |
unreliability | #83 |
disorders anxiety | #83 |
oros | #83 |
illness | #83 |
neurocognitive functioning | #83 |
substance disorders | #83 |
multifactorial inheritance | #83 |
management adhd | #83 |
21 months | #84 |
women adhd | #84 |
15q133 | #84 |
complex disorder | #84 |
adhd adhd symptoms | #84 |
hyperkinetic disorder | #85 |
european samples | #85 |
monitoring response | #85 |
brain asymmetry | #85 |
adhd assessment | #85 |
atomoxetine | #85 |
humans risk | #85 |
9r | #85 |
adhdrsiv | #85 |
recycling endosome | #85 |
linkage loci | #85 |
genomics consortium | #85 |
wide significance | #85 |
buprenorphine maintenance | #85 |
adhd subtypes | #85 |
paranoid | #86 |
child conduct | #86 |
parents | #86 |
findings implications | #86 |
humans inhibition | #86 |
siblings children | #86 |
affective psychosis | #86 |
pord | #86 |
risk alleles | #87 |
comparison children | #87 |
ptsd trauma | #87 |
bipolar spectrum disorder | #87 |
putamen volume | #87 |
3utr | #87 |
n203 | #87 |
bipolar | #87 |
synaptosomal protein | #87 |
common risk | #88 |
comorbid psychopathology | #88 |
bonferroni correction | #88 |
drug effects | #88 |
druggable | #88 |
hyperkinetic | #88 |
auditory attention | #89 |
comprehensive identification | #89 |
2455 | #89 |
chrna2 | #89 |
22 studies | #89 |
metaanalytic review | #89 |
empirically | #89 |
nucleotide schizophrenia | #89 |
machine learning analysis | #89 |
euphoric | #89 |
caars | #89 |
prenatal nicotine exposure | #89 |
watt | #90 |
pervasive | #90 |
242 | #90 |
1month | #90 |
attention deficit hyperactivity | #90 |
snps haplotypes | #90 |
association metaanalysis | #90 |
male neuropsychological | #90 |
linkage genome | #90 |
antidepressants pregnancy | #90 |
verbal ability | #90 |
parental socioeconomic status | #91 |
adhd efficacy | #91 |
complicates | #91 |
naturalistic study | #91 |
identified studies | #91 |
assertion | #91 |
adhd males | #91 |
cortical brain | #91 |
wcst | #91 |
adhd treatments | #91 |
callousness | #91 |
treatment mania | #92 |
studies association | #92 |
candidate gene | #92 |
h2snp | #92 |
studies sex | #92 |
documenting | #92 |
adults schizophrenia | #92 |
raise | #92 |
ymrs | #93 |
standardized differences | #93 |
referral consultation | #93 |
rate adult | #93 |
lifetime cannabis | #93 |
controls participants | #93 |
narrowly | #93 |
gottman | #94 |
gprc5b | #94 |
adhd measures | #94 |
hfasd | #94 |
cdh13 | #94 |
social development | #94 |
performance variability | #94 |
brain case | #94 |
sustained attention | #94 |
hyperactivity autistic | #94 |
underachievement | #94 |
aldh1l1 | #94 |
growing body | #94 |
studies differences | #95 |
total brain volume | #95 |
executive | #95 |
infa | #95 |
adolescents bipolar | #95 |
asd study | #95 |
mdd bip | #95 |
minisatellite | #95 |
cadps2 | #95 |
scq | #96 |
behavior rating inventory | #96 |
chromosome 9q34 | #96 |
nominally | #96 |
nxph1 | #96 |
phenotype polymorphism | #96 |
uvntr | #96 |
hcadherin | #97 |
low cardiorespiratory fitness | #97 |
genome‐wide association study | #97 |
7q36 | #97 |
adolescent onset | #97 |
children tics | #97 |
studies asthma | #97 |
driving behavior | #98 |
massachusetts general hospital | #98 |
syn2 | #98 |
linkage study | #98 |
identically | #98 |
wdpcp | #98 |
hyperactivity brazil | #98 |
induced hyperalgesia | #98 |
concerta | #98 |
single nucleotide receptor | #98 |
oppositionality | #98 |
nonfamilial | #98 |
bipolar disorder risk | #98 |
nonspecificity | #99 |
substrains | #99 |
adhd role | #99 |
disease genetics | #99 |
medication effects | #99 |
psychoactive | #99 |
disorder diagnosis | #99 |
metaanalysis trials | #99 |
xp114 | #99 |
motor timing | #99 |
neurodevelopmental processes | #99 |
methodssubjects | #99 |
chd6 | #99 |
abuse potential | #99 |
clinical effects | #100 |
reticence | #100 |
12year | #100 |
hippocampal subfield volumes | #100 |
adhd methylphenidate | #100 |
pelham | #100 |
terror | #100 |
obesity abdominal obesity | #100 |
neurocognitive impairments | #101 |
cosegregation | #101 |
harlan | #101 |
schizophrenia psychotic | #101 |
diagnostic boundaries | #101 |
genetic risk scores | #101 |
depression pregnant women | #101 |
addictive drugs | #101 |
roh | #101 |
advanced paternal age | #101 |
empirical test | #101 |
torture | #101 |
slc6a4 gene | #101 |
tsls | #101 |
genomewide | #101 |
upsit | #101 |
disorder psychiatric | #102 |
functional pathways | #102 |
individuals aud | #102 |
sob | #102 |
parents offspring | #102 |
treatment seeking | #102 |
klf13 | #102 |
male neuropsychological tests | #102 |
inhibition psychological | #102 |
touchstone | #103 |
symptom profile | #103 |
schizophrenia mood disorders | #103 |
genome wide association | #103 |
genetic pedigree polymorphism | #103 |
clinical picture | #103 |
pgc | #103 |
ocd children | #103 |
patients 12 months | #103 |
tourette disorder | #104 |
motor competence | #104 |
genetic mechanism | #104 |
individual sites | #104 |
schizophrenia metaanalysis | #104 |
controlled studies | #104 |
1934 | #104 |
genomic region | #104 |
schizophrenia probands | #105 |
neuropsychological dysfunction | #105 |
academic problems | #105 |
dsmiv diagnosis | #105 |
school dropout | #105 |
current article | #105 |
adhd review | #105 |
drug dyskinesia | #105 |
children methylphenidate | #106 |
humans lod | #106 |
cogs | #106 |
children odd | #106 |
disorder female | #107 |
ldn | #107 |
chronic tic disorders | #107 |
oral methylphenidate | #107 |
matter volumes | #107 |
λs | #107 |
lenticular | #107 |
functional correlates | #107 |
sequential analysis | #107 |
mothers adhd | #107 |
daao | #107 |
consecutive sample | #107 |
adolescents bipolar disorder | #107 |
growth outcomes | #107 |
pervasive developmental | #108 |
proband | #108 |
nesarc | #108 |
origin effects | #108 |
symptoms childhood | #108 |
n197 | #108 |
maternal warmth | #108 |
aged psychiatric | #108 |
site differences | #108 |
afni | #108 |
918 | #108 |
pediatric psychopharmacology | #108 |
antimanic agents | #108 |
association cigarette smoking | #108 |
adhd medication | #109 |
longitudinal trajectories | #109 |
irrespective | #109 |
neuroleptic medication | #109 |
depression bipolar | #109 |
total scores | #109 |
risk bipolar disorder | #109 |
worthy | #109 |
psychosis proneness | #109 |
gabra6 | #109 |
linkage association | #110 |
rat models | #110 |
markers genome | #110 |
enlistment | #110 |
adhd parent | #110 |
adult adhd symptoms | #110 |
affective symptoms | #111 |
dimorphisms | #111 |
n107 | #111 |
selective reporting | #111 |
symptom ratings | #111 |
dao | #111 |
5httlpr genotype | #111 |
affective psychoses | #111 |
independent studies | #112 |
childhood risk factors | #112 |
brain gene expression | #112 |
pediatric obsessive | #112 |
factors social | #112 |
bipolar parents | #112 |
unmedicated | #112 |
impact exposure | #112 |
substantial proportion | #112 |
dopamine d4 receptors | #112 |
male prevalence | #113 |
neuropsychological functions | #113 |
xr | #113 |
cronbach | #113 |
analysis statistical | #114 |
comorbid anxiety | #114 |
omim | #114 |
functional neuroanatomy | #114 |
liability | #115 |
n34 | #115 |
–r | #115 |
nuclear families | #115 |
endorsed | #115 |
schizophrenia severity | #115 |
genet | #115 |
formulating | #116 |
diseases twins | #116 |
schizophrenic psychology | #116 |
neuropsychological | #116 |
wm abnormalities | #116 |
prenatal smoking | #117 |
unipolar | #117 |
coordinated analysis | #117 |
trait impulsivity | #117 |
neurocognitive endophenotypes | #117 |
current symptoms | #117 |
z29 | #117 |
quality life outcomes | #117 |
polygenic association | #117 |
satisfaction questionnaire | #118 |
definitively | #118 |
genetic receptor serotonin | #118 |
grandiosity | #118 |
grandfathers | #118 |
large study | #118 |
academic functioning | #118 |
major female | #118 |
spm2 | #118 |
prevention science | #118 |
method data | #119 |
efd | #119 |
naa ratio | #119 |
dopaminergic genes | #119 |
midadolescence | #119 |
schizophrenia linkage | #119 |
differences children | #120 |
t01 | #120 |
misunderstandings | #120 |
new avenues | #121 |
aunts | #121 |
disorder autism | #121 |
subfield volumes | #121 |
neurocognitive deficits | #121 |
cgibp | #121 |
remittance | #121 |
n108 | #121 |
disregard | #122 |
urvs | #122 |
refute | #122 |
levels adhd | #122 |
pabs | #122 |
brain alterations | #122 |
v11 | #122 |
schizoaffective | #122 |
anxious | #122 |
structural brain alterations | #122 |
neuropsychiatric disorders | #122 |
male risk | #122 |
msit | #122 |
psychopathology symptoms | #122 |
adhd comorbidity | #122 |
disorder depressive | #122 |
age initiation | #123 |
clinical status | #123 |
wechsler | #123 |
chr psychosis | #123 |
adcy2 | #123 |
adhd ocd | #123 |
9q34 | #124 |
trios | #124 |
treatment subjects | #124 |
drug placebo | #124 |
maximum lod score | #124 |
twothirds | #124 |
laboratory observations | #124 |
wechsler intelligence scale | #124 |
attention regulation | #124 |
longitudinal sample | #124 |
g×s interaction | #124 |
p097 | #124 |
segregation analysis | #125 |
caregiver strain | #125 |
machine learning prediction | #125 |
disorder risk | #125 |
anxiety problems | #125 |
psychosis individuals | #125 |
patients chronic schizophrenia | #125 |
odd conduct disorder | #126 |
drug disorders | #126 |
positive negative symptoms | #126 |
familial influences | #126 |
memory adhd | #126 |
developmental aspects | #126 |
biological parents | #126 |
complex genetics | #126 |
parent version | #126 |
drd2 | #127 |
disinhibited | #127 |
genes | #127 |
taiwanese population | #127 |
attention child | #127 |
adult alleles | #127 |
psychiatric diagnoses | #127 |
stevenson | #127 |
aged 6 | #128 |
neuropsychological measures | #128 |
opiate antagonists | #129 |
behavioral outcome | #129 |
personality assessment | #129 |
familial | #129 |
implicate | #129 |
intactness | #129 |
n102 | #129 |
retrospective data analysis | #130 |
families | #130 |
adhd inattention | #130 |
1990a | #130 |
mood anxiety disorders | #131 |
register study | #131 |
bip mdd | #131 |
moderating effects | #131 |
adolescents ocd | #131 |
kinesthesia | #131 |
strong evidence | #131 |
animals attention | #131 |
incapacitation | #131 |
snps | #131 |
differed | #131 |
pair 15 chromosomes | #131 |
male prospective | #132 |
child cognition | #132 |
large european cohort | #132 |
learning disabilities | #132 |
linkage humans | #132 |
hkd | #132 |
childhood anxiety disorders | #132 |
n79 | #132 |
late adolescents | #132 |
entire brain | #132 |
sodas | #132 |
p074 | #132 |
mph | #133 |
onset bipolar disorder | #133 |
heroin dependence | #133 |
disorders social | #134 |
vntr | #134 |
preliminary examination | #134 |
children adults | #134 |
association analyses | #135 |
male massachusetts | #135 |
social deficits | #135 |
relied | #136 |
social environments | #136 |
sorcs3 | #136 |
firstborns | #136 |
risk factors smoking | #136 |
tspan8 | #136 |
olfactory identification | #136 |
adolescents young | #136 |
memantine treatment | #137 |
schizophrenia affective disorders | #137 |
adolescent bipolar | #137 |
association asthma | #137 |
expressed emotion | #137 |
gaming | #137 |
psychological male memory | #137 |
studies examined | #137 |
longitudinal evidence | #137 |
biomarkers diagnosis | #138 |
mtor activation | #138 |
control individuals | #138 |
6q | #138 |
asds | #138 |
evidence association | #138 |
mgh | #139 |
symptoms disorders | #139 |
meet | #139 |
n129 | #139 |
neuropsychiatric | #139 |
fhr | #139 |
schizophrenia studies | #139 |
schizotypal traits | #140 |
parental anxiety | #140 |
intriguing | #140 |
n115 | #140 |
haplotype block | #141 |
genetic vulnerability | #141 |
disorder comorbidity | #141 |
emotional symptoms | #141 |
prss | #141 |
disorders psychotic | #142 |
neurotrophic | #142 |
covid19 restrictions | #142 |
22q112 deletion syndrome | #142 |
5ht1b receptors | #142 |
disorders personality | #142 |
molecular genetics | #143 |
peripheral biomarkers | #143 |
hydrogen exchangers | #143 |
conduct | #143 |
risk factors obesity | #143 |
fetal movement | #143 |
rfg | #144 |
elston | #144 |
diagnostic procedure | #144 |
humans linear | #144 |
statistical female humans | #144 |
blind study | #144 |
child psychopathology | #144 |
g72 | #144 |
diagnosed attention | #144 |
agents tricyclic | #144 |
p00018 | #145 |
n105 | #145 |
genetic heterogeneity | #145 |
individual symptoms | #145 |
affs | #145 |
early initiation | #145 |
major psychoses | #145 |
pcb exposure | #145 |
studies depressive | #145 |
drug alcohol | #145 |
common genetic variants | #145 |
genome‐wide association studies | #145 |
twin studies | #146 |
warranted | #146 |
prenatal nicotine | #146 |
genders | #146 |
intelligence quotient | #146 |
atypicality | #146 |
oppositional behavior | #146 |
adult psychopathology | #146 |
p0016 | #147 |
abbreviated | #147 |
histrionic | #147 |
comprising | #147 |
intraindividual variability | #147 |
lras | #147 |
single locus | #148 |
basc | #148 |
cognitive variables | #148 |
adolescent young | #148 |
sabp | #148 |
brain correlates | #149 |
cdrsr | #149 |
schizotypy | #149 |
adhd symptoms children | #149 |
risk mdd | #149 |
parental substance | #149 |
chrnb2 | #150 |
nonmedical | #150 |
adhd relationship | #150 |
highlighting | #150 |
impulsive | #150 |
categorical | #150 |
sud treatment | #150 |
synaptic biology | #151 |
consisted | #151 |
higher burden | #151 |
atxn1 | #152 |
schizophrenia diagnosis | #152 |
undegraded | #152 |
xq21 | #152 |
functional impairment | #152 |
metaanalytic | #152 |
copy variants cnvs | #152 |
linkage disequilibrium mapping | #152 |
implicates | #152 |
increases risk | #152 |
parent report | #152 |
placebo subjects | #152 |
autistic traits | #152 |
diagnostic systems | #152 |
large sample | #152 |
httlpr | #152 |
alcohol conditions | #153 |
caucasian children | #153 |
schizophrenia bipolar disorder | #153 |
schizophrenia deficits | #153 |
marginally | #153 |
humans learning | #153 |
5 httlpr | #153 |
genomewide linkage | #153 |
editions | #153 |
demoralization | #153 |
wisc | #154 |
schizophrenia magnetic resonance | #154 |
dsm | #154 |
emphasizing | #154 |
exposure maternal | #154 |
disorder phenotype | #154 |
atomoxetine placebo | #154 |
year follow | #155 |
ncsr | #155 |
genomewide scan | #155 |
humans polymorphism | #155 |
snpheritability | #155 |
clarification | #155 |
genetic risk | #156 |
prospective controlled study | #156 |
tests male | #156 |
n84 | #156 |
600000 | #156 |
interpersonal functioning | #156 |
enigma consortium | #157 |
panic disorder agoraphobia | #157 |
dopamine d4 | #157 |
new knowledge | #157 |
htr2c | #158 |
drd4 genotype | #158 |
greatest | #158 |
cognitive tempo | #158 |
primary setting | #158 |
oprm1 | #158 |
ppp2r2b | #158 |
genetic linkage | #158 |
sledai | #158 |
myo5b | #158 |
clinical diagnostic | #158 |
adolescents | #158 |
teachers parents | #159 |
nonpersistent | #159 |
selfratings | #159 |
quetiapine treatment | #159 |
adult human brain | #159 |
patients substance | #159 |
dav | #159 |
medial temporal | #160 |
age onset | #160 |
separation anxiety disorder | #160 |
humans impulsive | #160 |
smds | #160 |
genetic component | #161 |
hyperactivity disorders | #161 |
tic symptoms | #161 |
population samples | #161 |
adult adhd patients | #161 |
schizophrenia bipolar | #161 |
behavioral difficulties | #161 |
140 | #162 |
empirical tests | #162 |
rats wky | #162 |
disorder clinical | #162 |
ksadspl | #162 |
cooccurring disorders | #162 |
disorder depression | #162 |
neurobiology | #163 |
5htt | #163 |
paternal age | #163 |
sample | #163 |
dn cells | #163 |
dsmiv | #163 |
neuropsychological tests | #163 |
anxiety attention | #164 |
familial liability | #164 |
diagnostic status | #164 |
illness schizophrenia | #164 |
complex phenotype | #164 |
impairments | #164 |
boys girls | #165 |
risk subsequent | #165 |
washington university | #165 |
neurocognitive performance | #165 |
years children | #165 |
genetic influence | #166 |
12–14 | #166 |
symptom reduction | #166 |
antidepressant therapy | #166 |
receptor gene | #166 |
linkage genetic | #166 |
earlyonset schizophrenia | #166 |
shared environment | #166 |
domain criteria | #166 |
cotwins | #166 |
alcohol disorders aud | #166 |
association obesity | #167 |
ipsych | #167 |
moderates | #167 |
wisciii | #168 |
neurocognitive functions | #168 |
polygenic architecture | #168 |
leonard | #168 |
children 6 years | #168 |
multifactorial | #169 |
genetic association analysis | #169 |
n111 | #169 |
international congress | #169 |
perseverations | #169 |
duration illness | #169 |
matter microstructure | #169 |
cfg | #170 |
risk gene | #170 |
pharmacodynamic properties | #170 |
anxiety child | #170 |
single nucleotide schizophrenia | #170 |
lgi | #170 |
traumas | #170 |
arrb2 | #170 |
disorders young | #170 |
conditional probability | #170 |
genesets | #171 |
n91 | #171 |
child psychiatry | #171 |
functional laterality humans | #171 |
immune disorders | #172 |
treatment studies | #172 |
inattention impulsivity | #172 |
interpersonal sensitivity | #173 |
enuresis | #173 |
disorders study | #173 |
male mental | #174 |
gabbr1 | #174 |
subsyndromal | #175 |
large samples | #175 |
tics | #175 |
confounds | #176 |
development schizophrenia | #176 |
mph placebo | #176 |
confounded | #177 |
suicide death | #177 |
kraepelin | #177 |
hyperactive children | #177 |
disorders sex | #177 |
independent datasets | #177 |
patients opioid | #177 |
ascertainment | #177 |
strong genetic component | #178 |
n78 | #178 |
cortical surface | #178 |
parent rated | #178 |
behaviorally | #179 |
genetic confounding | #179 |
gene interactions | #179 |
pregnancy children | #179 |
strongest evidence | #179 |
underpinnings | #179 |
atomoxetine atx | #179 |
nagelkerke | #180 |
connectivity networks | #180 |
cvlt | #180 |
copy variants | #180 |
unemotional traits | #181 |
perceptual disorders | #181 |
combinatory | #181 |
mothers pregnancy | #181 |
scz bip | #182 |
271 | #182 |
htr4 | #182 |
phenocopies | #182 |
structured | #182 |
control participants | #182 |
genotype humans | #183 |
mechanistic target | #183 |
psychometric testing | #183 |
rating | #183 |
studies gwas | #183 |
based morphometry | #184 |
reading difficulties | #184 |
effects atomoxetine | #184 |
wei | #184 |
pdd | #185 |
long acting | #185 |
phenocopy | #185 |
genome human | #185 |
reward sensitivity | #185 |
allison | #185 |
n‐acetylcysteine | #185 |
predominately | #186 |
hyperactivity symptoms | #186 |
biomarker studies | #186 |
218 | #186 |
statistical female | #186 |
stratifying | #187 |
schizophrenia major depression | #187 |
risperidone placebo | #187 |
schizophrenia evidence | #187 |
depression treatment | #188 |
parahippocampus | #188 |
blood biomarkers | #188 |
3 untranslated region | #188 |
autocorrelation | #188 |
enigma | #188 |
differential association | #189 |
bna | #189 |
genetic correlations | #189 |
undertreatment | #189 |
medication adhd | #190 |
linkage evidence | #190 |
functioning children | #190 |
childhood | #190 |
scwt | #190 |
social dysfunction | #191 |
implicated | #191 |
mph children | #191 |
psychiatric phenotypes | #191 |
greater activation | #191 |
fsiq | #191 |
clarify | #191 |
schedule female | #191 |
mood disorder | #191 |
dopamine genes | #191 |
iasp | #192 |
association response | #192 |
612 years | #192 |
inconsistent findings | #194 |
joseph | #194 |
freedman | #194 |
placebo p001 | #195 |
polymorphisms snps | #195 |
cognitive endophenotypes | #195 |
sza | #195 |
clinical global | #195 |
perinatal complications | #197 |
wm performance | #197 |
dependence symptoms | #197 |
neural substrates | #197 |
overactivity | #197 |
arhgef9 | #197 |
developmentally | #198 |
mdd scz | #198 |
snps schizophrenia | #198 |
lifetime diagnosis | #198 |
ptk2b | #198 |
g×s | #198 |
specific genes | #199 |
raises | #199 |
male | #199 |
childhood symptoms | #199 |
male phenotype | #199 |
bsd | #199 |
asic1a | #199 |
small samples | #200 |
childhood attention | #200 |
mri data | #200 |
disruptive disorders | #200 |
asd adhd | #200 |
neuropsychological battery | #200 |
catecholomethyltransferase | #201 |
parents schizophrenia | #201 |
functional genomics | #201 |
disorder humans | #201 |
cognitive flexibility | #202 |
pain tolerance | #202 |
stopsignal task | #203 |
genetic liability | #203 |
unaffected | #203 |
pdq | #203 |
childhood adulthood | #203 |
control association | #203 |
neuropsychological correlates | #203 |
extend | #204 |
microsatellite marker | #204 |
respond | #204 |
attentional control | #204 |
adolescent psychiatry | #204 |
concurrent validity | #204 |
schizophreniform | #204 |
nonshared | #206 |
selfdirectedness | #206 |
uptodate | #206 |
genes risk | #206 |
method drug | #207 |
sluggish cognitive tempo | #207 |
prolactin levels | #208 |
prkg1 | #208 |
parental alcohol | #208 |
susceptibility schizophrenia | #208 |
clinical benefits | #209 |
variable expression | #209 |
baseline follow | #209 |
park2 | #210 |
maudsley | #210 |
60mg | #210 |
correspondence | #210 |
5year followup | #210 |
acds | #210 |
n96 | #210 |
vntr polymorphism | #211 |
predisposition disease | #211 |
greater risk | #211 |
stroop task | #212 |
dimensional models | #212 |
ps005 | #212 |
apoe4 allele | #212 |
adult patients adhd | #212 |
hkdc1 | #212 |
grm7 | #212 |
replication studies | #213 |
trauma ptsd | #213 |
sought | #213 |
negative outcomes | #213 |
sampling strategy | #213 |
cvltii | #214 |
continuous performance test | #214 |
disorders models | #214 |
suggestive evidence | #214 |
humans neuropsychological | #214 |
rare cnvs | #214 |
schizophrenia chinese | #214 |
adult cognition | #215 |
bilag | #215 |
lifetime version | #215 |
male mental disorders | #215 |
vivo correlation | #216 |
functional mri study | #216 |
chromosome 15 | #217 |
glr | #217 |
antisocial personality | #217 |
male schizophrenia | #217 |
panic | #218 |
parental | #218 |
gene based | #218 |
hippocampal subfield | #218 |
trim31 | #218 |
polygenic | #219 |
study selection | #219 |
misunderstood | #219 |
drug double | #220 |
normal controls | #220 |
snpa | #220 |
irritable mood | #221 |
parental psychopathology | #221 |
telephone interview | #221 |
symptoms adults | #221 |
triangularis | #221 |
studies cognition | #221 |
childhoodonset | #222 |
n76 | #222 |
diagnoses | #222 |
score male | #222 |
patient engagement | #222 |
methyltransferase comt | #222 |
learning disability | #223 |
study findings | #223 |
revisited | #223 |
adhd sleep | #224 |
axis disorders | #224 |
effective treatments | #224 |
gria2 | #224 |
sensing ion | #224 |
abnormalities schizophrenia | #224 |
bipolar spectrum | #225 |
default network | #225 |
coordination disorder | #225 |
hk3 | #226 |
inattentiveness | #226 |
children placebo | #226 |
subfields | #226 |
unemotional | #227 |
disorder study | #227 |
criteria diagnosis | #227 |
dependent variables | #227 |
subcortical regions | #227 |
individual variability | #227 |
scales psychotic | #227 |
age subjects | #228 |
male twins | #228 |
atomoxetine treatment | #228 |
comorbid anxiety disorders | #228 |
control based | #228 |
birth complications | #229 |
overlapped | #229 |
equally | #229 |
structural abnormalities | #229 |
psychiatric outcomes | #230 |
commission errors | #231 |
heritable | #231 |
4years | #231 |
risk indicators | #231 |
international multicenter | #231 |
hyperactivity behavior | #232 |
differences prevalence | #232 |
serotonin transporter gene | #232 |
candidate genes | #234 |
study sample | #234 |
worse performance | #234 |
probabilistic forecasts | #235 |
disorder medication | #235 |
discriminating | #235 |
shr wky rats | #236 |
reliably | #238 |
agoraphobia | #238 |
route administration | #238 |
fifty years | #238 |
placebo response | #238 |
allelic heterogeneity | #239 |
nosology | #240 |
healthy siblings | #240 |
acid oxidase | #240 |
pdag | #240 |
scientific data | #240 |
patients siblings | #240 |
doubleblind | #241 |
symptoms quality | #241 |
adequately | #241 |
adolescent offspring | #241 |
disorder asd | #241 |
reward processing | #242 |
impulsive choice | #242 |
psychiatric comorbidities | #242 |
neurodevelopmental model | #242 |
joint analysis | #242 |
sodium hydrogen | #242 |
patients relatives | #243 |
aggressive behaviors | #243 |
female | #243 |
valid | #243 |
onset obsessive | #243 |
giftedness | #244 |
n74 | #244 |
adversity | #245 |
5ht2a receptor | #245 |
paliperidone | #245 |
population differences | #245 |
interregional | #245 |
disorder ptsd | #245 |
cadm2 | #246 |
community controls | #246 |
dsmivtr | #246 |
expression genetic | #246 |
motor performance | #247 |
812 | #247 |
epigenetic studies | #248 |
studies associations | #248 |
cigarette smoking | #248 |
chinese families | #248 |
developmental disorder | #249 |
behavioral characteristics | #251 |
childs | #251 |
german patients | #252 |
hypoactivation | #252 |
genomewide association | #253 |
intellect | #253 |
female subjects | #253 |
iqs | #253 |
tourette | #253 |
study schizophrenia | #254 |
kappas | #254 |
benzodiazepine | #254 |
cpt performance | #254 |
schizophrenia adult | #254 |
studies metaanalysis | #254 |
conduct problems | #255 |
biochemical studies | #256 |
shared genetic | #256 |
cacna1c gene | #256 |
larsson | #256 |
carlson | #257 |
children adhd symptoms | #257 |
year study | #259 |
parental depression | #259 |
endorsement | #259 |
piq | #260 |
n61 | #260 |
dexamphetamine | #261 |
pharmacotherapy | #261 |
anxiety depressive disorders | #261 |
diagnosis | #261 |
selfreports | #263 |
genomewide linkage scan | #263 |
obsessive compulsive disorder | #263 |
22q11ds | #263 |
sex factors | #263 |
fluid intelligence | #263 |
adverse health | #264 |
distinct subtypes | #264 |
attention problems | #264 |
disorder personality | #264 |
confirm | #264 |
conceptualized | #264 |
long term outcomes | #265 |
new models | #266 |
schizophrenia cases | #266 |
5090 | #266 |
ptsd risk | #266 |
diagnostic validity | #266 |
phenotype schizophrenia | #267 |
scz mdd | #267 |
strong support | #268 |
genetic approaches | #268 |
neuropsychological impairment | #268 |
diagnosis schizophrenia | #268 |
diagnostic process | #269 |
years baseline | #269 |
test scores | #269 |
segregate | #270 |
withdrawn | #270 |
largest | #270 |
phlda1 | #270 |
age effects | #270 |
symptoms assessed | #271 |
genetic overlap | #271 |
circadian genes | #271 |
adult psychiatric | #271 |
social adversity | #271 |
sibling pairs | #271 |
structural brain | #272 |
diagnostic issues | #272 |
statistics topic | #273 |
rora | #273 |
444 | #273 |
szs | #273 |
age | #273 |
schizophrenia siblings | #273 |
4year | #273 |
search terms | #273 |
alcohol smoking | #273 |
22 years | #274 |
sleep behavior | #274 |
maf1 | #275 |
surgency | #275 |
underlie | #275 |
reading disability | #275 |
missingness | #276 |
2q | #276 |
familial schizophrenia | #276 |
t102c | #276 |
mania symptoms | #277 |
adhd healthy controls | #277 |
nicotinic schizophrenia | #277 |
adolescent risk | #277 |
growing evidence | #277 |
early psychosis | #278 |
clinical setting | #278 |
manual | #278 |
nr3c1 | #278 |
synaptosomal | #278 |
silico approach | #279 |
ocd | #279 |
nicotine dependence | #279 |
intelligence scale | #279 |
n47 | #280 |
rating scale | #280 |
brain volumes | #280 |
cognition female | #280 |
abuser | #280 |
child parent | #280 |
remitted | #280 |
acting | #280 |
polygenic risk | #280 |
phenotyped | #281 |
individuals | #281 |
disorders adult | #281 |
psychotic bipolar | #281 |
premature death | #281 |
response inhibition | #282 |
onset ocd | #282 |
collaborative analysis | #282 |
reading problems | #282 |
5ht1b | #282 |
antisocial behaviors | #283 |
titrated | #283 |
velo | #283 |
continue | #283 |
aspd | #284 |
3untranslated region | #285 |
gria3 | #285 |
normal variation | #285 |
quantitative traits | #285 |
neoffi | #285 |
neuroanatomical | #285 |
swanson | #286 |
scale children | #286 |
quantitative analyses | #286 |
explication | #286 |
clues | #286 |
siblings patients | #286 |
effects age | #287 |
deficit schizophrenia | #288 |
schizophrenia abnormalities | #288 |
postmortem brain | #289 |
bmisds | #289 |
psychiatric traits | #290 |
pediatric ocd | #290 |
22q112 | #290 |
disease haplotypes | #290 |
publication bias | #291 |
low serum levels | #291 |
subcortical volumes | #291 |
substrain | #292 |
groups children | #293 |
modest | #293 |
cognition disorders | #294 |
subjective responses | #294 |
hypertensive rat | #294 |
salary | #294 |
psychosis schizophrenia | #295 |
interference control | #295 |
risk factors children | #295 |
post‐traumatic stress disorder | #295 |
dtnbp1 | #295 |
adverse impact | #295 |
european populations | #295 |
executive functions | #296 |
ldsc | #296 |
continuous performance | #296 |
anxiety disorder | #297 |
obesity overweight | #297 |
early onset | #297 |
asd traits | #297 |
reanalysis | #298 |
discriminated | #298 |
diagnostic approach | #298 |
predisposition | #299 |
negative symptom | #299 |
effects stress | #300 |
cortical thickness | #300 |
qvalues | #300 |
cognitive measures | #301 |
roc analysis | #301 |
psychiatric hospitalization | #301 |
prefrontal function | #302 |
states adolescent | #302 |
intrasubject variability | #302 |
emotional problems | #302 |
published literature | #302 |
height body | #303 |
permuted | #303 |
psychometrics | #303 |
psychiatric conditions | #304 |
795 | #304 |
affective disorders | #305 |
interviewers | #305 |
dsm5 | #305 |
manifest | #305 |
ats | #305 |
case subjects | #305 |
aggressive behavior | #305 |
dopamine transporter | #306 |
early morning | #306 |
n62 | #307 |
learning disorder | #307 |
general psychopathology | #308 |
spencer | #309 |
documented | #309 |
perseveration | #309 |
omission errors | #309 |
myh9 | #309 |
membrane transport | #309 |
gene environment | #309 |
genetic schizophrenia | #310 |
memory wm | #310 |
efficacy treatment | #310 |
motor domain | #310 |
life social support | #310 |
adolescent aggression | #310 |
rdoc | #311 |
stroop test | #312 |
childhood adolescence | #312 |
gender age | #312 |
mainstays | #312 |
npsr1 | #313 |
mapping female | #313 |
genetic analyses | #314 |
underscore | #314 |
risk estimation | #315 |
bedtimes | #315 |
asb | #317 |
dorsolateral prefrontal cortex | #317 |
replicated | #317 |
schizophrenia review | #318 |
demonstrable | #318 |
5ht2c | #319 |
individual genes | #319 |
n55 | #319 |
adolescent adrenergic | #320 |
gene | #321 |
shared genetic influences | #321 |
intelligence tests | #321 |
addictive disorders | #321 |
humans longitudinal | #322 |
risperidone treatment | #322 |
127 | #322 |
robins | #322 |
bipolar type | #322 |
time variability | #323 |
abusers | #323 |
nolan | #324 |
guanfacine | #324 |
conceptual models | #324 |
manic | #325 |
yielded | #326 |
sex characteristics | #326 |
neonatal abstinence syndrome | #326 |
status female | #327 |
impaired | #327 |
spurious | #327 |
xq26 | #327 |
etiologic | #328 |
comprised | #328 |
disorders pervasive | #329 |
8q | #329 |
metaanalyses | #330 |
sexdifferences | #330 |
overrepresented | #330 |
drug response | #331 |
htr2a | #331 |
scores patients | #331 |
women schizophrenia | #332 |
naltrexone | #333 |
txndc5 | #333 |
expression brain | #333 |
familial factors | #333 |
obesity diabetes | #334 |
multiple comparisons | #334 |
cognitive dysfunctions | #334 |
adler | #335 |
mood disorders | #335 |
24weeks | #335 |
forthcoming | #335 |
inferior parietal lobule | #336 |
persist | #336 |
humans mental | #336 |
methylphenidate placebo | #336 |
rey | #336 |
mobp | #337 |
neuropsychological test | #337 |
asd individuals | #337 |
tph2 | #337 |
777 | #337 |
disentangle | #338 |
evening | #339 |
replications | #339 |
patients attention | #339 |
psychopathological | #339 |
pnmt | #340 |
consistently | #340 |
exclusion criteria | #340 |
evidence linkage | #340 |
disorder ocd | #340 |
treatment bipolar | #341 |
placebo effects | #341 |
intelligence | #341 |
encompassing | #341 |
phobic | #342 |
maoa genotype | #342 |
bipolarity | #342 |
neuroimaging studies | #342 |
visual memory | #342 |
multicenter analysis | #342 |
frontal pole | #344 |
integrated analysis | #344 |
tbv | #344 |
comorbid diagnoses | #344 |
mood problems | #344 |
schizoaffective disorder | #344 |
casecontrol studies | #345 |
catechol methyltransferase | #345 |
systematically | #345 |
gifts | #346 |
864 | #346 |
mdd bpd | #347 |
confused | #347 |
study genotype | #347 |
psychotic | #348 |
converging | #348 |
tic severity | #348 |
collaborative study | #349 |
temporal processing | #349 |
schizotypal personality disorder | #349 |
adolescent anxiety | #350 |
aetiological | #350 |
methylphenidate atomoxetine | #350 |
suspiciousness | #351 |
receptor genes | #352 |
disequilibrium | #352 |
distractibility | #352 |
adults children | #352 |
impairing | #353 |
disease genome | #353 |
reln | #354 |
gabra1 | #354 |
genetic environmental | #354 |
substantial | #354 |
brain atlas | #354 |
executive attention | #354 |
disorders middle | #354 |
maob | #354 |
child attention | #354 |
rgs4 | #355 |
dsmiii | #355 |
prodh | #355 |
male adolescent | #355 |
schizophrenia data | #356 |
phobic disorders | #356 |
heterogeneous disorder | #356 |
chrna7 | #357 |
children anxiety disorders | #357 |
measures attention | #357 |
gottesman | #358 |
deviant | #359 |
maternal cigarette smoking | #359 |
persists | #359 |
psychiatric symptoms | #359 |
disorder patients | #359 |
symptom scores | #360 |
linkage analysis | #360 |
neuroleptic treatment | #361 |
n54 | #361 |
chromosomal regions | #361 |
social adjustment | #362 |
dorsolateral prefrontal | #363 |
genetic findings | #364 |
tid | #365 |
paralimbic | #365 |
core symptoms | #366 |
confirmation | #366 |
elevated risk | #366 |
memory load | #367 |
pediatric populations | #367 |
771 | #367 |
risk psychopathology | #368 |
comparison groups | #368 |
study entry | #368 |
bpd mdd | #368 |
702 | #369 |
differential involvement | #369 |
hyperactivityimpulsivity | #369 |
young adulthood | #369 |
nervousness | #370 |
representativeness | #370 |
differential susceptibility | #370 |
current concepts | #371 |
damphetamine | #371 |
schizophrenia risk | #371 |
endorse | #372 |
replicate | #372 |
prevention strategies | #372 |
comt gene | #372 |
executive function | #373 |
genomewide association studies | #373 |
5httlpr | #373 |
small sample | #374 |
driving performance | #374 |
snp heritability | #374 |
dozens | #375 |
916 | #375 |
wide analysis | #375 |
scz | #375 |
teenage | #376 |
medication children | #376 |
emphases | #376 |
memory short | #377 |
child adolescent | #377 |
genetic architecture | #377 |
data studies | #377 |
sas | #377 |
children medication | #377 |
impression | #378 |
children adolescents | #378 |
schizotypal personality | #378 |
control adults | #379 |
marriages | #379 |
youths | #380 |
opd | #380 |
ht1b | #380 |
pearson | #380 |
converged | #380 |
invaluable | #381 |
receptors dopamine | #381 |
culmination | #381 |
general cognitive ability | #381 |
overlap | #381 |
disorder diagnostic | #381 |
methylphenidate children | #381 |
relevant articles | #381 |
chisquare | #382 |
adolescent patients | #382 |
psychopathologies | #383 |
antimanic | #383 |
carefully | #383 |
psychopharmacological treatment | #383 |
researched | #384 |
summary statistics | #384 |
gad2 | #385 |
7r | #385 |
multigenerational | #386 |
treatment children | #386 |
18p | #386 |
chinese subjects | #387 |
neural activation | #387 |
evenings | #388 |
versa | #388 |
npas2 | #388 |
contrasted | #388 |
childhood depression | #389 |
adhd symptomatology | #389 |
handedness | #390 |
studies children | #390 |
disorder symptoms | #390 |
lefthandedness | #390 |
brain circuits | #390 |
perinatal morbidity | #390 |
genetic predisposition | #391 |
interaction genetic | #391 |
comorbid substance | #392 |
lambert | #392 |
schizophrenia susceptibility | #392 |
p54 | #393 |
substance users | #394 |
genes expression | #394 |
function humans | #395 |
dopamine norepinephrine | #395 |
hippocampal subfields | #395 |
adolescents adults | #396 |
disorders schizophrenia | #397 |
3methoxy4hydroxyphenylglycol | #397 |
psychometric | #397 |
fbat | #397 |
schizophrenia disorder | #397 |
mental health children | #397 |
earlier onset | #398 |
clinical risk psychosis | #398 |
spm8 | #398 |
wandering | #398 |
neuropsychological testing | #400 |
control sample | #401 |
core symptom | #402 |
suffocation | #402 |
academic outcomes | #402 |
inattention symptoms | #402 |
relations male | #403 |
implications findings | #403 |
inconsistencies | #403 |
hyperparameter | #405 |
psychostimulants | #405 |
diagnosis children | #406 |
n52 | #406 |
vntrs | #406 |
neuropsychiatric conditions | #406 |
parahippocampal | #406 |
attending | #407 |
childhood risk | #408 |
cognitive inhibition | #408 |
0038 | #409 |
behavior genetics | #409 |
communitybased | #409 |
distinct subsets | #410 |
substance | #410 |
reading comprehension | #411 |
children studies | #411 |
twin study | #411 |
impulsive behavior | #411 |
dextroamphetamine | #411 |
consistent evidence | #412 |
psychotic disorders | #412 |
neanderthal | #412 |
childhood anxiety | #412 |
apoe4 | #412 |
tourette syndrome | #412 |
interview | #412 |
systematic literature search | #413 |
anticipation | #413 |
moderated | #413 |
reviewing | #414 |
151 | #414 |
performance tests | #414 |
polymorphism snp | #415 |
volition | #415 |
elucidating | #416 |
genetic receptor | #416 |
schizotypal | #416 |
effects brain | #417 |
functional effects | #417 |
adult intelligence | #418 |
conferred | #418 |
adolescent psychiatric | #418 |
questionnaires adolescent | #419 |
srsa | #419 |
genetic association | #419 |
deletion syndrome | #419 |
antidepressive agents | #420 |
kdm4a | #420 |
dopamine d4 receptor | #420 |
daily doses | #420 |
sexes | #421 |
modestly | #421 |
adult subjects | #421 |
iccs | #422 |
operating characteristic | #422 |
cdis | #422 |
drug dependence | #422 |
tricyclic | #423 |
medicated | #423 |
reliability validity | #423 |
gcta | #424 |
characteristic curve | #424 |
subtests | #425 |
discovery sample | #425 |
transport proteins | #425 |
parent ratings | #426 |
cardiff | #426 |
hum | #427 |
attain | #427 |
brain volume | #428 |
spectrum disorders | #428 |
diversion | #428 |
persistent symptoms | #429 |
male obsessive | #430 |
personality development | #431 |
disentangling | #431 |
operating characteristics | #432 |
teacher | #432 |
uniquely | #433 |
peps | #434 |
wistarkyoto | #435 |
1433 | #436 |
cprs | #436 |
perceptual organization | #436 |
frequency genotype | #436 |
12q | #436 |
lower scores | #437 |
grin2a | #437 |
relatives patients | #437 |
disorder brain | #437 |
srs2 | #438 |
visual learning | #438 |
correlation coefficients | #438 |
toddlerhood | #438 |
impulsiveness | #438 |
adolescent psychopathology | #438 |
genetic genetic predisposition | #439 |
risk psychosis | #439 |
digit span | #439 |
nominal | #439 |
22q112ds | #439 |
snps association | #440 |
method female | #440 |
aged neuropsychological | #440 |
major risk factor | #440 |
trex | #441 |
post hoc analysis | #441 |
gmo | #441 |
corroborated | #441 |
allelic association | #441 |
white matter microstructure | #441 |
meaningful | #441 |
adult analysis | #442 |
planum temporale | #442 |
disorders autism | #442 |
female functional | #442 |
virtual histology | #442 |
logistic regression model | #442 |
n80 | #443 |
conferring | #444 |
disorders surveys | #444 |
10 year | #444 |
emphasize | #444 |
differential female | #444 |
pcdh10 | #445 |
nucleotide receptors | #446 |
ntrk3 | #446 |
862 | #446 |
534 | #446 |
statistic | #446 |
holland | #447 |
originally | #448 |
motor coordination | #448 |
genome wide | #448 |
behavior child | #448 |
expressiveness | #449 |
earlier age | #449 |
risk variants | #450 |
early response | #450 |
wistar kyoto | #450 |
exceptions | #451 |
sex | #451 |
prevalence correlates | #452 |
clinical expression | #452 |
subsequent risk | #452 |
brain abnormalities | #452 |
children adolescent | #456 |
chat | #456 |
psychiatry | #457 |
79 | #457 |
zscores | #457 |
structural magnetic | #458 |
preliminary study | #458 |
independently | #458 |
masse | #458 |
genetic correlation | #460 |
22q112 deletion | #460 |
522 | #460 |
psychotic disorders schizophrenia | #460 |
lander | #460 |
polygenic risk score | #460 |
hyperkinesis | #461 |
smoking pregnancy | #461 |
jw | #462 |
d4 | #463 |
neuroanatomy | #465 |
decrements | #465 |
life treatment | #465 |
affection | #465 |
pregnancy complications | #465 |
gene sets | #466 |
runs | #466 |
control rates | #466 |
mini | #467 |
anxiety depressive | #467 |
inbred wky | #467 |
bpad | #468 |
subjects patients | #469 |
disorders treatment | #470 |
patient adherence | #470 |
genetic effects | #470 |
cacna1c | #470 |
remission relapse | #471 |
receiver operating | #471 |
risk allele | #472 |
psychology adolescent | #472 |
response remission | #473 |
chrna4 | #473 |
plp1 | #474 |
norepinephrine transporter | #474 |
environmental risk factors | #474 |
cautious | #476 |
developmental coordination | #476 |
opioid addiction | #476 |
obesity children | #477 |
multiple measures | #477 |
broader | #478 |
multiplex families | #479 |
5th | #479 |
dysthymia | #479 |
humans | #480 |
genetic risk variants | #480 |
adds | #480 |
symptom | #480 |
semistructured | #481 |
diagnostic categories | #481 |
cortex child | #481 |
genotyped | #482 |
data extraction | #482 |
maternal anxiety | #482 |
etiology | #483 |
arithmetic | #483 |
verbal learning | #484 |
conception | #484 |
sml | #484 |
nfil3 | #484 |
treatment methylphenidate | #484 |
adulthood | #485 |
756 | #485 |
agents bipolar | #485 |
baseline age | #486 |
epidemiologically | #486 |
outcome variables | #486 |
symptom dimensions | #487 |
adult anxiety | #487 |
123 | #487 |
evaluates | #487 |
spontaneity | #488 |
longterm effects | #489 |
genetic disorders | #489 |
female adolescents | #489 |
unpublished | #489 |
neuropsychiatric disorder | #490 |
administration schedule | #490 |
shared environmental | #490 |
schizophrenia autism | #490 |
smoking prevention | #492 |
schizophrenia age | #492 |
common variant | #492 |
pnds | #493 |
overlapping | #493 |
late adolescence | #495 |
antisocial personality disorder | #495 |
frequency genetic | #495 |
restlessness | #497 |
pair human | #497 |
psychobiology | #497 |
separation anxiety | #497 |
anxiety | #497 |
schizophrenia patients | #497 |
longitudinal studies | #498 |
bonferroni | #498 |
genetic mechanisms | #499 |
addressed | #499 |
placebos | #499 |
candidate | #499 |
daoa | #499 |
identifying | #500 |
case reports | #500 |
comt val158met polymorphism | #500 |
rat strains | #501 |
nocebo | #501 |
d4 receptors | #501 |
verbal memory | #503 |
additional evidence | #503 |
865 | #503 |
circadian clock genes | #505 |
child executive | #505 |
n26 | #506 |
fallacy | #506 |
subscale | #506 |
cooperativeness | #507 |
continued | #507 |
tobacco disorder | #508 |
reflecting | #508 |
delay discounting | #509 |
developing schizophrenia | #509 |
agg | #510 |
shared | #511 |
educational status | #511 |
dichotomous | #511 |
identifiable | #512 |
obsessive compulsive | #512 |
95 death | #512 |
p80 | #512 |
risk haplotype | #513 |
lod | #513 |
disproportionate | #514 |
coaggregation | #514 |
phis | #515 |
morning | #515 |
assessments | #515 |
disorders depression | #515 |
normal control | #516 |
total sample | #516 |
cognitive traits | #517 |
contributing | #517 |
n39 | #517 |
15q | #518 |
missing link | #519 |
pbat | #520 |
fn1 | #520 |
environmental influences | #520 |
specificity ppv | #521 |
dichotic | #521 |
gyrus cinguli | #521 |
selfreport | #522 |
disorder obsessive | #522 |
social class | #522 |
polymorphism single | #522 |
dibenzothiazepines | #523 |
attention memory | #523 |
dedication | #524 |
adult bipolar | #524 |
phg | #524 |
dmi | #524 |
assortative | #524 |
sciencedirect | #525 |
covariates | #525 |
pacific island | #525 |
disorder treatment | #525 |
clinical diagnoses | #525 |
affiliations | #526 |
persistence | #527 |
functioning | #527 |
criminality | #527 |
adolescent children | #528 |
symptomatic remission | #528 |
design study | #528 |
adverse life events | #528 |
depression anxiety disorders | #528 |
flnc | #529 |
compulsive disorder | #529 |
community samples | #529 |
ruled | #529 |
abrupt | #529 |
parental reports | #529 |
control children | #530 |
tagsnps | #530 |
increased burden | #531 |
strongest | #531 |
medications | #531 |
existing studies | #532 |
autism schizophrenia | #532 |
n40 | #532 |
clinical sample | #533 |
subjects age | #533 |
analyses conducted | #534 |
temperament character | #534 |
asd | #535 |
selective review | #535 |
intercorrelations | #535 |
parsing | #537 |
global impression | #537 |
models genetic | #538 |
autistic symptoms | #538 |
child adhd | #538 |
d4 receptor | #539 |
milder | #541 |
personality factors | #541 |
lobe humans | #542 |
disease genotype | #543 |
single nucleotide | #543 |
taiwanese | #543 |
complexities | #544 |
severe symptoms | #544 |
independent samples | #544 |
population sample | #545 |
ld | #545 |
cognitive impairments | #546 |
choice behavior | #546 |
genetic influences | #547 |
computer program | #548 |
healthy control subjects | #548 |
functional variant | #548 |
dichotomized | #549 |
risk children | #549 |
clash | #549 |
nonclinical sample | #549 |
schizophrenia study | #549 |
patients schizophrenia | #549 |
oral route | #549 |
behavior male | #549 |
genetic pathways | #550 |
765 | #550 |
fam | #550 |
define | #551 |
motor inhibition | #551 |
case control | #551 |
ideally | #551 |
performance test | #552 |
major diagnosis | #552 |
verbal | #553 |
n29 | #553 |
preadolescent | #554 |
viewed | #555 |
prs schizophrenia | #555 |
release oral | #555 |
suggests | #555 |
phenotypic features | #556 |
spectrum disorder | #556 |
nogo task | #557 |
neuropsychiatric diseases | #557 |
child anxiety | #557 |
neurodevelopmental | #558 |
equivocal | #558 |
africanamerican | #558 |
justify | #559 |
response variability | #560 |
gray matter volumes | #560 |
higher rate | #561 |
caregivers children | #563 |
profoundly | #563 |
adolescents risk | #565 |
risk smoking | #565 |
patients sud | #566 |
intermediate phenotypes | #566 |
4th edition | #566 |
twins female | #566 |
risky behaviors | #566 |
neurocognitive impairment | #567 |
3050 | #567 |
haplotype | #567 |
unaffected relatives | #568 |
replication study | #569 |
onsets | #570 |
10−8 | #570 |
environment interaction | #570 |
diverging | #570 |
birthday | #571 |
risk genes | #571 |
keywords | #571 |
dose reduction | #573 |
irritability | #574 |
white matter abnormalities | #574 |
obesity body mass | #574 |
questionnaires adult | #575 |
inbred shr | #575 |
asd diagnosis | #576 |
gyri | #576 |
spaced | #576 |
chromosomes human | #577 |
individually | #577 |
medical genetics | #577 |
schizophrenia sample | #577 |
parent | #577 |
82 | #578 |
finetuning | #578 |
impulsivity | #578 |
symptoms children | #579 |
subsample | #579 |
preschool age | #580 |
5httlpr polymorphism | #580 |
cold pressor test | #580 |
development anxiety | #580 |
haplotype analysis | #581 |
apol1 | #582 |
rdc | #582 |
drd1 | #582 |
psychiatric association | #582 |
3rd | #583 |
delinquent behavior | #583 |
new approaches | #584 |
hk1 | #584 |
fine mapping | #585 |
separately | #585 |
data children | #585 |
neuroanatomical correlates | #586 |
traumatized | #587 |
examine | #588 |
defaultmode network | #588 |
nback task | #588 |
compared controls | #588 |
138 | #589 |
haplotypes humans | #590 |
behavior adult | #591 |
estonian | #591 |
patients comorbid | #591 |
40mg | #591 |
criticism | #593 |
concordant | #594 |
2005 | #594 |
brain child | #595 |
cognition schizophrenia | #596 |
overrepresentation | #596 |
snap25 | #597 |
generalizable | #597 |
discounted | #597 |
nonpharmacologic | #597 |
899 | #598 |
affymetrix | #598 |
new directions | #598 |
differences brain | #600 |
genetic factors | #601 |
specific phobia | #603 |
diagnosing | #604 |
diagnostic specificity | #604 |
clinical settings | #604 |
cognitive outcomes | #606 |
performance children | #606 |
disorganized | #606 |
clinician | #606 |
social environment | #607 |
personality traits | #607 |
small fraction | #608 |
sizeable | #608 |
4 6 | #608 |
executive dysfunctions | #609 |
gold standard | #609 |
antisocial behavior | #609 |
true | #609 |
polygenic risk scores | #610 |
functional outcomes | #610 |
informant | #611 |
complex disorders | #612 |
pleiotropic | #612 |
chromosome 6 | #613 |
schizophrenia brain | #614 |
grandmothers | #614 |
educational achievement | #614 |
curve analysis | #615 |
snp markers | #615 |
disease etiology | #615 |
behavior disorder | #615 |
memory deficits | #616 |
prevalence severity | #616 |
genetic epidemiology | #616 |
tscores | #617 |
genome scans | #617 |
african children | #618 |
val158met | #618 |
genetic associations | #618 |
differ | #618 |
correcting | #619 |
digeorge | #619 |
vigilance | #620 |
genetic markers | #620 |
antisocial behaviour | #621 |
md | #621 |
confer | #622 |
adverse health outcomes | #623 |
receptor serotonin | #624 |
juvenile delinquency | #624 |
executive dysfunction | #625 |
executive control | #625 |
misconceptions | #625 |
mood stabilizers | #626 |
attentional deficits | #627 |
hrr | #627 |
seeks | #627 |
child gender | #629 |
treatment disorder | #629 |
fibromyalgia | #629 |
schizophrenia findings | #630 |
reject | #631 |
deficits schizophrenia | #631 |
teacher ratings | #632 |
needed | #633 |
girls boys | #634 |
genetic basis | #635 |
tiny | #637 |
generalisability | #638 |
obsessivecompulsive disorder | #638 |
icv | #638 |
disease genotype humans | #639 |
longitudinal | #640 |
adult outcomes | #641 |
ranks | #641 |
advertisement | #641 |
illness duration | #642 |
gateway | #643 |
inconsistent | #643 |
expression genes | #644 |
twin pairs | #645 |
premorbid | #645 |
subjects schizophrenia | #646 |
functioning autism | #646 |
exacerbate | #647 |
methodological | #648 |
17 years | #649 |
galantamine | #650 |
avoidant | #652 |
gene association | #652 |
treatment effects | #652 |
physical conditions | #653 |
128 | #653 |
hyperactivity inattention | #653 |
stroop | #654 |
federation | #654 |
intergenerational transmission | #655 |
bipolar disorder schizophrenia | #656 |
random allocation rats | #656 |
reward anticipation | #656 |
studies evidence | #657 |
impairment | #658 |
groups compared | #658 |
psychosocial treatment | #658 |
boldness | #658 |
volumes | #659 |
hypomanic | #659 |
association exposure | #660 |
core feature | #661 |
poorer performance | #661 |
structural alterations | #662 |
referrals | #662 |
peer relations | #662 |
lowlevel | #665 |
permission | #665 |
digeorge syndrome | #665 |
dacc | #666 |
subcortical | #666 |
psychiatric illnesses | #667 |
mood | #668 |
swedish population | #669 |
prominent | #669 |
phenotypic expression | #672 |
neurobiological | #675 |
time children | #676 |
impulsive behaviors | #677 |
unselected | #678 |
disorders memory | #678 |
129 | #679 |
sleep difficulties | #679 |
mental disorders humans | #680 |
middle childhood | #680 |
psychopathological symptoms | #680 |
neurotic | #681 |
gene frequency | #681 |
trait | #682 |
soviet union | #682 |
semantic fluency | #682 |
quetiapine | #682 |
severe phenotype | #683 |
scales | #685 |
east asian | #685 |
remitting | #685 |
p0019 | #687 |
children groups | #688 |
17q | #688 |
chromosomal region | #688 |
younger children | #689 |
fibromyalgia patients | #689 |
postmortem brains | #689 |
average age | #694 |
disorder schizophrenia | #694 |
tcas | #694 |
testretest reliability | #695 |
participants | #696 |
parcellation | #696 |
cortical surface area | #696 |
pharmacokinetic profile | #697 |
5years | #697 |
4–5 | #697 |
relevant studies | #699 |
122 | #699 |
drug abuse | #699 |
effects methylphenidate | #700 |
quota | #701 |
adult mental | #701 |
illness surveys | #701 |
nonrandom | #701 |
pleiotropic effects | #704 |
treatmentnaïve | #704 |
gwa studies | #704 |
follow studies | #705 |
preschool years | #706 |
pathogenesis schizophrenia | #706 |
adaptive functioning | #706 |
autism spectrum | #708 |
p009 | #709 |
school settings | #709 |
children diagnosed | #710 |
chronic schizophrenia | #713 |
informative | #713 |
prs | #714 |
eric | #714 |
misuse | #714 |
dysphoric | #714 |
maternal report | #714 |
disorders substance | #715 |
728 | #715 |
ethanol consumption | #715 |
stress disorder | #715 |
641 | #716 |
3 weeks | #716 |
contradictory | #717 |
abstraction | #719 |
groundwork | #719 |
meta‐analysis | #720 |
clinical population | #721 |
multiple genes | #721 |
household income | #722 |
recurrence risk | #722 |
memory | #723 |
cognitive load | #724 |
cinguli | #725 |
proponents | #725 |
gender dysphoria | #726 |
common snps | #726 |
male adolescents | #726 |
lateonset | #726 |
attention deficits | #727 |
schizophrenics | #727 |
statistical | #728 |
dizygotic | #728 |
structured clinical interview | #729 |
assortative mating | #729 |
fmri study | #730 |
786 | #730 |
metabotropic glutamate | #731 |
prevention programs | #732 |
git | #733 |
correlates | #733 |
voxel based | #733 |
phenotypic heterogeneity | #734 |
finding | #734 |
wky | #735 |
gyrification | #737 |
life cycle | #737 |
health intervention | #737 |
opioid dependence | #738 |
substancerelated disorders | #738 |
inflation | #739 |
polygenic score | #739 |
validating | #740 |
rapid cycling | #741 |
boston | #742 |
caudate | #742 |
refill | #742 |
time task | #743 |
amphetamines | #744 |
comparators | #744 |
soviet | #745 |
bupropion | #745 |
topic twins | #745 |
neuropsychological status | #746 |
compulsive | #746 |
manifested | #747 |
duplications | #748 |
child interaction | #748 |
adrb1 | #749 |
examining | #750 |
934 | #750 |
twins dizygotic | #752 |
fulfilling | #752 |
347 | #754 |
molecular genetic analysis | #754 |
comt val158met | #755 |
post hoc | #755 |
bipolar depression | #756 |
recalled | #756 |
mental disorders | #756 |
neuroleptics | #756 |
schizophrenia scz | #757 |
nhe | #757 |
disease haplotypes humans | #759 |
renewal | #760 |
sads | #761 |
variation genome | #762 |
artifact | #763 |
workday | #764 |
matter abnormalities | #764 |
humans logistic | #765 |
likelihoods | #765 |
autism asd | #766 |
people schizophrenia | #767 |
substance misuse | #768 |
disinhibition | #769 |
emerged | #772 |
comt polymorphism | #772 |
performance patients | #774 |
birth rates | #776 |
parent reported | #776 |
depressive | #777 |
human pair | #777 |
behavioral phenotypes | #777 |
phenotypes | #778 |
euthymic | #779 |
deletion polymorphism | #779 |
risky behavior | #780 |
schizophrenia relationship | #780 |
weaknesses | #780 |
inheritance | #781 |
iowa gambling task | #782 |
wky rats | #782 |
combined analysis | #783 |
fourth edition | #783 |
questioning | #783 |
mega | #784 |
emerging roles | #784 |
teaes | #785 |
reformulation | #785 |
faced | #786 |
963 | #787 |
pbd | #787 |
adolescence | #787 |
niacin | #788 |
child temperament | #789 |
medial temporal lobe | #790 |
spelling | #791 |
behavioral | #791 |
cgi | #791 |
subtypes | #792 |
individuals schizophrenia | #793 |
clinical criteria | #793 |
symptom burden | #794 |
motivations | #794 |
association polymorphisms | #794 |
caveats | #796 |
delinquent | #796 |
separate | #797 |
additional studies | #800 |
363 | #800 |
genomic regions | #802 |
prenatal exposure | #803 |
dopamine d1 receptors | #803 |
randomized clinical trials | #804 |
stimulant drugs | #804 |
superior frontal | #805 |
clinically | #805 |
dysfunction | #805 |
latent classes | #806 |
dorsolateral | #806 |
novelty seeking | #806 |
male memory | #806 |
developmental perspective | #807 |
lobule | #808 |
hdrs | #809 |
ucla | #810 |
dopamine function | #810 |
adjusting | #811 |
dopamine serotonin | #811 |
phonemic | #811 |
preschool female humans | #811 |
blind | #813 |
coadministration | #815 |
mhpg | #816 |
declarative | #816 |
quantitative measures | #817 |
lasting | #817 |
breakthroughs | #817 |
cfb | #817 |
tryptophan hydroxylase | #817 |
single gene | #818 |
epigenetic factors | #818 |
memory attention | #818 |
substance dependence | #818 |
cortical development | #820 |
meeting | #820 |
counties | #821 |
rated | #821 |
patients psychotic disorders | #821 |
switches | #822 |
hme | #822 |
parental report | #824 |
transcriptomic analysis | #824 |
prefrontal regions | #824 |
common genetic | #825 |
rare coding variants | #825 |
adolescents asd | #827 |
humans models | #827 |
s100a6 | #828 |
treatment interventions | #829 |
multipoint | #830 |
timeframe | #830 |
lifetime prevalence | #831 |
prevalent | #831 |
multiple testing | #831 |
conduct disorders | #832 |
association tests | #832 |
liabilities | #833 |
college students | #834 |
gray | #837 |
sleep disorder | #837 |
n60 | #837 |
inbred shr rats | #838 |
matter humans | #838 |
aversion | #838 |
prescription | #839 |
obstetric complications | #839 |
symptom profiles | #839 |
neurocognition | #841 |
parenthood | #842 |
sporadic cases | #843 |
participants completed | #843 |
consensus statement | #844 |
biological basis | #844 |
facial emotion recognition | #845 |
n35 | #846 |
exception | #847 |
dnm | #847 |
gwas summary | #848 |
dysregulated | #848 |
dgcr8 | #848 |
factor model | #851 |
prefrontal | #855 |
nonsignificant | #857 |
putative | #857 |
estimated prevalence | #858 |
heightened risk | #858 |
putamen | #858 |
schizophrenia healthy | #858 |
nineteen | #859 |
6p | #859 |
preschool | #861 |
handbook | #862 |
heterogeneity | #863 |
delayed effects | #865 |
seventy | #866 |
global assessment | #866 |
glossary | #866 |
crosssectional studies | #867 |
nnt | #869 |
hypothesized | #869 |
mental | #869 |
neurobiological basis | #870 |
specialized | #872 |
753 | #873 |
shr rats | #874 |
perseverative errors | #874 |
pediatric | #874 |
existing evidence | #875 |
comorbidity depression | #875 |
hypotheses | #876 |
manova | #876 |
positive symptoms | #876 |
genetic counseling | #876 |
test performance | #877 |
gender differences | #879 |
externalizing disorders | #879 |
sizes | #881 |
memory functions | #882 |
association genetic | #883 |
altered | #884 |
12p | #886 |
psychedelics | #886 |
171 | #887 |
dynamism | #888 |
delayed | #890 |
cpts | #891 |
obsessive | #893 |
n95 | #893 |
n17 | #893 |
decade | #894 |
bonn | #894 |
veterans affairs | #895 |
480 | #897 |
164 | #898 |
cortical thinning | #902 |
anterior cingulate | #903 |
biological psychiatry | #903 |
weight body | #904 |
aptitude | #904 |
reinforcer | #904 |
genetic contribution | #904 |
bipolar illness | #904 |
sibling | #904 |
visit | #905 |
late childhood | #906 |
psychosocial functioning | #906 |
826 | #906 |
adult aggression | #907 |
standardized difference | #909 |
morphometric | #910 |
ggc | #911 |
symptom control | #911 |
psychosocial | #912 |
pedigrees | #912 |
amygdala reactivity | #912 |
complications pregnancy | #913 |
visuospatial memory | #913 |
underlying pathophysiology | #914 |
versions | #914 |
association age | #916 |
school performance | #917 |
disorder specific | #917 |
cousins | #918 |
sleep children | #920 |
177 | #923 |
pharmacogenetic | #924 |
screening tool | #924 |
vulnerability | #925 |
dysthymic | #925 |
wide | #926 |
developmental trajectories | #927 |
dividing | #927 |
affective disorder | #928 |
participating | #930 |
cpg sites | #930 |
nucleotide | #930 |
permutation | #933 |
heroin addiction | #933 |
194 | #933 |
20mg | #934 |
adolescence young adulthood | #935 |
d5 | #935 |
environment interactions | #936 |
smoking risk | #936 |
3040 | #937 |
study designs | #938 |
diagnostic | #938 |
female genotype | #938 |
irrs | #940 |
robustly | #940 |
severe form | #941 |
critics | #941 |
tdt | #943 |
brain regions | #946 |
gwas | #946 |
22q | #948 |
sles | #948 |
risk developing | #949 |
fetal exposure | #950 |
albeit | #950 |
subtest | #952 |
personality disorder | #954 |
relapsers | #954 |
amphetamine | #954 |
behavioral treatment | #955 |
effects sex | #956 |
prompted | #956 |
112 | #959 |
qam | #960 |
clinical disorders | #960 |
cytoarchitecture | #962 |
children epilepsy | #963 |
female frontal | #963 |
clinical assessment | #963 |
tandem repeat | #965 |
cgis | #965 |
dopamine uptake | #965 |
scores | #965 |
scarce | #966 |
body height | #966 |
heritability estimates | #967 |
cuneus | #968 |
splicing factor | #968 |
freesurfer | #969 |
mtbi | #970 |
examined | #970 |
pharmacological treatment | #970 |
schizophrenia association | #970 |
medication treatment | #971 |
aggression | #972 |
risky sexual behavior | #972 |
262 | #973 |
chromosome mapping | #974 |
diva | #975 |
autism spectrum disorder | #976 |
fluphenazine | #977 |
vmat2 | #978 |
resolve | #978 |
psychosis risk | #978 |
2–4 | #980 |
neurodevelopmental disorder | #980 |
educational | #982 |
pertaining | #982 |
459 | #982 |
seriousness | #985 |
alleles | #986 |
logistic regression models | #986 |
symptoms age | #986 |
patients sle | #987 |
difficulties | #988 |
tci | #990 |
small proportion | #990 |
ranked | #990 |
depressed mothers | #991 |
polymorphism genetic | #994 |
pathway analysis | #995 |
temporal stability | #996 |
colleagues | #996 |
internal consistency | #997 |
comorbid conditions | #998 |
detoxification | #999 |
keystone | #999 |
diathesis | #999 |
adolescent analysis | #1000 |
child child | #1001 |
stata | #1003 |
interviews | #1003 |
comparative efficacy | #1004 |
haplotypes | #1006 |
allele | #1007 |
long‐term outcome | #1007 |
confounding factors | #1007 |
daughter | #1007 |
preschool cohort | #1007 |
0016 | #1007 |
norms | #1008 |
structural mri | #1008 |
qualifications | #1009 |
posttraumatic stress disorder | #1009 |
multiplex | #1009 |
risk alcohol | #1009 |
discriminant | #1010 |
genes environment | #1012 |
ltc | #1014 |
7 years | #1014 |
maturational | #1020 |
metabotropic | #1020 |
conclusive | #1021 |
relates | #1024 |
risk prediction | #1024 |
insufficient | #1026 |
004 | #1027 |
pharmacotherapies | #1027 |
obsessive – | #1028 |
persistent | #1028 |
pharmacologic | #1029 |
weiss | #1030 |
wwwclinicaltrialsgov | #1031 |
analytic | #1031 |
frontostriatal | #1031 |
symptoms child | #1032 |
patients panic disorder | #1032 |
preface | #1034 |
73 | #1034 |
predicted | #1034 |
– compulsive | #1034 |
brain disorders | #1035 |
rodent models | #1035 |
total score | #1035 |
negative symptoms | #1035 |
exploratory analyses | #1037 |
eventual | #1037 |
major depressive episode | #1039 |
general framework | #1040 |
general intelligence | #1041 |
serotonin | #1041 |
twin | #1043 |
mental health treatment | #1044 |
gaf | #1044 |
relate | #1045 |
heightened | #1045 |
antecedents | #1046 |
inv | #1046 |
ffi | #1050 |
late gestation | #1051 |
subtle | #1052 |
onset schizophrenia | #1052 |
benzodiazepines | #1053 |
disorders post | #1054 |
school age | #1055 |
vice | #1056 |
psychiatric morbidity | #1056 |
major humans | #1058 |
nogo | #1058 |
youth report | #1060 |
obscure | #1060 |
adolescence adulthood | #1061 |
bipolar disorders | #1062 |
illicit | #1063 |
genes involved | #1063 |
199 | #1063 |
memory disorders | #1064 |
europe female | #1065 |
paediatric patients | #1065 |
pooled | #1068 |
heritability | #1068 |
paranoia | #1068 |
awakenings | #1068 |
childhood trauma | #1068 |
emotional | #1069 |
negative impact | #1069 |
memantine | #1069 |
memory impairments | #1070 |
human genetics | #1070 |
word reading | #1070 |
reading ability | #1071 |
controlled clinical | #1071 |
risk scores | #1071 |
genetic model | #1071 |
social problems | #1071 |
single nucleotide receptors | #1071 |
character inventory | #1072 |
4q | #1072 |
associations | #1073 |
validity | #1073 |
obesity risk | #1074 |
3′utr | #1075 |
studying | #1075 |
general hospital | #1076 |
mapping chromosomes | #1077 |
schizophrenia spectrum disorders | #1078 |
exposure delayed | #1080 |
transdiagnostic | #1080 |
adult antipsychotic | #1082 |
schizophrenia social | #1082 |
anxiety children | #1083 |
contiguous | #1084 |
psds | #1086 |
onset psychosis | #1086 |
autoreceptors | #1086 |
european continental | #1088 |
alcohol marijuana | #1089 |
distinctive | #1090 |
subtype | #1090 |
development disorders | #1092 |
polygenic scores | #1092 |
obsessivecompulsive disorder ocd | #1093 |
gifted | #1094 |
irritable | #1096 |
scientific literature | #1096 |
semistructured interview | #1096 |
smoking | #1099 |
metaanalysis | #1102 |
external validity | #1103 |
daughters | #1103 |
future work | #1103 |
cnvs | #1104 |
odds | #1106 |
10 weeks | #1107 |
psychosis | #1107 |
diagnostic groups | #1107 |
bip | #1108 |
emotional behavioral | #1108 |
prioritized | #1110 |
experimental test | #1110 |
psychoses | #1110 |
share | #1111 |
10−5 | #1111 |
male children | #1112 |
depressive disorder | #1113 |
new developments | #1114 |
effects children | #1116 |
discusses | #1117 |
schizophrenia subjects | #1119 |
psychotropic | #1121 |
children anxiety | #1122 |
632 | #1123 |
exchangers | #1123 |
556 | #1124 |
mts | #1125 |
coexisting | #1125 |
projects | #1127 |
dysthymic disorder | #1128 |
quantifies | #1128 |
enriched | #1128 |
similarities | #1128 |
investigator | #1129 |
adult alcoholism | #1130 |
weighting | #1130 |
attention performance | #1134 |
n28 | #1134 |
psychiatric diagnosis | #1135 |
birth outcomes | #1136 |
independent sample | #1136 |
laterality humans | #1138 |
blood pressure response | #1138 |
susceptibility loci | #1139 |
clinical samples | #1142 |
social phobia | #1142 |
signal task | #1144 |
cognitive domains | #1145 |
early adolescent | #1145 |
prodromal | #1145 |
demographic factors | #1146 |
emotionality | #1147 |
measurement invariance | #1147 |
normal volunteers | #1147 |
refine | #1149 |
humans intellectual | #1150 |
children association | #1150 |
discounting | #1150 |
discriminability | #1150 |
developmental model | #1152 |
continents | #1152 |
quick | #1152 |
generalizability | #1153 |
refinements | #1153 |
normals | #1153 |
alspac | #1154 |
sensory gating | #1154 |
clinical profiles | #1154 |
differential humans | #1160 |
ht2c | #1160 |
uncorrected | #1160 |
phenotype | #1161 |
review findings | #1163 |
” “ | #1163 |
studies data | #1164 |
phobia | #1164 |
neurocognitive function | #1165 |
affective | #1166 |
deteriorated | #1166 |
clinical groups | #1166 |
congress | #1167 |
catecholaminergic | #1168 |
medication status | #1169 |
social outcomes | #1170 |
292 | #1171 |
quality measures | #1174 |
mspi | #1175 |
gwas data | #1176 |
cohen | #1176 |
bpd patients | #1176 |
genetic risk factors | #1177 |
nicotine exposure | #1177 |
male subjects | #1178 |
clinical validation | #1178 |
study gwas | #1179 |
persisting | #1182 |
childhood exposure | #1182 |
reward | #1182 |
cinguli humans | #1182 |
nonverbal | #1183 |
addressing | #1184 |
triads | #1184 |
paradox | #1184 |
standardized | #1187 |
functional polymorphisms | #1188 |
hydrochloride | #1189 |
dysbindin | #1189 |
64 | #1190 |
child preschool | #1192 |
psychology | #1193 |
assess | #1194 |
parenting behavior | #1197 |
onequarter | #1198 |
addictions | #1198 |
compulsivity | #1198 |
wm | #1199 |
placebo | #1199 |
230 | #1200 |
asian continental | #1200 |
wisconsin | #1201 |
morbidity | #1202 |
systematic search | #1204 |
sib | #1204 |
millennium | #1207 |
problems children | #1209 |
nationwide cohort study | #1209 |
externalizing symptoms | #1209 |
conceptualizations | #1210 |
neuropsychology | #1210 |
p004 | #1211 |
term treatment | #1215 |
sample sizes | #1218 |
male mass | #1219 |
underlying | #1220 |
lbw | #1220 |
antecedent | #1221 |
child cognitive | #1222 |
prospects | #1222 |
study role | #1224 |
profile | #1226 |
approximated | #1227 |
partly | #1227 |
0011 | #1229 |
refining | #1232 |
molecular alterations | #1232 |
subgroup | #1232 |
poster | #1233 |
pregnancy prenatal | #1234 |
health organization | #1234 |
gprotein | #1235 |
children ages | #1235 |
shortcomings | #1237 |
educational attainment | #1239 |
brain structure | #1242 |
tandem repeats | #1242 |
interpersonal relations | #1244 |
short form | #1245 |
avenues | #1247 |
kf | #1247 |
risk asthma | #1247 |
enjoyment | #1247 |
cidi | #1248 |
psychosocial outcomes | #1248 |
cpg islands | #1249 |
roc | #1251 |
delineate | #1251 |
debilitating | #1252 |
alcohol disorders | #1255 |
risk ratio | #1256 |
summarize | #1256 |
serotonin transporter | #1256 |
dysfunctions | #1257 |
goal | #1257 |
nervous | #1257 |
onset depression | #1259 |
combine | #1260 |
consensus statements | #1263 |
characterize | #1266 |
onset age | #1267 |
likewise | #1270 |
logistic regression analyses | #1271 |
child mental | #1273 |
statistical methods | #1274 |
developmental pathways | #1277 |
386 | #1277 |
entire | #1277 |
n24 | #1278 |
04 | #1281 |
study evidence | #1281 |
priori | #1282 |
paternal | #1282 |
increased rates | #1283 |
behavior adolescent | #1283 |
hopes | #1283 |
neuroimaging | #1283 |
variance | #1284 |
spontaneously hypertensive | #1285 |
general cognitive | #1286 |
087 | #1286 |
orbitofrontal | #1288 |
somatic complaints | #1288 |
male nerve | #1288 |
warmth | #1289 |
aspect | #1289 |
posttraumatic | #1291 |
unmyelinated | #1291 |
dual psychiatry | #1291 |
1hmrs | #1291 |
clomipramine | #1292 |
quantitative trait | #1292 |
animal conditioning | #1292 |
misclassification | #1292 |
negative emotion | #1295 |
136 | #1297 |
pvalue | #1297 |
chromosomes | #1298 |
cures | #1301 |
atx | #1303 |
935 | #1305 |
1520 | #1305 |
cortical volume | #1306 |
sgas | #1309 |
prediction accuracy | #1309 |
extant | #1310 |
vin | #1310 |
risperidone | #1311 |
arrests | #1312 |
motor speed | #1313 |
factor analyses | #1313 |
criteria | #1314 |
76 | #1315 |
factors smoking | #1316 |
minds | #1317 |
class analysis | #1317 |
adolescents children | #1318 |
current findings | #1320 |
hypothetical | #1321 |
predictability | #1322 |
short | #1323 |
parents adolescents | #1323 |
polymorphism | #1324 |
hypothesis | #1325 |
response treatment | #1327 |
confusion | #1330 |
influencing | #1330 |
defining | #1331 |
polysubstance | #1334 |
measures | #1334 |
253 | #1335 |
psychopharmacology | #1335 |
genetic background | #1336 |
authors | #1336 |
nonuse | #1337 |
obsessive–compulsive disorder | #1338 |
fronto | #1338 |
clinical phenotypes | #1342 |
longterm outcome | #1342 |
542 | #1344 |
registry data | #1344 |
explaining | #1345 |
llysine | #1345 |
interpretation statistical | #1349 |
compared children | #1353 |
early adulthood | #1353 |
psychoticism | #1355 |
cocaine abuse | #1356 |
loci genetic | #1356 |
diagnostic tool | #1356 |
variabilities | #1357 |
flush | #1357 |
simon | #1357 |
seekers | #1358 |
antidepressive | #1359 |
gene discovery | #1359 |
broad spectrum | #1361 |
middle frontal gyrus | #1362 |
mammalian target | #1362 |
intergenerational | #1365 |
abcd | #1367 |
school teachers | #1369 |
unexplored | #1369 |
neuronal development | #1369 |
uptake inhibitors | #1369 |
reliance | #1370 |
intellectual functioning | #1371 |
observer variation | #1374 |
covert | #1377 |
larger | #1378 |
pallidum | #1380 |
inositol | #1382 |
ghr | #1385 |
thought disorder | #1386 |
new onset | #1386 |
highlighted | #1386 |
dimensional approach | #1389 |
treatment depression | #1391 |
familial aggregation | #1391 |
6 years | #1391 |
prodrome | #1391 |
illicit drugs | #1393 |
vendors | #1394 |
satisfying | #1395 |
manuscripts | #1395 |
thalamic | #1395 |
rats shr | #1395 |
racial | #1398 |
emotional stimuli | #1399 |
timely | #1399 |
lability | #1400 |
suggesting | #1400 |
17 | #1402 |
blinded | #1403 |
sufficient | #1403 |
brain region | #1404 |
hippocampal volumes | #1405 |
placebo treatment | #1407 |
hama | #1408 |
create | #1409 |
preparations | #1410 |
personality inventory | #1412 |
1998 | #1413 |
issue | #1414 |
shyness | #1414 |
independent | #1415 |
prepubertal children | #1416 |
impressions | #1416 |
332 | #1417 |
carry | #1419 |
logical | #1419 |
humans memory | #1421 |
parents children | #1422 |
discoveries | #1422 |
exploratory factor analysis | #1423 |
greater | #1426 |
dosed | #1427 |
linkage disequilibrium | #1430 |
163 | #1431 |
taps | #1431 |
cognitive profiles | #1432 |
interaction effects | #1432 |
affairs | #1434 |
social perception | #1436 |
publication adult analysis | #1438 |
bche | #1439 |
academic | #1443 |
holidays | #1444 |
personality | #1447 |
psychotic illness | #1448 |
443 | #1448 |
chp | #1449 |
prevalence obesity | #1450 |
hydroxylase | #1450 |
ratings | #1451 |
ewas | #1453 |
height | #1453 |
square | #1453 |
78 | #1453 |
population stratification | #1454 |
hypermethylation | #1454 |
switching | #1455 |
replicability | #1457 |
collaborations | #1457 |
dorsal striatum | #1457 |
generalized anxiety | #1458 |
comparisons | #1459 |
severe depression | #1462 |
biological pathways | #1463 |
stronger | #1463 |
treatment duration | #1464 |
discordant | #1467 |
principal | #1467 |
valuable | #1468 |
partial remission | #1468 |
untranslated | #1468 |
groups differences | #1469 |
hippocampi | #1469 |
contrast effects | #1472 |
statistically | #1474 |
openlabel | #1474 |
cognition patients | #1474 |
amygdala volume | #1477 |
risk relapse | #1479 |
conducted | #1480 |
medication | #1481 |
cortex dlpfc | #1487 |
prodromal symptoms | #1488 |
issues | #1489 |
apt | #1492 |
adrb2 | #1493 |
hypomethylation | #1495 |
smaller | #1497 |
mri studies | #1497 |
allele carriers | #1497 |
lifespan | #1499 |
small sample sizes | #1499 |
twins monozygotic | #1499 |
converge | #1500 |
populationbased study | #1501 |
patients bipolar | #1502 |
cpt | #1503 |
ddc | #1505 |
multisite | #1505 |
male mothers | #1505 |
examination | #1508 |
salience network | #1510 |
manifestation | #1510 |
existing literature | #1511 |
objectivity | #1511 |
emotions female | #1513 |
attained | #1513 |
reports | #1513 |
messaging | #1514 |
cognitive ability | #1515 |
pedigree | #1516 |
eicosapentaenoic acid | #1517 |
screening instrument | #1517 |
repeat | #1518 |
criminal behavior | #1519 |
165 | #1521 |
topic | #1523 |
114 | #1523 |
cna | #1523 |
inconsistency | #1526 |
bipolar patients | #1526 |
psychiatric disorder | #1528 |
nacetylaspartate | #1528 |
inferior frontal | #1528 |
symptomatology | #1530 |
512 | #1535 |
began | #1536 |
arntl | #1540 |
nucleotide risk | #1541 |
default | #1541 |
dopamine receptor | #1542 |
poses | #1542 |
adult life | #1542 |
stress disorders | #1543 |
gwass | #1544 |
treatment schizophrenia | #1545 |
yale | #1545 |
omission | #1547 |
traits | #1549 |
card | #1551 |
influenced | #1554 |
problem behaviors | #1554 |
automobile | #1556 |
857 | #1556 |
failed | #1559 |
early exposure | #1559 |
loci | #1560 |
0009 | #1561 |
0013 | #1564 |
subscales | #1565 |
insular | #1565 |
475 | #1565 |
interpersonal | #1566 |
humans interpersonal | #1569 |
wise | #1570 |
191 | #1573 |
consortium | #1573 |
swedish | #1573 |
depression children | #1574 |
neurochemistry | #1575 |
attempted | #1576 |
life quality | #1579 |
meta | #1579 |
gene networks | #1580 |
selfreport questionnaires | #1580 |
single nucleotide polymorphism | #1582 |
located | #1582 |
findings studies | #1582 |
network dmn | #1583 |
cutoffs | #1583 |
models male | #1583 |
social functioning | #1584 |
hyperactivation | #1587 |
rs4680 | #1588 |
firstepisode schizophrenia | #1588 |
major depressive | #1588 |
genetic data | #1589 |
pain patients | #1589 |
edinburgh | #1590 |
advent | #1591 |
55 | #1592 |
phobias | #1593 |
temperament | #1594 |
162 | #1596 |
subcortical structures | #1596 |
symptom presentation | #1598 |
tpv | #1599 |
moderators | #1599 |
psychotropic medications | #1601 |
statistics nonparametric | #1601 |
jan | #1602 |
managed | #1603 |
utr | #1604 |
suffer | #1604 |
spontaneously | #1605 |
heritabilities | #1606 |
classifying | #1608 |
academic achievement | #1609 |
1979 | #1610 |
proneness | #1610 |
monoamine oxidase | #1611 |
emotional faces | #1613 |
alcoholism | #1613 |
status | #1614 |
ancestry female | #1615 |
male maternal | #1616 |
drawn | #1619 |
broadly | #1620 |
large body | #1622 |
risk mental | #1622 |
distinguishing | #1622 |
childhood asthma | #1624 |
hbr | #1624 |
snp | #1626 |
paucity | #1626 |
ht2a receptor | #1627 |
spatial organization | #1627 |
louis | #1628 |
dysphoria | #1628 |
genomics humans | #1629 |
verbal behavior | #1629 |
kyoto | #1630 |
study children | #1630 |
emrs | #1631 |
ambiguous | #1631 |
memory task | #1631 |
198 | #1633 |
susceptibility gene | #1634 |
supporting | #1635 |
mental illnesses | #1637 |
positive predictive | #1638 |
lag | #1639 |
brain female | #1640 |
alpha7 | #1643 |
tendency | #1643 |
rack1 | #1643 |
social communication | #1643 |
bprs | #1644 |
potential effects | #1646 |
socially | #1647 |
interrelations | #1649 |
treating | #1650 |
rea | #1653 |
controlled | #1653 |
nucleotide polymorphisms | #1655 |
adolescents age | #1657 |
detect | #1658 |
maximize | #1658 |
psychotic disorder | #1659 |
require | #1659 |
personality disorders | #1661 |
symptom severity | #1662 |
comorbid depression | #1663 |
presentations | #1663 |
asm | #1664 |
510 | #1665 |
dlpfc | #1666 |
mood symptoms | #1666 |
chronic patients | #1666 |
association analysis | #1667 |
human rights | #1670 |
indexed | #1670 |
bipolar disorder patients | #1671 |
13 years | #1672 |
transmitted | #1673 |
asd symptoms | #1674 |
early signs | #1675 |
alcohol spectrum | #1675 |
statements | #1675 |
53 | #1677 |
calling | #1678 |
introns | #1678 |
registers | #1678 |
social anxiety | #1679 |
homogeneous | #1679 |
seat | #1680 |
beagle | #1680 |
mathematical models | #1682 |
mildly | #1684 |
prescribed | #1684 |
46 | #1684 |
ancestries | #1685 |
memory deficit | #1685 |
github | #1689 |
mdd | #1689 |
autistic disorder | #1689 |
psychotropic drugs | #1692 |
agenda | #1692 |
impulse control | #1693 |
recruited | #1698 |
motor skills | #1698 |
diagnose | #1699 |
91 | #1702 |
memory consolidation | #1704 |
item | #1704 |
conceptualization | #1705 |
middle frontal | #1710 |
reduced activation | #1711 |
health records | #1712 |
rater | #1712 |
personality characteristics | #1712 |
neuroscience | #1712 |
schizophrenia spectrum | #1713 |
net | #1716 |
perpetrators | #1725 |
nhe1 | #1728 |
autistic | #1729 |
epigenetics | #1730 |
inhibitory control | #1731 |
107 | #1731 |
cbs | #1732 |
hindered | #1733 |
machine | #1735 |
highlight | #1735 |
stand | #1736 |
identical | #1736 |
predictors | #1739 |
aimed | #1739 |
dopamine receptors | #1741 |
sex age | #1743 |
curated | #1746 |
forum | #1746 |
longitudinal analysis | #1747 |
cognitive difficulties | #1748 |
pds | #1749 |
occipital lobe | #1750 |
tremors | #1752 |
02 | #1753 |
selfreport measures | #1753 |
questionnaires young | #1755 |
sertraline | #1756 |
326 | #1756 |
5ht2a | #1758 |
120 | #1758 |
genetic models | #1761 |
social | #1761 |
ventral striatum | #1761 |
drowsiness | #1763 |
bipolar affective | #1763 |
includes | #1765 |
chance | #1765 |
adult onset | #1766 |
mystery | #1768 |
operant | #1768 |
reflects | #1769 |
sisters | #1770 |
dopamine | #1772 |
dizygotic twins | #1773 |
treatment implications | #1773 |
patients systemic | #1775 |
depressive episode | #1775 |
patients adult | #1776 |
267 | #1776 |
establishing | #1777 |
mental recall | #1777 |
utrs | #1779 |
10−7 | #1780 |
early childhood | #1781 |
higher doses | #1786 |
major | #1786 |
commonalities | #1786 |
social anxiety disorder | #1787 |
defined | #1789 |
frustration | #1791 |
male motor | #1791 |
transdermal | #1793 |
disorder mdd | #1795 |
harbor | #1796 |
disabilities | #1797 |
positive association | #1797 |
causal variants | #1797 |
autism spectrum disorders | #1800 |
aged models | #1801 |
members | #1801 |
reporters | #1801 |
genetic variance | #1802 |
chapters | #1803 |
shr | #1804 |
females | #1805 |
families children | #1806 |
covariation | #1807 |
based analysis | #1807 |
168 | #1809 |
expanded | #1812 |
nucleotide polymorphism | #1812 |
european descent | #1813 |
aetiology | #1813 |
146 | #1813 |
frequently | #1815 |
internationality | #1815 |
brain imaging | #1816 |
purchases | #1816 |
lds | #1819 |
hippocampal volume | #1819 |
cohens | #1819 |
correlate | #1823 |
suicide attempt | #1825 |
endpoint | #1827 |
followup | #1830 |
splenium | #1831 |
foundation | #1833 |
binocular | #1833 |
psychotic patients | #1837 |
suggested | #1838 |
94 | #1840 |
neural activity | #1841 |
patterns | #1841 |
assessment tools | #1842 |
trauma exposure | #1842 |
distinctions | #1845 |
twins | #1845 |
initiative | #1845 |
literacy | #1846 |
psychological | #1847 |
pertinent | #1847 |
warrant | #1848 |
environmental risk | #1848 |
polymorphisms | #1849 |
limited | #1850 |
fearful | #1851 |
individual | #1851 |
vocabulary | #1851 |
nonparametric | #1852 |
young | #1853 |
differentiating | #1853 |
brainderived neurotrophic factor | #1853 |
persons | #1855 |
abuse | #1856 |
auditory hallucinations | #1856 |
prevalence | #1859 |
tph | #1859 |
incentives | #1860 |
behavioral measures | #1860 |
cnb | #1861 |
affiliation | #1861 |
8p | #1862 |
obstacle | #1864 |
vocalization | #1865 |
poison | #1865 |
multilevel | #1865 |
switch | #1865 |
severely | #1867 |
18 | #1869 |
structural functional | #1875 |
constitute | #1876 |
manuscript | #1877 |
roc curve | #1879 |
histograms | #1879 |
animal model | #1880 |
shrs | #1880 |
delusions | #1881 |
afb | #1882 |
longer duration | #1882 |
common genetic variation | #1883 |
genome | #1885 |
false | #1888 |
differs | #1888 |
substance abuse | #1890 |
metaanalysis studies | #1890 |
heterogeneous | #1894 |
spanning | #1894 |
susceptibility genes | #1896 |
latent class analysis | #1899 |
maintained | #1899 |
correspondences | #1901 |
psychostimulant | #1902 |
chinese | #1903 |
analyses | #1903 |
illicit drug | #1904 |
actigraphy | #1905 |
increasingly | #1907 |
specific symptoms | #1907 |
emotion | #1908 |
epidemiologic | #1909 |
majority | #1909 |
ads | #1910 |
disorders mental | #1911 |
support vector machine | #1911 |
structural differences | #1912 |
generation antipsychotics | #1913 |
africanamericans | #1915 |
χ2 | #1916 |
10h | #1920 |
inform | #1921 |
liking | #1923 |
satisfied | #1923 |
association maternal | #1923 |
child cross | #1926 |
aggregate | #1926 |
overview | #1927 |
sleep problems | #1928 |
251 | #1928 |
advertising | #1928 |
empirical studies | #1929 |
ssri | #1930 |
asd children | #1934 |
95 cis | #1934 |
simulation study | #1937 |
borderline personality disorder | #1937 |
exomes | #1938 |
stratified | #1939 |
general | #1942 |
25 years | #1945 |
literature review | #1947 |
neurobehavioral | #1949 |
representing | #1950 |
traumatic brain injury | #1950 |
trait loci | #1952 |
accumbens | #1953 |
normal children | #1954 |
efficacious | #1957 |
msp | #1958 |
neurotransmitter release | #1959 |
mems | #1961 |
intolerant | #1962 |
micronesia | #1963 |
896 | #1964 |
sdq | #1967 |
brain networks | #1968 |
vital signs | #1969 |
sorting | #1971 |
correctly | #1972 |
clinical implications | #1972 |
depression | #1972 |
connectivity | #1974 |
hoc | #1975 |
factors surveys | #1976 |
repeats | #1977 |
child depression | #1977 |
conflicting | #1978 |
listing | #1978 |
hippocampus humans | #1981 |
ptsd | #1981 |
common mental disorders | #1984 |
chinese population | #1984 |
phase 3 trial | #1986 |
pax5 | #1986 |
secondary analysis | #1987 |
brain | #1989 |
school | #1990 |
predisposing | #1991 |
current paper | #1994 |
genetic differences | #1996 |
226 | #1997 |
fmr | #1998 |
pattern | #1999 |
diagnosed | #2001 |
comparable | #2002 |
spouses | #2003 |
formulations | #2005 |
asian continental ancestry | #2005 |
harm avoidance | #2007 |
functional variants | #2010 |
behavioral symptoms | #2011 |
nos1 | #2012 |
akt1 | #2014 |
absence | #2014 |
muscle function | #2014 |
sms | #2015 |
noradrenergic | #2015 |
possibility | #2016 |
cognitive deficits | #2016 |
prescribers | #2021 |
schoolage children | #2023 |
159 | #2023 |
serve | #2026 |
phenomenology | #2030 |
sleep disturbances | #2030 |
brain responses | #2031 |
memory verbal | #2031 |
regional brain | #2032 |
neurodevelopmental disorders | #2033 |
morbid | #2036 |
prenatally | #2037 |
receptors nicotinic | #2037 |
diminished | #2040 |
retest reliability | #2040 |
asperger | #2041 |
erythematosus systemic | #2041 |
nicotinic acetylcholine | #2045 |
227 | #2046 |
cognitive processing | #2046 |
informants | #2048 |
erythematosus | #2049 |
functional | #2050 |
cognition | #2050 |
juvenile | #2052 |
contribute | #2054 |
adolescent behavior | #2056 |
external control | #2057 |
chapman | #2058 |
insula | #2061 |
common diseases | #2061 |
educated | #2062 |
stabilizers | #2064 |
ongoing | #2065 |
demography | #2066 |
overweight obesity | #2066 |
val158met polymorphism | #2067 |
preschool humans | #2068 |
massachusetts | #2069 |
functional mri | #2069 |
0008 | #2071 |
parental education | #2072 |
phenotypic | #2072 |
psychotic symptoms | #2077 |
international consensus | #2078 |
degree | #2078 |
wake disorders | #2079 |
descent | #2079 |
heterogeneity studies | #2082 |
psychomotor | #2084 |
male gender | #2085 |
5 ht2a | #2087 |
latent class | #2090 |
43 | #2090 |
factors child | #2093 |
49 | #2095 |
wky shr | #2096 |
aud | #2096 |
subsets | #2099 |
69 | #2100 |
dopaminergic | #2100 |
142 | #2102 |
general factor | #2106 |
age children | #2107 |
ht2a | #2108 |
adult population | #2108 |
causation | #2109 |
specific genetic | #2112 |
nicotinic | #2112 |
child relations | #2112 |
279 | #2115 |
brain dysfunction | #2115 |
83 | #2117 |
postpartum period | #2119 |
relative age | #2119 |
poorer | #2119 |
monoamine | #2119 |
84 | #2121 |
pgs | #2122 |
51 | #2122 |
career | #2122 |
sixth | #2124 |
pbls | #2126 |
identifies | #2126 |
dysfunctional | #2128 |
biased | #2129 |
ovid | #2130 |
functional polymorphism | #2132 |
rates | #2134 |
dbh | #2137 |
episode schizophrenia | #2137 |
psychosocial factors | #2140 |
adversities | #2141 |
interpretability | #2141 |
discrepant | #2142 |
relevant literature | #2143 |
pvs | #2145 |
methods participants | #2145 |
behavioral disorders | #2146 |
105 | #2147 |
receptors adrenergic | #2147 |
intraclass | #2147 |
juveniles | #2148 |
abnormalities | #2149 |
glutamatergic | #2150 |
232 | #2150 |
finemapping | #2150 |
represents | #2150 |
repositioning | #2151 |
assessing | #2151 |
mao | #2153 |
rrr | #2153 |
psychiatric patients | #2155 |
abdominal obesity | #2164 |
differentiated | #2164 |
clinical assessments | #2166 |
declarative memory | #2167 |
shr wky | #2167 |
genetic association studies | #2168 |
differing | #2168 |
differential diagnostic | #2168 |
glx | #2169 |
major depressive disorder | #2170 |
adversely | #2171 |
mb | #2171 |
prevalences | #2171 |
severity | #2172 |
tardive dyskinesia | #2172 |
aggregated | #2177 |
irt | #2180 |
externalizing | #2181 |
moderating | #2181 |
environmental factors | #2183 |
author | #2185 |
report measures | #2186 |
teachers | #2187 |
computerassisted imaging | #2188 |
thought | #2188 |
processing speed | #2189 |
differential expression | #2189 |
generalized anxiety disorder | #2192 |
scale | #2192 |
regular | #2192 |
serotonin 5 | #2193 |
imaging fmri | #2195 |
lifecycle | #2197 |
conceptual | #2197 |
pharmacological agents | #2199 |
achievement | #2200 |
confounding | #2201 |
ages | #2201 |
double | #2205 |
developing brain | #2206 |
brain mapping | #2206 |
abstract background | #2207 |
ottawa | #2209 |
remained | #2209 |
169 | #2209 |
homozygosity | #2210 |
surveys questionnaires | #2210 |
accidents | #2210 |
illness severity | #2211 |
antenatal | #2211 |
genetic relationship | #2212 |
occurrences | #2217 |
adverse event | #2217 |
intronic | #2219 |
completed | #2220 |
biologically | #2220 |
complex diseases | #2220 |
hippocampal formation | #2220 |
autism | #2221 |
val66met | #2222 |
cognitive task | #2225 |
visuospatial | #2225 |
20th | #2226 |
replicating | #2227 |
single | #2228 |
caudate putamen | #2229 |
trail making | #2230 |
clinical profile | #2232 |
attainment | #2234 |
community sample | #2235 |
controls age | #2238 |
hexokinase | #2241 |
prototypical | #2241 |
implications | #2242 |
qualities | #2244 |
insensitivity | #2245 |
consultation | #2246 |
preliminary data | #2248 |
hamilton | #2253 |
val66met polymorphism | #2254 |
pubertal development | #2257 |
genomic analysis | #2260 |
treatment guidelines | #2260 |
novo mutations | #2263 |
cognitive deficit | #2263 |
cigarette | #2264 |
earlier | #2264 |
criterion | #2265 |
pathways | #2266 |
bds | #2266 |
rewards | #2266 |
clinical measures | #2267 |
evident | #2273 |
overdiagnosis | #2274 |
remain | #2275 |
cognitive development | #2275 |
axis | #2275 |
gray matter volume | #2275 |
tend | #2276 |
mtl | #2277 |
random allocation | #2277 |
imaging male | #2277 |
apneahypopnea | #2279 |
systemic lupus | #2279 |
lithium | #2283 |
moderation | #2283 |
psychiatric illness | #2285 |
cognitive | #2287 |
controlling | #2290 |
minority | #2292 |
update | #2293 |
regions | #2294 |
physical health | #2294 |
diverse populations | #2294 |
socialization | #2295 |
retained | #2297 |
monitored | #2298 |
11 years | #2299 |
corticotropin | #2301 |
239 | #2304 |
clinic | #2304 |
biology | #2304 |
adjunctive | #2306 |
virtue | #2307 |
consisting | #2308 |
difficult | #2310 |
lupus | #2310 |
enormous | #2311 |
brain anatomy | #2313 |
pregnancy | #2313 |
edition | #2315 |
behaviors | #2317 |
adequate | #2318 |
performance reaction | #2319 |
tests | #2321 |
brain systems | #2321 |
fmri | #2325 |
casecontrol study | #2326 |
memory performance | #2328 |
higher prevalence | #2330 |
257 | #2331 |
questionnaires | #2332 |
organ size | #2332 |
subset | #2333 |
mind | #2334 |
archives | #2335 |
disorganization | #2335 |
covariate | #2335 |
early risk | #2336 |
depression female | #2340 |
utility | #2342 |
lesser extent | #2342 |
nature | #2344 |
functional networks | #2344 |
20th century | #2345 |
cingulate | #2346 |
schedule | #2350 |
time perception | #2353 |
providing | #2353 |
mapping child | #2358 |
powered | #2362 |
adolescent brain | #2364 |
endosome | #2365 |
factor structure | #2367 |
limited evidence | #2368 |
concurrently | #2368 |
smallest | #2369 |
symptoms schizophrenia | #2369 |
efforts | #2376 |
social cognitive | #2377 |
catecholamine | #2379 |
antipsychotic agents | #2379 |
tapping | #2384 |
predicts | #2385 |
ecologically | #2386 |
gyrus | #2388 |
drugs abuse | #2391 |
unresolved | #2393 |
raising | #2395 |
convergence | #2395 |
problem solving | #2398 |
essence | #2401 |
gray matter | #2401 |
frontal | #2403 |
pubmed | #2406 |
addictive | #2407 |
sirolimus | #2407 |
adolescent alcohol | #2408 |
distinguished | #2410 |
validate | #2412 |
preserved | #2414 |
genetic factor | #2417 |
statistical significance | #2418 |
alternative | #2418 |
modules | #2419 |
illumina | #2422 |
starting | #2423 |
classified | #2425 |
salience | #2426 |
disease genetic | #2426 |
143 | #2428 |
term outcome | #2429 |
bdnf | #2429 |
fmri data | #2431 |
confounders | #2431 |
protein interactions | #2433 |
clinical trial | #2433 |
241 | #2433 |
protein interaction | #2436 |
analyzes | #2440 |
careful | #2443 |
intellectual | #2447 |
timepoints | #2448 |
dimorphism | #2448 |
items | #2449 |
multiple studies | #2450 |
mvr | #2452 |
deconvolution | #2452 |
overweight children | #2456 |
systemic lupus erythematosus | #2456 |
prefrontal cortical | #2456 |
moderately | #2458 |
myoinositol | #2459 |
genetic susceptibility | #2459 |
anxiety symptoms | #2460 |
brain maturation | #2460 |
concordance | #2461 |
logistic | #2461 |
traumatic stress | #2461 |
autosomes | #2462 |
crossover study | #2464 |
sex distribution | #2464 |
factor bdnf | #2466 |
hungary | #2469 |
unique | #2473 |
unclear | #2473 |
relatedness | #2482 |
brain activation | #2486 |
reaction time | #2488 |
prescriptions | #2489 |
higher scores | #2489 |
psychomotor performance | #2491 |
cerebrum | #2494 |
normative data | #2495 |
180 | #2496 |
hoc analysis | #2496 |
caucasian | #2497 |
israeli | #2500 |
workplace | #2502 |
original | #2504 |
establish | #2504 |
random forest | #2507 |
interactome | #2509 |
randomized placebo | #2511 |
21st | #2512 |
preschool diagnosis | #2512 |
heterosis | #2513 |
quotient | #2515 |
thresholds | #2515 |
preceded | #2516 |
tricyclic antidepressants | #2518 |
evaluate | #2521 |
perceptual | #2523 |
temporal gyrus | #2526 |
12 years | #2528 |
rel | #2531 |
october | #2532 |
alterations | #2532 |
preliminary report | #2533 |
indicators | #2534 |
thinner | #2539 |
limitations | #2541 |
categories | #2545 |
neurosecretory | #2546 |
medication adherence | #2548 |
animals anxiety | #2550 |
risky | #2553 |
psychotic features | #2553 |
depressive disorders | #2554 |
neural responses | #2555 |
quantitative | #2555 |
exploratory study | #2555 |
memory tasks | #2557 |
bipolar affective disorder | #2557 |
risk loci | #2560 |
chronological | #2560 |
income | #2560 |
assisted magnetic | #2561 |
060 | #2562 |
273 | #2563 |
447 | #2565 |
demographic characteristics | #2565 |
sensation seeking | #2569 |
174 | #2570 |
discontinued | #2571 |
document | #2572 |
30 years | #2573 |
numerous | #2573 |
19 years | #2574 |
cool | #2575 |
depressed | #2576 |
socioeconomic | #2579 |
osmosis | #2580 |
smoking alcohol | #2581 |
adolescent females | #2584 |
correction | #2585 |
elucidate | #2585 |
brothers | #2586 |
pvalues | #2586 |
problems | #2586 |
pituitary adrenal | #2587 |
baseline | #2591 |
post traumatic | #2594 |
disrupted | #2595 |
exist | #2595 |
229 | #2596 |
brain response | #2598 |
internalizing externalizing | #2598 |
temporal pole | #2600 |
encouraging | #2601 |
iowa | #2603 |
simplex | #2603 |
n10 | #2605 |
neo | #2606 |
percentile | #2607 |
literature | #2608 |
infrequent | #2610 |
increased activation | #2611 |
advances | #2611 |
occipital | #2612 |
draft | #2614 |
lateralization | #2616 |
surveys humans | #2619 |
pooling | #2620 |
genotype | #2623 |
multiple levels | #2624 |
evidence role | #2624 |
kynurenine | #2625 |
psycinfo | #2625 |
mothers | #2630 |
bdnf gene | #2633 |
imaging studies | #2633 |
preliminary | #2634 |
institute | #2636 |
odors | #2638 |
182 | #2639 |
global functioning | #2642 |
fetal alcohol | #2642 |
preschool female | #2644 |
behavior | #2644 |
genetic variants | #2644 |
inability | #2645 |
medical conditions | #2645 |
future | #2648 |
borderline personality | #2652 |
brain derived | #2655 |
tmax | #2659 |
dysregulation | #2663 |
electronic health | #2664 |
puzzle | #2665 |
periodicals | #2665 |
n14 | #2666 |
health disorders | #2669 |
089 | #2669 |
88 | #2670 |
chromosome | #2670 |
genetic evidence | #2670 |
polysomnography | #2671 |
pcps | #2675 |
spectrum | #2675 |
inconclusive | #2676 |
partially | #2676 |
mediating | #2676 |
memory tests | #2678 |
adolescent development | #2678 |
physiotherapy | #2678 |
maternal behavior | #2679 |
increased activity | #2681 |
disadvantaged | #2685 |
adrenergic | #2687 |
widespread | #2688 |
conditional | #2689 |
triad | #2689 |
age range | #2689 |
listening | #2690 |
reading | #2692 |
entry | #2692 |
promoter region | #2694 |
evaluating | #2695 |
tfs | #2696 |
immaturity | #2698 |
evidenced | #2698 |
extended | #2700 |
chr | #2701 |
attenuate | #2702 |
neurite | #2702 |
interrogation | #2702 |
flares | #2703 |
ext | #2707 |
delinquency | #2707 |
hemispheric asymmetry | #2709 |
internalizing problems | #2710 |
404 | #2713 |
occurring | #2714 |
aggressive | #2714 |
quarter | #2718 |
positively correlated | #2719 |
purposes | #2721 |
choosing | #2723 |
thinking | #2724 |
internalizing | #2726 |
hold | #2727 |
teens | #2731 |
curve | #2731 |
awakening | #2732 |
systematic literature review | #2733 |
doubt | #2733 |
thicker | #2733 |
alcohol dependence | #2736 |
potential association | #2740 |
pdi | #2752 |
cortices | #2753 |
prepubertal | #2753 |
eventually | #2755 |
patients bipolar disorder | #2760 |
collaboration | #2760 |
naa | #2760 |
gt | #2761 |
manifestations | #2762 |
4 years | #2765 |
unadjusted | #2765 |
created | #2768 |
ccs | #2769 |
psychiatric diseases | #2773 |
reproducibility | #2773 |
phencyclidine | #2775 |
depression severity | #2776 |
25 | #2777 |
preventive measures | #2777 |
mechanisms underlying | #2783 |
clinical heterogeneity | #2783 |
children symptoms | #2784 |
bivariate | #2784 |
panic attacks | #2785 |
6 12 | #2788 |
tactile | #2790 |
dna copy | #2791 |
411 | #2791 |
dyslexia | #2792 |
neurotrophic factor | #2794 |
overt | #2794 |
auditory perception | #2796 |
constellation | #2796 |
suicidality | #2799 |
explained | #2802 |
958 | #2803 |
dependence | #2804 |
references | #2806 |
recognition visual | #2808 |
clinical experience | #2808 |
397 | #2809 |
misdiagnosis | #2809 |
monetary | #2809 |
goodness | #2810 |
predefined | #2812 |
disc1 | #2815 |
midnight | #2816 |
gene polymorphism | #2816 |
primary caregivers | #2817 |
subsequent | #2819 |
circuitry | #2823 |
indexes | #2823 |
1300 | #2824 |
telephone | #2824 |
comorbidities | #2825 |
pediatric obesity | #2827 |
intervention strategies | #2828 |
and or | #2830 |
refusal | #2833 |
disorder characterized | #2835 |
tested | #2838 |
discriminant validity | #2839 |
early recognition | #2839 |
adoption | #2841 |
reelin | #2843 |
treatment study | #2843 |
prefrontal cortex | #2844 |
socioeconomic status | #2846 |
emotional intelligence | #2849 |
early identification | #2850 |
matter volume | #2852 |
parent child | #2853 |
disabled | #2856 |
restless legs syndrome | #2857 |
suicide attempted | #2858 |
depression scale | #2863 |
continental ancestry | #2863 |
parenting parents | #2865 |
addresses | #2866 |
screened | #2866 |
mothers children | #2867 |
internal external | #2867 |
discordance | #2868 |
cognition humans | #2868 |
focus | #2869 |
silico | #2870 |
psychosocial stress | #2872 |
splicing | #2875 |
diagnosis differential | #2876 |
gwa | #2878 |
sixteen | #2880 |
measure | #2884 |
appeared | #2884 |
shifting | #2885 |
age differences | #2885 |
citations | #2885 |
rare variants | #2887 |
protective effects | #2889 |
trinucleotide | #2890 |
brain size | #2900 |
asr | #2901 |
alternate | #2902 |
debate | #2903 |
duplicate | #2905 |
low birth weight | #2906 |
alcohol disorder | #2907 |
newer | #2909 |
independent component analysis | #2911 |
etiologies | #2912 |
behavior children | #2913 |
precursor | #2914 |
cognitive control | #2916 |
amph | #2916 |
biological mechanisms | #2919 |
variability | #2919 |
institutes | #2919 |
age study | #2921 |
genetic contributions | #2922 |
115 | #2924 |
attentional | #2925 |
subject | #2928 |
behavioral outcomes | #2931 |
486 | #2931 |
adherence | #2932 |
92 | #2935 |
machine learning | #2941 |
disorders sleep | #2942 |
causal relationship | #2942 |
distinct | #2946 |
disorders patients | #2946 |
motor control | #2953 |
pcb | #2956 |
smoked | #2959 |
journal | #2965 |
facilitating | #2967 |
previous | #2968 |
331 | #2970 |
markers | #2971 |
overlaps | #2971 |
models neurological | #2976 |
stratification | #2981 |
725 | #2983 |
qtl | #2983 |
weight height | #2988 |
investigators | #2989 |
attempts | #2991 |
imaging mri | #2991 |
tic | #2997 |
performance measures | #2997 |
overweight | #2998 |
variants | #2999 |
subjective | #3000 |
bold | #3002 |
referral | #3005 |
196 | #3006 |
centres | #3006 |
377 | #3007 |
19th century | #3010 |
genetic variation | #3011 |
remission | #3011 |
genetic promoter regions | #3012 |
resonance imaging | #3016 |
987 | #3017 |
chen | #3018 |
worldwide | #3020 |
response relationship | #3021 |
inferior frontal gyrus | #3022 |
disease susceptibility | #3023 |
mouse models | #3024 |
choice | #3028 |
conference | #3030 |
models psychological | #3033 |
familiarity | #3034 |
emotion dysregulation | #3036 |
symptoms patients | #3039 |
difficulties questionnaire | #3039 |
female humans life | #3040 |
thomson | #3044 |
neural correlates | #3047 |
variants genes | #3053 |
developmental | #3054 |
treatment adherence | #3054 |
protective factor | #3057 |
improvement | #3058 |
280 | #3061 |
pilot | #3061 |
fear female | #3063 |
117 | #3064 |
ultimately | #3065 |
339 | #3068 |
216 | #3072 |
stress reactivity | #3073 |
p0004 | #3074 |
frontal lobe | #3076 |
appears | #3077 |
cortical | #3078 |
driving | #3078 |
positive | #3079 |
sociodemographics | #3081 |
males | #3089 |
key findings | #3092 |
pairwise | #3093 |
allelic | #3094 |
pregnancy women | #3095 |
predictable | #3098 |
stressful life | #3098 |
modified version | #3099 |
central nervous | #3104 |
intron | #3105 |
076 | #3107 |
brain health | #3107 |
naïve | #3110 |
siemens | #3111 |
interviewed | #3114 |
symptoms study | #3116 |
articles | #3123 |
amygdala hippocampus | #3123 |
marijuana abuse | #3124 |
mass screening | #3125 |
383 | #3127 |
ptsd symptoms | #3127 |
functional laterality | #3129 |
tcc | #3132 |
psychiatrist | #3133 |
temporal cortex | #3134 |
childhood adversity | #3135 |
pharmacies | #3137 |
maternal | #3142 |
accuracies | #3144 |
nation | #3146 |
european countries | #3146 |
99 | #3150 |
exploratory | #3150 |
ancestry | #3151 |
behavior social | #3152 |
pharmacokinetic | #3157 |
oxford | #3157 |
explanations | #3165 |
spd | #3165 |
biological processes | #3166 |
functional consequences | #3166 |
aggregation | #3168 |
hippocampal | #3169 |
teenagers | #3170 |
caution | #3171 |
status humans | #3171 |
report | #3174 |
hypophyseal | #3175 |
math | #3176 |
wealth | #3178 |
contrast | #3180 |
imaging study | #3187 |
methyltransferase | #3187 |
adolescents young adults | #3187 |
receiver | #3188 |
prodrug | #3189 |
published | #3190 |
view | #3190 |
collect | #3195 |
emotion processing | #3195 |
comprehension | #3201 |
attempt | #3202 |
initial treatment | #3202 |
erythematosus sle | #3205 |
answers | #3208 |
normative | #3209 |
naming | #3212 |
snvs | #3214 |
gene polymorphisms | #3216 |
pathophysiological | #3216 |
psychotherapy | #3222 |
environment | #3223 |
angeles | #3228 |
discontinuity | #3229 |
scanner | #3229 |
situation | #3229 |
65 | #3235 |
depression study | #3236 |
mediation analysis | #3237 |
htt | #3237 |
414 | #3239 |
abstinence | #3241 |
databases genetic | #3247 |
determine | #3250 |
features | #3254 |
210 | #3255 |
211 | #3257 |
correlated | #3257 |
publicly | #3265 |
caudate nucleus | #3265 |
humans magnetic | #3266 |
interactive effects | #3266 |
17p | #3266 |
moderator | #3269 |
370 | #3270 |
symbols | #3271 |
researchers | #3272 |
prefrontal cortex pfc | #3274 |
expertise | #3276 |
memory processing | #3281 |
increased likelihood | #3282 |
longitudinal cohort | #3282 |
cognitive functioning | #3289 |
condition | #3291 |
glutamate receptor | #3296 |
replication | #3297 |
surveys | #3299 |
strict | #3304 |
contributed | #3305 |
clinical severity | #3306 |
synaptic function | #3306 |
genomics | #3309 |
restrictions | #3314 |
corrected | #3315 |
attribute | #3316 |
spearman | #3321 |
digit | #3322 |
neuroimaging data | #3323 |
differently | #3325 |
fewer | #3331 |
earlier studies | #3333 |
mrt | #3334 |
clock gene | #3336 |
ambiguity | #3336 |
metropolitan | #3336 |
417 | #3340 |
6 | #3343 |
slide | #3345 |
revealing | #3348 |
clinical | #3351 |
hoc analyses | #3352 |
healthy control | #3354 |
affect | #3357 |
national institute | #3359 |
functional studies | #3361 |
april | #3362 |
friend | #3366 |
motivational | #3367 |
retest | #3369 |
067 | #3370 |
glycolysis | #3371 |
frontal regions | #3371 |
battery | #3371 |
treatment strategies | #3373 |
cortex pfc | #3375 |
088 | #3376 |
marker | #3379 |
functional neuroimaging | #3382 |
initially | #3384 |
sex chromosomes | #3385 |
impaired performance | #3386 |
typically developing | #3386 |
stressful life events | #3387 |
monozygotic | #3389 |
multimorbidity | #3390 |
clock genes | #3390 |
health children | #3392 |
accounting | #3393 |
cnp | #3393 |
ifg | #3398 |
358 | #3402 |
baseline followup | #3404 |
depression symptoms | #3405 |
traumatic brain | #3405 |
desirability | #3406 |
oxidase | #3411 |
performing | #3413 |
pool | #3413 |
aucs | #3415 |
lack | #3419 |
health surveys | #3422 |
therapeutic response | #3423 |
longitudinal data | #3426 |
stepwise | #3431 |
03 | #3433 |
pediatric population | #3436 |
experiencing | #3439 |
definition | #3439 |
exert | #3441 |
fluency | #3446 |
lca | #3448 |
children mothers | #3448 |
showing | #3448 |
schoolaged children | #3449 |
lowered | #3450 |
supports | #3455 |
psychotropic medication | #3455 |
inception | #3457 |
schooling | #3461 |
estimating | #3463 |
differentiate | #3464 |
cognitive behavioral | #3466 |
genomewide association study | #3466 |
hallucinations | #3466 |
male sex | #3472 |
bilaterally | #3473 |
scan | #3475 |
remaining | #3477 |
methylation | #3477 |
behavioral response | #3478 |
irr | #3480 |
transmission | #3482 |
postmortem | #3482 |
slower | #3488 |
convergent | #3489 |
lesser | #3489 |
exposure pregnancy | #3489 |
applying | #3492 |
epidemiological study | #3492 |
aged polymorphism | #3497 |
social behaviors | #3497 |
alpha2 | #3497 |
short stature | #3497 |
083 | #3497 |
matched healthy | #3502 |
identifier | #3506 |
p002 | #3506 |
brain function | #3506 |
antidepressants | #3512 |
checklist | #3514 |
sans | #3518 |
104 | #3519 |
specificity | #3519 |
113 | #3520 |
antipsychotic | #3524 |
spouse | #3525 |
constitutes | #3527 |
basis | #3527 |
pediatricians | #3527 |
asperger syndrome | #3529 |
reflect | #3529 |
clinical phenotype | #3533 |
rett syndrome | #3535 |
preferentially | #3536 |
reliable | #3536 |
enrichment analysis | #3538 |
social behavior | #3539 |
school aged | #3540 |
mother child | #3541 |
sleep wake | #3544 |
cognitive behavioral therapy | #3544 |
fact | #3544 |
coming | #3545 |
rts | #3546 |
documentation | #3547 |
score | #3548 |
dmn | #3550 |
344 | #3557 |
preventive interventions | #3558 |
ecgs | #3558 |
neuronal function | #3558 |
prevalence estimates | #3563 |
suggestions | #3564 |
genetic analysis | #3567 |
psychiatrists | #3568 |
prevent | #3569 |
prospectively | #3570 |
developmental stages | #3573 |
psychosocial interventions | #3579 |
genotyping | #3580 |
reliability | #3583 |
mse | #3585 |
collaborative | #3585 |
neurite outgrowth | #3587 |
mpfc | #3587 |
crh | #3603 |
interrater reliability | #3604 |
major gene | #3606 |
cardio | #3606 |
consists | #3609 |
299 | #3613 |
screen | #3614 |
modalities | #3617 |
questions | #3618 |
methylation status | #3618 |
348 | #3620 |
races | #3621 |
pharmacogenetics | #3622 |
objectives | #3623 |
reviewed | #3624 |
article | #3625 |
214 | #3626 |
101 | #3628 |
neglect | #3630 |
185 | #3631 |
hypothalamo | #3634 |
posttraumatic stress | #3640 |
prior | #3640 |
seeking | #3641 |
wgs | #3648 |
cohesion | #3653 |
enrolment | #3654 |
facilitate | #3660 |
negative | #3661 |
downward | #3662 |
study association | #3663 |
increased prevalence | #3666 |
socioeconomic factors | #3668 |
weight | #3669 |
93 | #3670 |
administration oral | #3672 |
captured | #3675 |
360 | #3681 |
1st | #3682 |
genotype data | #3686 |
behavior problems | #3690 |
frontal lobes | #3691 |
marijuana | #3695 |
online survey | #3696 |
nacetylcysteine | #3700 |
disorders animals | #3703 |
oe | #3705 |
problem behavior | #3707 |
effort | #3711 |
brain cognition | #3719 |
manipulations | #3722 |
9 years | #3729 |
situations | #3730 |
pha | #3732 |
070 | #3733 |
ultimate | #3734 |
neurotransmission | #3735 |
daily life | #3735 |
fifty | #3736 |
hapmap | #3737 |
depressed mood | #3737 |
population | #3738 |
international | #3744 |
therapy cbt | #3744 |
relative | #3745 |
offer | #3746 |
reply | #3750 |
persisted | #3751 |
shortterm | #3753 |
epigenesis genetic | #3755 |
depression risk | #3756 |
proportional | #3757 |
333 | #3758 |
neurophysiological | #3758 |
interim analysis | #3760 |
comprehensive assessment | #3767 |
315 | #3777 |
addiction | #3780 |
transitions | #3781 |
recognition psychology | #3782 |
cocaine disorders | #3783 |
peers | #3787 |
promoter polymorphism | #3787 |
1012 | #3791 |
nonresponse | #3794 |
predictive validity | #3797 |
discriminate | #3800 |
forecast | #3802 |
monozygotic twins | #3803 |
statistical analyses | #3806 |
355 | #3809 |
ways | #3814 |
scientific | #3822 |
dimensions | #3824 |
030 | #3825 |
neurotransmitter | #3829 |
acetylcysteine | #3835 |
inclusion | #3837 |
exchanger | #3844 |
male marijuana | #3844 |
disease genes | #3850 |
developmental disorders | #3850 |
children aged | #3850 |
risk development | #3851 |
elevations | #3851 |
midlife | #3852 |
36 | #3854 |
rely | #3856 |
test | #3858 |
animal dopamine | #3859 |
superior temporal | #3862 |
strong | #3863 |
drug administration | #3866 |
prospective | #3872 |
explain | #3874 |
influences | #3876 |
74 | #3876 |
208 | #3876 |
p001 | #3879 |
ireland | #3882 |
mark | #3883 |
globus | #3886 |
child cohort | #3888 |
reevaluation | #3888 |
tesla | #3890 |
p0003 | #3895 |
neurology | #3898 |
plasma membrane | #3898 |
histories | #3901 |
obstetric | #3905 |
congruent | #3913 |
clinicians | #3915 |
ethnicities | #3922 |
monotherapy | #3923 |
variable | #3924 |
illnesses | #3925 |
robust | #3929 |
dbd | #3930 |
drug targets | #3931 |
suicidal behavior | #3932 |
antidepressant treatment | #3935 |
frontal gyrus | #3937 |
preexisting | #3937 |
specific factors | #3937 |
females males | #3944 |
2nd | #3945 |
directions | #3947 |
controversy | #3951 |
integrate | #3953 |
nicotine | #3956 |
normalization | #3959 |
support | #3960 |
systematic review metaanalysis | #3962 |
indicating | #3967 |
older children | #3969 |
trauma | #3970 |
disease control | #3971 |
untreated | #3976 |
alcohol | #3978 |
brain functional | #3980 |
forecasts | #3981 |
categorization | #4000 |
preliminary evidence | #4000 |
factorial | #4000 |
vulnerabilities | #4003 |
medial prefrontal | #4004 |
primary aim | #4005 |
initiating | #4012 |
kappa | #4013 |
cortex | #4018 |
eqtls | #4021 |
construct | #4023 |
fusiform gyrus | #4032 |
represent | #4036 |
clinical improvement | #4046 |
common variants | #4047 |
diabetes risk | #4047 |
discussion | #4051 |
modeled | #4051 |
mathematics | #4051 |
consequences | #4052 |
relevant | #4057 |
jointly | #4058 |
contextual factors | #4058 |
criminal | #4060 |
divergent | #4062 |
intellectual disability | #4063 |
causal role | #4064 |
serotonin uptake | #4068 |
magnetic resonance | #4068 |
cag | #4068 |
forecasting | #4071 |
statistics | #4072 |
118 | #4074 |
portion | #4075 |
child age | #4076 |
outcomes children | #4078 |
birth order | #4082 |
belgium | #4086 |
genetic loci | #4088 |
study efficacy | #4090 |
heroin | #4090 |
clinical characteristics | #4096 |
lobe | #4098 |
temporal lobe | #4098 |
genetic variations | #4100 |
maternal depression | #4100 |
limbic | #4102 |
age matched | #4103 |
psychologists | #4103 |
list | #4105 |
evidence base | #4107 |
062 | #4109 |
eicosapentaenoic | #4113 |
traumatic | #4115 |
vary | #4117 |
comprises | #4121 |
plausible | #4121 |
epigenesis | #4128 |
cortical areas | #4130 |
relationship | #4136 |
principal components | #4139 |
244 | #4140 |
german | #4145 |
dosing | #4145 |
span | #4146 |
neuronal migration | #4148 |
sectional | #4150 |
mj | #4156 |
regression | #4158 |
extensively | #4160 |
259 | #4161 |
124 | #4164 |
indicative | #4166 |
pathophysiology | #4167 |
fm | #4169 |
somatization | #4170 |
risk depression | #4174 |
bioinformatics | #4177 |
mapping | #4178 |
sedation | #4180 |
340 | #4182 |
dopamine d3 | #4184 |
109 | #4187 |
mri scans | #4188 |
preventive | #4190 |
military | #4191 |
lupus erythematosus | #4192 |
morphometry | #4193 |
structural connectivity | #4194 |
study differences | #4195 |
268 | #4196 |
describes | #4198 |
116 | #4199 |
transporter | #4204 |
growing | #4213 |
children age | #4215 |
route | #4216 |
helpful | #4216 |
based sample | #4218 |
suicidal thoughts | #4219 |
subgroups | #4219 |
functional magnetic | #4223 |
copy variations | #4224 |
determining | #4227 |
valproic | #4230 |
calcineurin | #4237 |
administration | #4239 |
tap | #4245 |
rat model | #4247 |
1987 | #4251 |
predict | #4253 |
gpcr | #4253 |
differential female humans | #4254 |
emerge | #4256 |
mortem | #4259 |
representative | #4263 |
trajectory | #4263 |
confers | #4264 |
posttreatment | #4268 |
antipsychotic medication | #4269 |
225 | #4270 |
follow‐up | #4273 |
early intervention | #4276 |
paediatric | #4280 |
principal component analysis | #4282 |
contributors | #4285 |
polymorphisms genes | #4292 |
select | #4293 |
deletion | #4296 |
pressor | #4302 |
outpatients | #4305 |
demographic variables | #4309 |
child development | #4314 |
potential targets | #4315 |
adequacy | #4315 |
highest risk | #4319 |
mutual | #4324 |
cardiovascular effects | #4326 |
patients diagnosed | #4327 |
buprenorphine | #4332 |
occasion | #4341 |
cingulate cortex | #4348 |
occurs | #4350 |
chart review | #4352 |
catechol | #4353 |
acute treatment | #4353 |
segregation | #4358 |
dropouts | #4361 |
searched | #4362 |
adjunct | #4363 |
166 | #4369 |
cambridge | #4370 |
aging brain | #4372 |
logistic regression analysis | #4373 |
relation | #4375 |
exists | #4375 |
mediate | #4378 |
intolerance | #4378 |
066 | #4382 |
psychological adolescent | #4383 |
clarity | #4383 |
transcriptomic | #4391 |
solving | #4391 |
docosahexaenoic | #4391 |
human | #4393 |
volumetric | #4395 |
privacy | #4396 |
low dose | #4399 |
exon | #4404 |
sexual dimorphism | #4409 |
corpus striatum | #4410 |
impulse | #4412 |
survive | #4413 |
diverse | #4413 |
membrane glycoproteins | #4416 |
polychlorinated biphenyls | #4418 |
ethnic differences | #4424 |
intranasal | #4426 |
opioids | #4429 |
terminology | #4434 |
concurrent | #4438 |
morbidities | #4444 |
197 | #4445 |
bias | #4447 |
human studies | #4449 |
striatal dopamine | #4449 |
genotypes | #4454 |
62 | #4454 |
192 | #4461 |
symposium | #4462 |
locomotor | #4464 |
serotonergic | #4465 |
outgrowth | #4467 |
dna methylation | #4470 |
219 | #4471 |
entered | #4473 |
emissioncomputed | #4476 |
smell | #4477 |
synapse | #4482 |
compilation | #4486 |
ethical | #4490 |
criterion validity | #4491 |
fourth | #4495 |
informal | #4500 |
superior temporal gyrus | #4501 |
parametric | #4508 |
313 | #4509 |
valuation | #4516 |
visits | #4516 |
disorders cognitive | #4516 |
alcohol abuse | #4517 |
investigate | #4521 |
notion | #4525 |
laterality | #4526 |
postnatal day | #4540 |
considerable | #4540 |
multiple | #4541 |
children families | #4542 |
incentive | #4546 |
transmit | #4548 |
pharmacology | #4552 |
higher level | #4553 |
employment | #4553 |
preschool children | #4564 |
birth | #4564 |
emr | #4565 |
component | #4572 |
22 | #4573 |
psd | #4587 |
neuronal differentiation | #4587 |
address | #4593 |
origin | #4595 |
initiated | #4599 |
006 | #4603 |
≤ | #4609 |
february | #4610 |
009 | #4612 |
indices | #4613 |
israel | #4617 |
attributed | #4630 |
genomic data | #4633 |
ssris | #4634 |
television | #4636 |
head injury | #4638 |
clinical risk | #4643 |
q1 | #4643 |
question | #4648 |
trouble | #4651 |
unmet | #4651 |
regression model | #4652 |
marriage | #4658 |
deliveries | #4660 |
centers | #4660 |
microsatellite | #4660 |
anterior cingulate cortex | #4661 |
trajectories | #4662 |
243 | #4662 |
children study | #4665 |
homogeneity | #4667 |
mitigate | #4668 |
fg | #4668 |
european | #4669 |
healthy individuals | #4670 |
psychometric properties | #4673 |
routes | #4676 |
disease onset | #4679 |
subsequently | #4680 |
pregnancy risk | #4682 |
264 | #4684 |
names | #4689 |
hunt | #4696 |
accurate diagnosis | #4699 |
concerns | #4705 |
5 | #4706 |
cardiorespiratory | #4707 |
imply | #4710 |
autosomal | #4711 |
vector machine | #4715 |
hazards models | #4715 |
estimate | #4716 |
smd | #4717 |
mbr | #4719 |
sed | #4719 |
appropriateness | #4720 |
positional | #4725 |
cinahl | #4729 |
fusiform | #4730 |
eqtl | #4731 |
participants included | #4732 |
biological factors | #4735 |
drug addiction | #4736 |
prototypes | #4745 |
val | #4747 |
unemployment | #4747 |
pons | #4753 |
cooperative | #4755 |
drug | #4757 |
taiwan | #4757 |
77 | #4760 |
conflict | #4760 |
tasks | #4762 |
portions | #4763 |
heavily | #4763 |
fumarate | #4773 |
231 | #4774 |
mother | #4782 |
subjects risk | #4784 |
samples | #4791 |
noncarriers | #4791 |
sharing | #4795 |
publication administration | #4798 |
mp | #4798 |
cleaning | #4804 |
coronary artery disease | #4814 |
fractional anisotropy | #4820 |
cognitive tests | #4825 |
modafinil | #4825 |
excluding | #4832 |
surge | #4835 |
visual perception | #4836 |
experts | #4837 |
223 | #4838 |
continuity | #4843 |
sparse | #4849 |
recognized | #4853 |
imaging female | #4858 |
41 | #4865 |
rg | #4873 |
specific | #4874 |
207 | #4875 |
deterioration | #4880 |
wave | #4880 |
young age | #4881 |
cigarettes | #4881 |
subsamples | #4881 |
omega3 | #4882 |
fp | #4882 |
prisma | #4885 |
facts | #4890 |
cascades | #4891 |
eliminated | #4894 |
antiepileptic drugs | #4910 |
operating | #4914 |
002 | #4915 |
preclinical studies | #4916 |
achievements | #4923 |
early adolescence | #4923 |
additive | #4924 |
bdi | #4929 |
scored | #4929 |
parietal lobe | #4930 |
outcome measures | #4932 |
034 | #4933 |
brain activity | #4937 |
inventory | #4941 |
relating | #4947 |
delays | #4949 |
hemispheric | #4949 |
powerful | #4951 |
pooled analysis | #4951 |
snap | #4957 |
rule | #4959 |
diffusion tensor imaging | #4962 |
acetylcholine receptor | #4965 |
srs | #4967 |
212 | #4969 |
altered expression | #4972 |
eye tracking | #4973 |
explosion | #4978 |
empirical data | #4979 |
continental | #4983 |
lower | #4994 |
170 | #4995 |
022 | #5001 |
treatment modalities | #5005 |
timing | #5008 |
esr1 | #5015 |
aged nerve | #5017 |
caucasians | #5021 |
selective attention | #5021 |
disagreement | #5024 |
aug | #5025 |
rarely | #5027 |
serotonin receptors | #5029 |
variation | #5030 |
adolescent health | #5031 |
specialty | #5036 |
task | #5038 |
discuss | #5039 |
probabilistic | #5039 |
distinguish | #5040 |
correct | #5040 |
auc | #5047 |
cingulate gyrus | #5047 |
anxiety depression | #5047 |
sga | #5050 |
convergent validity | #5051 |
early | #5051 |
marital | #5051 |
predictor | #5052 |
2003 | #5055 |
analgesics | #5056 |
obesity | #5064 |
gender identity | #5067 |
bidirectional | #5067 |
18 years | #5070 |
continuation | #5077 |
cadherins | #5079 |
decreasing | #5085 |
reductions | #5086 |
chinese children | #5092 |
placebo patients | #5095 |
aes | #5097 |
epilepsy | #5099 |
reached | #5101 |
09 | #5101 |
103 | #5104 |
screening | #5104 |
relative contributions | #5105 |
qtc | #5106 |
volume reduction | #5107 |
ancestral | #5112 |
time points | #5118 |
relevance | #5119 |
variables | #5127 |
substances | #5129 |
single nucleotide polymorphisms | #5132 |
mediation | #5132 |
maladaptive | #5133 |
ppv | #5134 |
individuals risk | #5136 |
mechanisms | #5142 |
readers | #5143 |
mental retardation | #5145 |
inherent | #5146 |
difference | #5146 |
pharmacogenomics | #5147 |
involves | #5147 |
carrying | #5158 |
enrichment | #5160 |
administered | #5162 |
homozygote | #5166 |
dropout | #5168 |
biological | #5170 |
diffusivity | #5177 |
picture | #5178 |
ventral | #5181 |
reuptake inhibitors | #5182 |
extent | #5183 |
dopamine d1 | #5187 |
adjustment | #5190 |
238 | #5193 |
disability | #5193 |
predictive | #5195 |
weighted | #5197 |
pleiotropy | #5205 |
characteristic | #5212 |
molecular biology | #5215 |
remains | #5215 |
term | #5218 |
conclude | #5223 |
dopaminergic neurons | #5224 |
167 | #5226 |
nonsmokers | #5231 |
dutch | #5233 |
256 | #5234 |
fail | #5237 |
smoking behavior | #5240 |
interaction | #5242 |
accurately | #5245 |
119 | #5246 |
critical period | #5248 |
tolerated | #5255 |
generated | #5260 |
boundaries | #5261 |
americans | #5263 |
exceeded | #5264 |
delineation | #5266 |
genotypic | #5269 |
daytime sleepiness | #5278 |
ws | #5278 |
cell surface receptors | #5280 |
brain injuries | #5283 |
001 | #5286 |
participated | #5287 |
variety | #5289 |
normality | #5290 |
written | #5291 |
trend | #5295 |
billion | #5295 |
eye movements | #5296 |
motor | #5298 |
oligodendrocytes | #5299 |
thalamus | #5299 |
learning | #5301 |
234 | #5302 |
emotion recognition | #5306 |
life events | #5308 |
072 | #5308 |
52 | #5309 |
healthy participants | #5310 |
environmental | #5312 |
observer | #5313 |
dense | #5316 |
hints | #5321 |
definite | #5322 |
treatment initiation | #5323 |
genomic imprinting | #5333 |
credibility | #5335 |
inferences | #5339 |
predictive tests | #5345 |
individual level | #5345 |
social interactions | #5345 |
classic | #5351 |
prenatal | #5353 |
word | #5354 |
estimated | #5359 |
cerebellum | #5363 |
nonresponders | #5368 |
nervosa | #5369 |
interplay | #5375 |
eventrelated potentials | #5376 |
penetrance | #5380 |
higher frequency | #5380 |
suicide attempts | #5382 |
lost | #5382 |
internet addiction | #5390 |
sweden | #5391 |
huntington disease | #5392 |
domains | #5396 |
potential confounders | #5402 |
label | #5403 |
37 | #5403 |
empirical | #5410 |
register | #5411 |
daily | #5413 |
0007 | #5419 |
average | #5424 |
tensor imaging | #5432 |
224 | #5436 |
pcp | #5449 |
172 | #5451 |
wiley | #5452 |
adjunctive therapy | #5454 |
modifiers | #5464 |
hour | #5467 |
york | #5468 |
risk individuals | #5468 |
× 10 | #5471 |
aim | #5474 |
settings | #5475 |
borderline | #5478 |
environmental effects | #5484 |
brains | #5486 |
copy | #5488 |
recall | #5491 |
confirms | #5494 |
locomotor activity | #5499 |
homozygotes | #5502 |
year | #5505 |
clinics | #5517 |
commission | #5518 |
termed | #5519 |
promoter regions | #5525 |
verbal fluency | #5525 |
fdr | #5534 |
320 | #5536 |
anxiety behavior | #5537 |
155 | #5547 |
modulate | #5547 |
elevated | #5549 |
closely | #5549 |
prevention | #5551 |
restraint | #5552 |
flanking | #5552 |
occur | #5553 |
154 | #5559 |
copy variation | #5562 |
health conditions | #5563 |
icd10 | #5564 |
baseline treatment | #5565 |
frontal cortex | #5565 |
15 | #5567 |
european ancestry | #5567 |
213 | #5574 |
predominance | #5578 |
significance | #5578 |
mediators | #5579 |
240 | #5579 |
spatial memory | #5581 |
subacute | #5584 |
175 | #5590 |
locus | #5592 |
epidemiological | #5593 |
scientists | #5596 |
narcolepsy | #5597 |
nrg1 | #5607 |
anhedonia | #5608 |
amygdala | #5623 |
percent | #5628 |
heavier | #5631 |
total | #5640 |
allocation | #5657 |
perinatal | #5663 |
lower risk | #5663 |
divided | #5666 |
exploring | #5670 |
probability | #5677 |
calculate | #5678 |
proportional hazards | #5684 |
40 years | #5686 |
1999 | #5686 |
gene variants | #5687 |
markov | #5688 |
vbm | #5688 |
published data | #5689 |
oculomotor | #5690 |
brain development | #5694 |
normal | #5696 |
databases | #5696 |
systems biology | #5703 |
cognitive functions | #5713 |
primary outcome measure | #5713 |
58 | #5723 |
signal detection | #5725 |
pleasure | #5727 |
thirty | #5728 |
focused | #5728 |
psychological surveys | #5735 |
020 | #5739 |
19 | #5745 |
definitions | #5746 |
cognitive tasks | #5751 |
missing data | #5755 |
divorce | #5758 |
approaches | #5761 |
nac | #5762 |
interactive | #5765 |
aged children | #5767 |
additional | #5773 |
deficient | #5778 |
oral | #5779 |
72 | #5780 |
rats inbred | #5786 |
susceptibility locus | #5788 |
extracted | #5792 |
206 | #5796 |
preferential | #5797 |
16 | #5799 |
139 | #5802 |
deaths | #5811 |
intracranial | #5814 |
nuclear | #5815 |
0002 | #5819 |
0005 | #5820 |
aaa | #5823 |
133 | #5826 |
98 | #5827 |
nerve net | #5827 |
ethnic groups | #5834 |
multidimensional | #5836 |
fell | #5841 |
dependency | #5846 |
cannabis | #5849 |
deletions | #5857 |
current understanding | #5860 |
signaling peptides | #5862 |
gene expression profiles | #5869 |
fetuses | #5872 |
membership | #5874 |
auditory | #5875 |
retrospective chart review | #5879 |
sexual behavior | #5880 |
synaptophysin | #5887 |
16 years | #5894 |
small | #5898 |
september | #5901 |
imputation | #5910 |
council | #5910 |
appendix | #5916 |
characterizing | #5917 |
broad | #5919 |
activity level | #5919 |
ethics | #5923 |
parietal | #5925 |
statement | #5928 |
linked | #5928 |
region | #5928 |
individuality | #5929 |
rights | #5930 |
prolactin | #5931 |
medical treatment | #5933 |
rapamycin | #5937 |
biphenyls | #5940 |
striatal | #5955 |
community | #5956 |
electroencephalography evoked | #5964 |
clearance | #5965 |
132 | #5966 |
cmax | #5969 |
091 | #5971 |
missed | #5974 |
explore | #5994 |
website | #6000 |
exclusively | #6001 |
threshold | #6003 |
rois | #6005 |
moderating role | #6005 |
matched | #6006 |
chromosomal | #6009 |
module | #6011 |
functional connectivity | #6013 |
newcastle | #6017 |
extreme | #6020 |
运行报告 | |
Prominent publications by Stephen V Faraone∗
IMPORTANCE: Attention-deficit/hyperactivity disorder (ADHD) is a heritable neurodevelopmental disorder. It has been linked to reductions in total brain volume and subcortical abnormalities. However, owing to heterogeneity within and between studies and limited sample sizes, findings on the neuroanatomical substrates of ADHD have shown considerable variability. Moreover, it remains unclear whether neuroanatomical alterations linked to ADHD are also present in the unaffected siblings of ...
闻名 Unaffected Siblings | Putamen Volume | Participants Adhd | Hyperactivity Disorder | Total Brain |
Motor coordination problems in children and adolescents with ADHD rated by parents and teachers: effects of age and gender
[ PUBLICATION ]
Summary.Objective. ADHD is frequently accompanied by motor coordination problems. However, the co-occurrence of poor motor performance has received less attention in research than other coexisting problems in ADHD. The underlying mechanisms of this association remain unclear. Therefore, we investigated the prevalence of motor coordination problems in a large sample of children with ADHD, and the relationship between motor coordination problems and inattentive and hyperactive/impulsive ...
闻名 Motor Coordination Problems | Children Adhd | Boys Girls | Hyperactivity Child Child | Parents Prevalence |
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
[ PUBLICATION ]
We examined the status of the neural network mediating the default mode of brain function, which typically exhibits greater activation during rest than during task, in patients in the early phase of schizophrenia and in young first-degree relatives of persons with schizophrenia. During functional MRI, patients, relatives, and controls alternated between rest and performance of working memory (WM) tasks. As expected, controls exhibited task-related suppression of activation in the default ...
闻名 Default Network | Patients Relatives | Rest Task | Wm Performance | Mpfc Dlpfc |
Patterns of Psychopathology and Dysfunction in High-Risk Children of Parents With Panic Disorder and Major Depression
[ PUBLICATION ]
OBJECTIVE: The purpose of the study was to evaluate 1) whether an underlying familial predisposition is shared by all anxiety disorders or whether specific risks are associated with specific disorders, and 2) whether panic disorder and major depression have a familial link.
METHOD: The study compared four groups of children: 1) offspring of parents with panic disorder and comorbid major depression (N=179), 2) offspring of parents with panic disorder without comorbid major depression ...
闻名 Major Depression | Panic Disorder | Offspring Parents | Risk Children | Factors Social |
OBJECTIVE: Attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and obsessive-compulsive disorder (OCD) are common neurodevelopmental disorders that frequently co-occur. The authors sought to directly compare these disorders using structural brain imaging data from ENIGMA consortium data.
METHODS: Structural T1-weighted whole-brain MRI data from healthy control subjects (N=5,827) and from patients with ADHD (N=2,271), ASD (N=1,777), and OCD (N=2,323) from 151 ...
闻名 Adhd Asd | Cortical Thickness | Children Adolescents | Brain Volume | Disorder Ocd |
BACKGROUND: Neuroimaging studies have shown structural alterations in several brain regions in children and adults with attention deficit hyperactivity disorder (ADHD). Through the formation of the international ENIGMA ADHD Working Group, we aimed to address weaknesses of previous imaging studies and meta-analyses, namely inadequate sample size and methodological heterogeneity. We aimed to investigate whether there are structural differences in children and adults with ADHD compared with ...
闻名 Brain Volume | Adults Adhd | Attention Deficit | Hyperactivity Disorder | Subcortical Structures |
AIMS: To determine comorbidity patterns in treatment-seeking substance use disorder (SUD) patients with and without adult attention deficit hyperactivity disorder (ADHD), with an emphasis on subgroups defined by ADHD subtype, taking into account differences related to gender and primary substance of abuse.
DESIGN: Data were obtained from the cross-sectional International ADHD in Substance use disorder Prevalence (IASP) study.
SETTING: Forty-seven centres of SUD treatment in 10 ...
闻名 Disorder Patients | Psychiatric Comorbidity | Attention Deficit | Seeking Substance | Presence Adhd |
CONTEXT: Controversy exists about the appropriate criteria for a diagnosis of adult attention-deficit/hyperactivity disorder (ADHD).
OBJECTIVE: To examine the structure and symptoms most predictive of DSM-IV adult ADHD.
DESIGN: The data are from clinical interviews in enriched subsamples of the National Comorbidity Survey Replication (n = 131) and a survey of a large managed health care plan (n = 214). The physician-administered Adult ADHD Clinical Diagnostic Scale (ACDS) was used to ...
闻名 Adult Adhd | Hyperactivity Disorder | Illness Surveys | Clinical Diagnostic | Symptoms Childhood |
The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives
[ PUBLICATION ]
With the single exception of SUDs, no statistically significant gender-by ADHD interactions were identified in the multiple, outcomes evaluated. These results suggest that with the exception of SUDs, ADHD expresses itself similarly in boys and girls relative to comparison subjects of the same gender, indicating that ADHD-associated impairments are correlates of ADHD in both genders. Gender differences, such as the higher prevalence of symptoms of inattention and lower rates of ...
闻名 Girls Adhd | Hyperactivity Disorder | Gender Differences | Higher Prevalence | Symptoms Inattention |
OBJECTIVE: To complete an exploratory uncontrolled study of the effects of lisdexamfetamine dimesylate (LDX) on growth of children treated for attention-deficit/hyperactivity disorder (ADHD).
METHOD: Height, weight, and body mass index (BMI) from 281 children ages 6 to 13 years from longitudinal assessments up to 15 months were compared to norms from the Centers for Disease Control.
RESULTS: At study entry, children were taller and heavier than average. Growth delays were largest for ...
闻名 Lisdexamfetamine Dimesylate | Height Weight | Growth Children | Ldx Bmi | Centers Disease Control |
Psychopathology in Adolescent Offspring of Parents With Panic Disorder, Major Depression, or Both: A 10-Year Follow-Up
[ PUBLICATION ]
OBJECTIVE: The authors examined the specificity and course of psychiatric disorders from early childhood through adolescence in offspring of parents with confirmed panic disorder and major depressive disorder.
METHOD: The authors examined rates of psychiatric disorders at 10-year-follow-up (mean age, 14 years) in four groups: offspring of referred parents with panic and depression (N=137), offspring of referred parents with panic without depression (N=26), offspring of referred parents ...
闻名 Panic Disorder | Offspring Parents | Parental Depression | Disruptive Behavior | Year Follow |
BACKGROUND: The goal of this study was to investigate the occurrence, severity and clinical correlates of emotional lability (EL) in children with attention deficit/hyperactivity disorder (ADHD), and to examine factors contributing to EL and familiality of EL in youth with ADHD.
METHODS: One thousand, one hundred and eighty-six children with ADHD combined type and 1827 siblings (aged 6-18 years) were assessed for symptoms of EL, ADHD, associated psychopathology and comorbid psychiatric ...
闻名 Symptoms Adhd | Emotional Lability | Hyperactivity Disorder | Attention Deficit | Odd Disruptive Behavior |
A Controlled Study of Behavioral Inhibition in Children of Parents With Panic Disorder and Depression
[ PUBLICATION ]
OBJECTIVE: "Behavioral inhibition to the unfamiliar" has been proposed as a precursor to anxiety disorders. Children with behavioral inhibition are cautious, quiet, introverted, and shy in unfamiliar situations. Several lines of evidence suggest that behavioral inhibition is an index of anxiety proneness. The authors sought to replicate prior findings and examine the specificity of the association between behavioral inhibition and anxiety.
METHOD: Laboratory-based behavioral observations ...
闻名 Behavioral Inhibition | Major Depression | Children Parents | Panic Disorder | Controlled Study |
Traumatic Brain Injury and Schizophrenia in Members of Schizophrenia and Bipolar Disorder Pedigrees
[ PUBLICATION ]
OBJECTIVE: Schizophrenia following a traumatic brain injury could be a phenocopy of genetic schizophrenia or the consequence of a gene-environment interaction. Alternatively, traumatic brain injury and schizophrenia could be spuriously associated if those who are predisposed to develop schizophrenia have greater amounts of trauma for other reasons. The authors investigated the relationship between traumatic brain injury and psychiatric diagnoses in a large group of subjects from families ...
闻名 Traumatic Brain Injury | Bipolar Disorder | Subjects Schizophrenia | Mental Illness | Genetic Vulnerability |
关键人物 Hyperactivity Disorder
Stephen V Faraone∗:专家影响
哪个概念Stephen V Faraone∗具有直接影响:Hyperactivity disorder, Bipolar disorder, Attention deficit, Deficit hyperactivity, Disorder adhd, Anxiety disorders, Disorder hyperactivity, Children adhd.
Stephen V Faraone∗:KOL的影响
与其他作者的工作有关的概念for which Stephen V Faraone∗ 有影响力:Bipolar disorder, Attention deficit, Children adhd, Executive function, Mental health, Schizophrenia patients.
Tools
这是您的个人资料吗? 要求您的个人资料 复制URL 嵌入到您的个人资料的链接 |